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ADR Adenosine-5'"diphosphate
AK(I) Adenylate kinase (increment)
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ATP Adenosine-5'-triphosphate
BMD Becker muscular dystrophy
CP Creatine phosphate
CPK Creatine phosphokinase
GPK-Bg Creatine phosphokinase (Boehringer system)
CPK-Bk Creatine phosphokinase (Baker system)
DHAP Dihydroxyacetone phosphate
DMD Duchenne muscular dystrophy
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GA-3-P Glyceraldehyde-3-phosphate
GDH Glycerophosphate dehydrogenase
GOT Aspartate aminotransferase
G-6-P Glue ose-6-phosphate
G-6-PDH Glucose-6-phosphate dehydrogenase
GPT Alanine aminotransferase
If-GT ^“glutamyl transpeptidase
HGPRT Hypoxanthine-guanine phosphoribosyltransferase 
HK Hexokinase
vii
IMP Inosine monophosphate
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LDH Lactate dehydrogenase
MDH Malate dehydrogenase
NA3 Nicotinamide-3 *-adenylate
NAD(H) Nicotinamide-adenine dinucleotide (reduced)
NADP(H) Nicotinamide-adenine dinucleotide phosphate (reduced)
NON Non-collagen nitrogen
PA3 Procaine adenosine-3'-monophosphate
PA3 Procaine adenosine-3'-triphosphate
PEP Phosphoenol pyruvate
PGI Phosphoglucose isomerase
Pi Inorganic phosphate
PK Pyruvate kinase
PK-Ala Alanine inhibited pyruvate Itinase
PK-LM Liver and muscle pyruvate kinase
PK-M Muscle pyruvate kinase
PRPP Phosphoribosylpyrophosphate
6-PG 6-phosphogluc onate
rbcs Erythrocytes (red blood cells)
TIM Triosephosphate isomerase
wbcs Leucocytes and platelets (white blood cells)
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SUMMARY
Reconstituted commercial kits for serum enzyme assay were 
found to be contaminated, apparently by the very enzyme to be 
measured. With multiple-assay kits using kinetic methods saline 
instead of serum gave blank values that could be subtracted from 
the readings obtained to give dependable results. However, with 
boxes of single-assay vials the between-vial variation in contam­
ination was substantial and, in diagnosis, could lead to unfor­
tunate clinical consequences.
Recently serum pyruvate kinase (PK) has been reported superior 
to creatine phosphokinase (CPK) in diagnosing Duchenne muscular 
dystrophy (DMD) patients and carriers. The allosteric properties 
of the PK isoenzyme abundant in muscle allowed both forms to 
assayed and compared with CPK. Normal ranges were obtained for 
CPK using 2 different thiol activators and for 4 PK modalities; 
both sex and seasonal differences were noted. CPK in clotted blood 
and serum retained its activity, on storage at room temperature 
and lower, far better than did PK, which lost activity when kept 
as serum though whole blood chilling caused its gross efflux from 
blood cells. CPK elevations in known DMD carriers were much more 
decisive than those of PK, which were frequently equivocal and 
only barely above the normal upper limit. CPK is accordingly 
markedly superior to PK in sensitivity, stability and convenience.
Deducting the adenylate kinase increment (AKI) further refined 
the CPK assay, eliminating the effect of haemolysis in diagnosis 
and enabling studies of blood cell contents. Differential centri­
fugation separated rbcs from wbcs; and although chilling and
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disruption showed both had a high PK content, only the former 
contained an appreciable amount of CPK. The erythrocyte content 
of CPK appeared to match that of serum, as if by rapid passage 
across the cell membrane.
Reasons are given to suggest that DMD may have some origin in 
a severe deficiency of total muscle adenine nucleotides, and thus 
perhaps in some defect of purine metabolism. Using double-blind 
techniques this possibility was tested in 16 DMD patients by 
giving oral allopurinol, a synthetic inhibitor of the purine cata­
bolic enzyme xanthine oxidase, in an attempt to increase the 
adenine nucleotides of muscle by better salvage and recycling of 
available purines. Sublingual procaine adenylate was also tested. 
Instances of clinical improvement quickly occurred, statistically 
significant and accompanied by significant increases in physical 
strength and urinary creatinine output, together with the expected 
decrease in both serum and urinary urate values. At muscle biopsy 
ATP v/as found to be reduced to 40% of normal in untreated patients, 
but after a year on daily allopurinol this more than doubled to 
81% of normal, accompanied by an even larger increase in creatine 
phosphate (CP). As initial clinical improvements have been 
maintained for over a year, the view that DMD may be the expression 
of some defect in purine synthesis is plainly upheld. Indeed, 
sustained clinical arrest in this otherwise relentlessly progres­
sive disease may even appear possible.
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CHAPTER I 
INTRODUCTION
Most of the work reported here is directly related to the 
Duchenne type of muscular dystrophy (DMD). By far the most 
common and most severe of the various dystrophies, DMD is inherited 
as an X-linked recessive gene, and estimates of incidence range 
from 13 to 33 per 100,000 live male births. This means that 
around 1 in 5,000 males are afflicted and that in the United 
Kingdom there may be as many as 5,000 patients at different stages 
of the disease. Duchenne de Boulogne (1868), in a series of 6 
reports on the cases of 11 boys and 2 girls, was the first to 
describe DMD adequately. He gave the principal characteristics 
of the disease as: 1) a weakness of movement progressively 
worsening to an abolition of mobility, 2) an increase in volume 
of some of the ••paralysed” muscles, and 3) an abundant production 
of fibrous tissue or fatty vesicles in the more advanced stages. 
Duchenne called the disease •’psuedohypertrophic muscular paralysis”, 
though this last word has since been correctly modified to 
•’dystrophy'’.
Clinical evidence of the disease becomes apparent usually 
about the third year of life, though weakness may occur as early 
as the first or as late as the seventh. In fact Toop and Emery 
(1974) and Vassilopoulos and Emery (1977) even suggest that the 
disorder is manifest ^  utero by the second trimester of pregnancy. 
The boy is late in walking, and soon becomes unsteady, with frequent 
falls and increasing difficulties ascending stairs. This growing 
disability is occasionally erroneously attributed to a trivial
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complaint such as flat feet or general laziness. The weakness is 
thus first apparent in the muscles of the pelvic girdle and the 
thigh. In 80% of the patients the calves appear to he enlarged 
(Walton and Nattrass, 1954) and other muscles, such as the glutei 
and those of mastication, may also show this pseudohypertrophic 
phase. These regions initially feel firm but later become soft 
though remaining relatively enlarged when compared with other 
wasted regions. The pseudohypertrophy may precede noticable 
weakness by many months, although it usually disappears as the 
disease progresses, and may even be mistaken for good muscular 
development.
Before long the boys have increasing difficulty in running 
and climbing stairs. They rise characteristically from a supine 
position by rolling over face-down to the prone position, and with 
both hands on the floor throughout, attain a kneeling posture then 
stand erect by using both hands to "climb up" their legs and 
support the weak pelvic extensor muscles. This manoeuvre, called 
Gowers' sign (Gowers, 1879), may be the earliest evidence of 
definite pelvic weakness in a child. Weakness of the muscles of 
the trunk, the shoulder girdle and the upper extremities is often 
not reported until up to 5 years after the onset, yet it can 
usually be found at examination long before this. Once the 
shoulder girdle muscles are noticably affected the scalpulae 
"wing" from the thorax, and the patient is too weak to keep his 
arms down when being lifted under the axillae.
At the age of 4 or 5 years growth may outstrip progress of 
the disease giving a false impression of improvement, otherwise 
deterioration is continuous. Wasting in all muscles generally
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parallels weakness, 'becoming more, severe proximally though the 
calf muscle may remain remarkably strong for several years.
Tendon reflexes are often depressed more than the weakness would 
suggest, commonly being absent in muscles that can still overcome 
gravity and moderate resistance. Neck muscles usually become 
weak only in the later stages but those of the face are often not 
seriously affected.
In most patients muscle is replaced by fat and fibrous tissue, 
which later shrinks to give contractures of the large limb joints, 
with early progressive plantar-flexion and inversion of the feet 
and finally hip contractures. Contractures also develop even­
tually in the knee, elbow, shoulder and wrist joints. The early 
inversion of the feet prevents the patient bringing his heels to 
the floor, so that he walks on his toes, feet wide apart, with a 
pronounced waddle and lumbar lordosis due to weakness of the hip 
extensors.
Life in a wheelchair becomes necessary, usually between 7 
and 11 years, when the patient can no longer walk at all. 
Confinement to bed leads to a rapid increase in weakness and a 
speedy decline to the wheelchair, and must be avoided, so that 
surgical procedures designed to lengthen the Achilles tendon are 
often disastrous because of this. Once chairbound the contractures 
develop more rapidly and weakness of the spinal muscles invar­
iably leads to increasing scoliosis, with displacement of vital 
organs. Progressive deterioration of respiratory function occurs 
and may very occasionally lead to severe terminal carbon dioxide 
retention. Some boys become generally wasted as the disease 
progresses but others become very obese, presumably due to a
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combination of excessive feeding and immobility, however studies 
of endocrine function have failed to reveal the origin of this 
difference (Walton and Gardner-Medwin, 1974). Sexual development 
is usually normal, though puberty may be delayed.
Eventually pronounced deformities by fixed contractures may 
make even a chairbound existence impossible and herald the final 
stages of DMD where the patient is confined to bed, just able to 
speak, swallow, breath and feebly grimace, but is otherwise all 
but helpless. Survival beyond the age of 20 years is unusual and 
beyond 25 years rare. Death usually results from inanition, 
chest infection or cardiac failure.
Intellectual impairment is common in DMD and was recognised 
by Duchenne in 5 of his 13 cases, leading him to believe that the 
disorder was cerebral in origin. About 10% to 25% of the patients 
are retarded with verbal ability the most severely affected; but 
progressive deterioration does not occur and there is no correl­
ation between muscular and intellectual involvement. Skeletal 
deformity includes a narrowing of the shafts and rarefaction of 
the ends of the long bones.giving coxa valga. At later stages 
there is severe scoliosis, widespread décalcification and disor­
ganisation of the skeletal system. These changes render the 
affected bones liable to fracture on minimal trauma, when even a 
fall from the wheelchair may fracture a femur. Walton and Warrick 
(1 9 5 4) concluded that these bone changes were the result of disuse 
and the absence of normal muscular stresses, compounded by the 
distorted posture due to the disease, and were not caused by a 
dystrophy of the bone itself.
Myocardial involvement is probably invariable in DMD although 
it may not be detectable in the early stages. Persistant tachy­
cardia, arrhythmias and non-specific murmurs are common and 
sudden death from myocardial failure may occur (Berenbaum and 
Horowitz, 1956) though congestive cardiac failure is rare. The 
electrocardiogram (EGG) in DMD, which is characteristic, shows 
tall R waves in the right precordial leads with deep Q waves in 
the limb and left precordial leads. Emery (1972) has shown that 
this EGG pattern may be of diagnostic value in distinguishing 
DMD from other forms of muscular dystrophy.
DMD is also characterised by the diagnostically important 
elevations in the activity of some serum enzymes. Sibley and 
Lehninger (1949) first discovered elevated serum ALD activities 
in 2 patients with muscular dystrophy and confirmatory reports 
followed (Evans and Baker, 1957). Ebashi ^  ai. (1959) were the 
first to report extremely high values of CPK activity in serum 
of DMD patients, now generally recognised as the most sensitive 
index of muscle disease, since CPK occurs almost exclusively in 
muscle (Colombo al,, I9 6 2; Schmidt, 1964; Dawson and Fine,
1967; Smith, 1972) with small amounts in the brain and myocardium 
and only traces elsewhere. Gross elevations of the activity of 
CPK and other serum enzymes may be evident long before any clinical 
symptoms of DMD appear. These elevations have been monitored 
from birth in the brother of a DMD patient (Heyck at ad., 1966).
At birth the infant had values which were raised in comparison to 
those found in normal neonates. The elevations reached a peak 
between I4 and 22 months with a slow decline in the years thereafter 
and although the disease had already been confirmed at biopsy 
there was still no clinical indications of DMD at 2^ - years old.
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Early in the course of DMD activities of many thousand units, 
several hundred times the normal upper limit, are commonly found. 
Thomson at al. (1974) found a significant steady decline of serum 
CPK as the age of the patients increased and muscle mass diminished. 
The rate of decline was the same for both ambulant and wheelchair 
boys, though the values were almost halved after confinement of 
the individual to the chair. Thus CPK in DMD specifically measures 
active muscle mass and may assess prospective therapy if activity 
and mass remain the same over a short period. There can be little 
doubt that the increased amounts of these serum enzymes originate 
mainly from muscle, though it has been suggested (Kleine, 1970) 
that part of the elevation is derived from other tissues. 
Nevertheless, the quantity of enzyme in the serum only represents 
a minute fraction of that found in muscle as Ig of normal human 
muscle has 10^ times the activity of 1ml of serum (Dreyfus ^  ,
1956).
The fact that DMD is inherited as an X-linked recessive gene 
is confirmed by its appearance in 2 sons by different fathers of 
the same carrier mother (Thomson, 1971) and by its equally rare 
occurrence in 2 carrier daughters in the same way (Thomson,1975h). 
These carriers have an XX genotype, with one X-chromosorne carrying 
the DMD gene abnormality which is masked by normal factors on the 
other X-chromosome. Moreover, the random fusion during early 
growth of mononucleate myoblasts from clones with one or other 
X-chromosome already randomly inactivated (Lyon, 1962) gives a 
dual population of nuclei regulated by either a normal or a 
dystrophic X-chromosome in the mature multinucleated cell, with 
different proportions of each in different individuals giving a 
uniform X-chroraosomal mosaic (Emery, 1965). Since DMD seems
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myogenic (Thomson _et , 1974) this implies a range of carrier 
manifestation from the undetectable, with fev^  X-chromosomes 
carrying the DMD gene and no clinical or biochemical evidence of 
the carrier state, to the florid DMD itself with the gene present 
in most. X-chromosomes. Undetectable obligate carriers do occur 
(Thomson, 1969a)> as well as cases of marked disability (Moser 
and Emery, 1974) and even rapid crippling and early death (Frazer, 
1 96 3) of occasional females in typical pedigrees of male DMD.
Females carrying the gene would only manifest the condition 
fully if they were of XO genotype (Turner's syndrome) or 
homozygous. Both Walton (1936) and Perrier _et (1965) found 
DNiD in girls with Turner's syndrome in accord with gene location 
on the X-chromosome. Girls homozygous for the gene are of extreme 
rarity as DMD patients are not likely to reproduce and there is 
little likelihood of a female carrier marrying a male in whom a 
gonadal mutation of the DMD gene has occurred. There are, 
nevertheless a number of instances of females described as cases 
of DMD where the pattern of inheritance has suggested autosomal 
recessive inheritance, lonasescu and Zellweger (1974) extensively 
examined 4 such females v/ho were clinically, histologically and 
enzymatically very similar to male DMD. However, no absolute 
determination of the mode of inheritance could be made in these 
cases, which may in fact be simply very severely manifesting 
carriers, as suggested by Thomson et (1975b).
DMD is sometimes referred to as the "malignant" or "fast" 
variant of pseudohypertrophic muscular dystrophy, whereas Becker 
(Becker, 1955; Becker and Kiener, 1955; Becker, 1957; Becker, I9 62) 
later described a "benign" or "slow" X-linked recessive form,
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Becker muscular dystrophy (BMD). Emery _et ai. (1968-1969) and 
Sld.nner et ai. (1974) have reported evidence suggesting that the 
genes for BMD and DMD are at 2 different loci and that the 2 forms 
are quite distinct, with BÎ4D not merely part of the spectrum of 
severity of DMD. BMD is clinically similar to DM! hut it has a 
much slower course, with very gradual progression of weakness and 
wasting, apparent first in the pelvic and then in the pectoral 
muscles as in DMD. The age of onset is usually between 5 and 25 
years and ability to walk is not lost until middle or even late 
adult life, some 25 years or more later. In most cases there is 
no cardiac involvement or contractures and deformities do not 
usually occur. The life span may even be normal, with patients 
fathering offspring and transmitting the disorder through obligate 
carrier daughters to grandsons, but never to sons. The biochemical 
identification of BMD carriers is uncertain and though some can be 
identified it seems probable that the detection rates are lower 
than for DMD carriers.
The question whether the primary disorder in DMD is located 
in voluntary muscle or elsewhere has not so far been resolved.
Some 50 years ago a deficiency of vitamin E was thought responsible 
when it was noted that several animal species, when deprived of 
dietary vitamin E, developed an experimental muscular dystrophy 
closely resembling the human form. Hopes of a cure for DMD were 
raised when cK-tocopherol produced a prompt and dramatic recovery 
in rabbits with this disease. However in DMD patients neither 
o<-tocopherol nor its esters, administered orally or intramuscularly, 
had the least effect (Milhorat £t ad, , 1945). It v/as then thought 
that vitamin E v/as either not absorbed or poorly utalized, and 
various derivatives mre then tested. Though some results see.med
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encouraging, no real success was achieved. Many other potential 
therapies were tried but in 1954 a comprehensive list of 82 
treatments (Milhorat, 1954) reported that not one had shown any 
significant, lasting effect on the course of the disease. The 
fact that the pathogenesis of muscular dystrophy still remains 
unknown explains the great diversity of the medications tried.
These ranged from vitamins, sugars and amino acids to enzymes, 
hormones and products of the gastrointestinal tract.
In 1955 o. mutant strain of mouse, the Bar Harbor 129, afflicted 
with a hereditary disorder which resembled human muscular dystrophy, 
was bred (Michelson _et ai. , 1955). The availability of this 
animal stimulated a great deal of work in which it was used as an 
experimental model for the human disease. However, Baker _et al. 
(1958) found several differences between the human and murine 
disease with tremors, unusual reflexes of the head and hind leg 
and periocular inflamation frequently occurring in the latter.
The serology is different (Schapira and Dreyfus, 1963) and the 
mode of inheritance is autosomal recessive (Stevens _et ^1., 1957), 
not X-linked recessive as in DMD. Askanas and Hee (1974) suggest 
that the dystrophy in mice and chickens may be of neurogenic origin, 
but stress that analogies between animal and human muscular dyst­
rophies can be very misleading and findings should only be related 
to the human disease with great caution. Hironaka and Miyata (1973) 
also found evidence that murine dystrophy may be neurogenic but 
work suggesting that DMD arises in the same way (McComas ^  ad., 
197 0) is open to criticism (Scarpalezos and Panayitopoulos, 1973; 
Desmedt and Borenstein, 1973; Rosselle and Stevens, 1973) with 
Harriman (1976) finding no morphological evidence to support the 
concept of DMD as a neurogenic disease. Moreover Thomson ^  al.
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(1974) nia de observations that cannot be explained by a neurogenic 
but only by a myogenic origin. Work with animal models must 
therefore be of limited use as there is no Imown hereditary or 
experimentally induced animal dystrophy which exactly resembles 
DMD or any other human dystrophy.
Therapies tested in more recent years include procaine-3’- 
adenylate as sub-lingual tablets (Bourne and Golarz, 1962) which 
appeared to have beneficial effects after a year, with patients 
showing no muscular deterioration for up to 4 years (Golarz and 
Bourne, 1962). There was, however, no follow-up to this prelim­
inary investigation nor any precise diagnosis of the muscle 
disorder. Intravenous infusion of Laevadosin, a mixture of 
nucleotides and nucleosides did seem to help (Thomson and Guest, 
1963), but Pearce jet ai. (I964) and Walton ^  (1965) found it
to have no effect, though their methods were criticised (Thomson, 
1 9 6 4; Thomson, 1965). Anabolic steriods gave apparently encour­
aging results (Dowben, 1963) but Gamstorp (1964) repeated this 
work using oral methandrosenolone and found that although 75% of 
DMD patients showed moderate improvement this was followed by rapid 
deterioration, often with unpleasant side effects. After a year 
on androstenolone marked decreases in strength occurred in most 
DMD patients tested by Fowler jet al. (1965) who believed the 
treatment to be positively harmful. More recent work has concen­
trated on treating only the consequences of the disease. Chou ^  
al. (1975) reported the beneficial effect of penicillamine in
chickens, which appears to inhibit collagen formation in inherited
blind
avian muscular dystrophy. A double/^controlled trial of penicill­
amine in DMD is presently in progress but after 6 months no 
definite improvement had been seen (Enomoto and Bradley, 1977),
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though little could be expected so soon* Diethylstilbestrol 
lowers serum enzyme activities in DMD (Cohen and Morgan, 1976) 
but this is not associated with changes in weakness or muscle mass. 
Munsat and Bradley (1977) state that a reduction in CPK activity 
does not necessarily imply theraputic benefit. Prednisone, 
another steriod has been offered as a palliative treatment 
(Drachman et ai., 1974; 1975) but this has been severely criticised 
(Munsat and Walton, 1975; Rowland, 1975).
Demos (1961a and b) advanced the vascular hypothesis suggesting 
that muscle degeneration in DMD was due to an abnormality of muscle 
blood flow. The use of a vasodilating agent, to test his suppos­
ition met with moderate success (Demos, 1965). Bradely £t al.
(1975) and Boyson and Engel (1975) however, both reported evidence 
contradicting the Demos hypothesis. A disorder of connective 
tissue has been proposed as another explanation for DMD. Bourne 
and Golarz (1959) and Golarz _et al. (196I) found evidence of excess 
dephosphorylating activity in connective tissue; but their findings 
could not be substantiated by Engel (I962). More recently 
lonasescu et (1971a) demonstrated a 4-5 fold increase in
collagen synthesis by the heavy polyribosomes of dystrophic muscle 
compared with those of normal controls. A similar increased rate 
of collagen synthesis has also been found in DMD carriers 
(lonasescu e^ ^1., 1 9 7 3) and recently it has been suggested that 
the basic defect in DMD is misdirected regeneration with a tendency 
to synthesise more collagen than contractile proteins (lonasescu, 
1 97 5). However the overproduction of connective tissue may not 
be the primary fault but rather a non-specific response to injury,
A cell membrane defect has also been invoked and many abnorm-
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alities have indeed been found in the membranes of DMD muscle 
(Takagi ^  ) 1973; Mav/atari et , 1974) and erythrocytes,
where; 1) the phospholipid content differs (Kunze et al., 1973; 
Kalofoutis ejt , 1977), 2) potassium (Howland, 1974) and sodium 
contents (Sha’afi ^  , 1975) are abnormal and 3) the membrane
protein kinase also is abnormal (Roses ^  al., 1975). These 
studies suggest that the fault is expressed biochemically in 
membranes, but again this may be secondary rather than primary 
and it is still a matter for conjecture which defect in DMD so 
far observed is the cause and which is the result.
In the most widely accepted classification, carriers of the 
DMD gene are divided into 3 categories (Walton and Gardner-Medwin, 
1974). Definite carriers are those mothers who have an afflicted 
son and another male relative with the disease in the female line 
of inheritance; for example a brother, maternal uncle or sister’s 
son. Probable carriers are the mothers of 2 or more affected sons 
but no other affected relatives, and possible carriers are the 
mothers of isolated cases and the female relatives of affected 
males. Thomson (1969a) however, defined a female carrier by 
exclusively female transmission to affected male relatives in a 
generation (A) directly succeeding (a son or a daughter's son) 
or (B) indirectly succeeding or preceding (a brother or a sister's 
son or a mother's brother). An obligate carrier has both A and 
B often with further biochemical evidence, and a presumed carrier 
has A or B with biochemical evidence of the carrier state.
In some carriers a slight degree of myopathy may often be 
detected by investigation. Occasionally this appears as actual
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weakness (Chung ^  , I960) with apparent hypertrophy of the
calves (Emery, 1963) though the latter was shown by systematic 
measurement to be mere supposition (Thomson et , 1975b). In 
the majority of cases carrier manifestition is subclinical.
Carriers are best detected, therefore by a manifestation of 
DMD which survives attenuation in the X-chromosomal carrier mosaic. 
This is found in the serum CPK activity originating from muscle, 
which in health shows very low values, in DMD gross elevations, 
and in carriers values ranging from low but undoubted elevations 
to those resembling actual DMD, Serum CPK can thus detect 30- 
88% of definite and probable carriers (Walton and Gardner-Medwin, 
1 97 4) though around 70% seems to be the best that can usually be 
expected. Thomson (1969a) in precisely defined circumstances 
identified 86% of inevitable carriers using one of the most 
sensitive of the many methods available to measure CPK activity. 
Several CPK determinations should be carried out before a female 
at risk of being a carrier is pronounced normal since Perry and 
Frazer (1973) found that in serial CPK estimations all 10 carriers 
tested had at least 1 normal value , with 3 giving several normal 
results. They recommended that 4 CPK determinations be made for 
each female at risk in order to maximise the chances of detection.
There have been numerous attempts to improve the CPK detection 
rate by assaying the enzyme after physical exertion. Emery (1967) 
found standardised exercise had little effect in normal women but 
may produce a significant increase in enzyme values in some 
carriers and be useful in the genetic counselling of suspected
carriers with equivocal serum CPK values. Hughes et al. (1971)
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however, could not improve the rate of carrier detection using 
CPK with controlled ischaemic exercise. Recently Daniel! and 
Angelini (1976) measured haemopexin (a ^ -globulin) and increased 
the level of detection of definite and probable carriers by CPK 
determination from 70 to 80%.
Spurious elevation of serum CPK activity may occur after 
exertion (Griffiths, 1966a) and in small children after a brief 
struggle at venepuncture (Thomson, 1971). Pregnancy in normal 
women was reported by Emery and Pascasio (1963) as having little 
effect on CPK activity but King et (1972) found there were
significantly lower values at 8-20 weeks gestation. 2 more 
investigations (Emery and King, 1971; Blyth and Hughes, 1971) 
found carriers with elevated values that had even been brought 
within the normal range by pregnancy.
Other methods of carrier detection are often more complex and 
usually less sensitive except for the measurement of ribosomal 
protein synthesis (lonasescu ejb , 1971b) by estimating amino 
acid incorporation by polysomes, in vitro from biopsied muscle, 
when it was found to be significantly raised in 8 out of 10 
suspected carriers, 3 of whom had elevated serum CPK values.
Further work (lonasescu _et , 1973; lonasescu e_k al., 1976) 
confirmed the abnormality in a total of 37 out of 38 known carriers 
(98%), with CPK estimation detecting 36 (62%). Because of the 
complexity of this method its use ils only justified after normal 
serum CPK values have been obtained on 3 separate occasions 
(lonasescu ej^  , 1973). Again pregnancy is a complicating factor 
as normal pregnant women may also show elevated ribosomal protein 
synthesis (lonasescu et , 1 97 4).
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Gardner-Medwin (1968) thought electromyography (EMG) useful 
in identifying some carriers with normal CPK values and Moosa et 
al. (197 2) refined the technique somewhat. A report by Valli 
al. (1 9 7 6) claims that EMG, with 3 muscles per patient tested, 
gave a detection rate of 82% though previously only 30-70% of 
definite carriers could be identified. Walton and Gardner-Medwin 
(1 9 7 4) however, warn that a most careful comparison with normal 
controls is essential if errors are to be avoided.
The histology of muscle biopsy material has been examined, 
using the light microscope, by Emery (1963) and Pearce et al. 
(196 6) and although obvious and diagnostic changes were seen in 
some carrier specimens most were either normal or showed minimal 
and non-specific changes. Electron microscopy is perhaps more 
successful. Fisher ^  (1972) reported abnormalities in 19
carriers, but without mentioning CPK activity, and Afifi ^  al.
(1 9 7 3) in a study of 3 carriers found that 2 were abnormal under 
the light microscope, 4 had elevated CPK activities, but all 3 
were abnormal using the electron microscope.
Nagai _et (1969) described how the biological half-life
86of Rb was diminished in all carriers tested, though Bradley et 
al. (1971) and Thomson jet (1975b) could not substantiate this,
perhaps because the original comparison had been with normal males 
and not females as in the 2 other investigations. Using the same 
technique, whole body counting, Blahd et al. (1967) found signif­
icant reductions in total body potassium and although Thomson £t 
al. (1975b) also found similar reductions the complexity of the 
method and the expensive instrumentation required severely limits 
its usefulness. Another extremely complex method which is not a
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practical proposition in most laboratories is the measurement of 
limb blood flow which Demos et (I962O found to be significantly
altered in a proportion of carriers. Askanas (1967), using 
immunoelectrophoresis, found abnormalities in the^-globulin 
fraction of serum proteins in some carriers, but this work could 
not be confirmed by Emery (I97I). Emery (1969) also studied the 
EGG of carriers, and although certain irregularities were found 
its use is likely to be limited to differentiating the severely 
manifesting DMD carrier from the limb-girdle type of muscular 
dystrophy where the EGG is normal.
Using a scanning electron microscope Matheson and Rowland
(1 9 7 4) found that carriers had an increased proportion of deformed 
erythrocytes (echinocytes); further work by Dumb and Emery (1975) 
failed to obtain a clear cut normal range, however, and although 
Howells (197 6) reported automated methods for discriminating 
echinocytes from erythrocytes Matheson et (1976) could not 
reproduce the original work, as they found the erythrocytes very 
sensitive to different handling procedures. Manual muscle testing 
by Roses et (1977) demonstrated a pattern of proximal muscle 
weakness in carriers which they found a valuable adjunct to other 
methods of carrier detection. Very good results have been 
obtained by the use of a combination of several methods for each 
potential carrier. Radu et al. (1968), using serum enzymes before 
and after exercise, with EMG and muscle biopsy, detected 53 out 
of the 56 carriers tested (95%); and Gardner-Medwin _et (197I), 
even although they found CPK to be by far the most superior single 
method, recommend that a battery of tests be used to obtain the 
best results.
16
Abnormal results In any of these investigations indicates 
the carrier state. However, when the result is normal difficulties 
arise since no result is invariably positive for all carriers.
It has been suggested that, of these phenotypically normal 
heterozygous carriers, the percentage undetectable by laboratory 
tests may be 6-20% (Graham et , 1975), so that, complete 
detection is approached but never attained. When a suspected 
carrier does not give any positive result advice may still be 
given in terms of probability which can be estimated using the 
precise value of CPK in serum, within the normal range, together 
with the application of Bayes’ theorem to her pedigree (Emery and 
Morton, 1968). Studies on the lethal X-linked recessive gene 
indicate that the proportion of new female mutants may be as high 
as one half (Franke ^  al., 1976). Roses (1976) and Roses at al. 
(1976) presented evidence suggesting that new mutations producing 
DMD males, are rare and, though Zatz ©t (1977) could not 
verify these results in a study of Brazilian pedigrees, differences 
in reproductive performance may explain the contradictions. These 
findings, whereby many DMD boys are born to apparently sporadic 
carriers, indicate a pressing need by the genetic advisory service 
for even more accurate routine methods of carrier detection.
Serum PK, however, has recently been compared with CPK, so 
far the simplest and most sensitive single test available, and 
reported to be markedly superior, even without recourse to its 
specific isoenzymes (Harano £t al., 1973; Alberts and Samaha,
1974). These reports merit careful examination with complete 
analysis throughout for tissue specificity, and extensive 
comparative studies have accordingly been undertaken.
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There is evidence that ATP mediates the retention of enzyme 
molecules in the intact cell, thereby influencing mean serum values. 
Enzyme efflux ^  vitro is increased by metabolic inhibitors, lack 
of glucose, anoxia and stimulation (Zieler, 1958). Similarly in 
vivo excessive amounts of skeletal muscle CPK and other enzymes 
appear in the serum after hypoxia at rest (Griffiths, 1966b;
Highman and Altman, I960) and after prolonged exertion in health 
(Griffiths, 1966a; Sanders and Bloor, 1975) with rapid restoration 
afterwards and neither evidence nor likelihood of muscle cell 
damage. These different causes of enzyme efflux share a common 
tendency to diminish intracellular ATP. Sweetin and Thomson 
(1973b) showed that a decline in plasma glucose caused failure of 
the erythrocyte membrane (NaK)-ATPase, which has an absolute 
requirement for ATP (Glynn, 1968), allowing sudden effux of 
intracellular K"*" closely followed by that of ALD and LDH, suggesting 
that their retention also required ATP. This work received direct 
support from Wilkinson and Robinson (1974). Evidence of muscle 
enzyme efflux into the circulation after stimulation was described 
in the intact cat by Thomson _et (1975a.). Efflux occurred only 
after indications of exhaustion of ATP.
In DMD there is a 30-50% reduction in muscle ATP, part of a 
marked depletion of total adenine nucleotides (Vignos and Warner, 
1963; Stengel-Rutkowski and Barthelmai, 1973), essential to every 
aspect of cell metabolism. This may cause chronic dilution of the 
cell contents in body fluids beyond prolonged survival, with the 
typical gross serum enzyme elevations proportional to the decreasing 
muscle mass. If the basic defect in DMD is a chronic lack of 
muscle ATP an explanation is found, not only for the dilution of 
cell content, but for many other apparently unrelated disorders
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of DMD muscle. The delayed motor development in male DMD infants 
could he due to weakness, caused by a lack of ATP, before real 
muscle loss begins; likewise the rapid failure on standard exercise 
of symptomatic DMD carriers with apparently adequate contractile 
equipment is explained (Thomson , 1975b). Brief bed rest,
which spares muscle ATP, greatly reduces efflux and serum enzyme 
values both in DMD patients and carriers (Thomson and Guest, 1963; 
Thomson, 1962; Stephens and Lewin, 1965); and likewise wheelchair 
confinement immediately halves CPK efflux in DMD patients (Thomson 
_et ^1., 1 9 7 4).
Vignos and Warner (1963) found a reduction of 30% in ATP, 
unchanged ADP values and no AMP at all in the muscle of DMD 
patients; whereas Stengel-Rutkowski and Barthelmai (1973), using 
more precise methods, found reductions of 50, 70 and 80% in ATP,
ADP and AMP respectively in DMD muscle compared with normal.
Barak jet (1974) reported decreased ATP levels in dystrophic
mice. Diminished muscle ATP is also a principal feature in the 
reversible myopathy of vitamin E deficiency in rats, with a 22% 
reduction accompanied by a 118% rise in the less abundant ADP, 
though the total muscle adenine nucleotides alter only slightly 
(Dhalla ^  al., 1971). Thus the formation of ATP from ADP seems 
defective in this myopathy. This does not appear to be the case 
in DMD, since the normal performance of DMD mitochondria in a 
suitable medium (lonasescu ejk al., 1967; Peter, 1968; Peter ejb 
al., 197 0) suggests that the cause of the ATP deficiency lies 
elsewhere, perhaps in disordered muscle purine metabolism by either 
excessive breakdown or insufficient synthesis. Elevated serum and 
urinary uric acid values, the end product of purine catabolism in 
man, were reported by Lahoda (1972) but this present work refutes
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these findings and indicates that the opposite is the case (see
later), so that a defect in purine synthesis seems the more
likely possibility. In fact, the serum uric acid values reported 
were
by Lahoda (1972)/above the level at which tophi formation could 
be expected (Seegmiller, 1965), a symptom never found in DMD.
The DMD gene in the dystrophic nucleus may thus exert its whole 
effect by insufficient provision of essential muscle purines.
Smellie ^  al. (1956) suggest there might be 2 types of tissue; 
those that, like liver, can make sufficient purine nucleotide for 
their requirements, and those, like bone marrow, that depend on 
a supply of purines formed in other tissues. Much of the ^  novo 
purine synthesis seems to occur in the liver with some peripheral 
tissues dependant on the salvage of erythrocyte-borne hypoxanthine 
(Murray ^  al., 1970). This purine salvage pathway does in fact 
require only 1 molecule of ATP to produce inosinic acid, whereas 
de novo synthesis, using more basic substrates, requires no less 
than 5 (Fox, 1975). Purine metabolism in muscle itself does not 
appear to have been investigated.
Ailopurinol, a synthetic isomer of hypoxanthine, and its 
metabolite oxipurinol (Figure 1) inhibits xanthine oxidase 
(xanthine : oxygen oxidoreductase, E.G. 1.2.5.2.) ( Chalmers et 
al., 1 9 6 8), thus reducing irreversible purine loss as uric acid.
In a detailed study of xanthine oxidase inhibition Elion ab al. 
(196 6) found ailopurinol to be a more potent competitive inhibitor 
than oxipurinol (structurally similar to xanthine). Synthesis of 
the enzyme is neither induced nor depressed by the subnormal 
activity caused by the presence of an inhibitor. Also, ailopurinol 
is cleared from man at a rate similar to that of hypoxanthine and
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xanthine but oxipurinol is cleared' much more slowly with some 
accumulation, and probably plays a significant rôle in the 
theraputic effect of ailopurinol* Recent work indicates there 
is a slow reaction whereby oxipurinol complexes with molybdenum 
at the active site of xanthine oxidase (Spector, 1977), indicating 
a further reason for the efficacy of ailopurinol.
Ailopurinol markedly enhances incorporation of hypoxanthine 
into nucleotides and nucleic acids in mice (Pomales et , 1963), 
as well as increasing the exogenous hypoxanthine metabolised in 
man by L].0% (Bundles at , 1966), and its administration to 
healthy human subjects raises in vivo erythrocyte ATP levels by 
30% within 3 days (Manzke and Dorner, 1973)' Experimentally 
induced haemorrhagic shock in animals causes a reduction in tissue 
adenine nucleotides, particularly ATP (Ghaundry _et al., 1974), but 
pretreatment with ailopurinol greatly increases the survival rate 
(Baker, 1972) probably by preventing the purine loss which made 
the shock irreversible (Crowell et , 1969). The actual values 
of liver adenine nucleotides return to normal far more quickly in 
dogs treated with ailopurinol than in untreated controls (Hopkins 
et al., 1973). Similar observations were made in other viscera 
(Keaveny at , 1973), as in the ischaemic kidney of rats 
(Cunningham ^  , 1974); and pretreatment with ailopurinol for
3 days induced marked increases of ATP in the canine myocardium 
after operative arrest (Lindsay at al., 1973). These findings 
encourage expectations of similar effects in DMD muscle after 
ailopurinol, with accompanying clinical improvement dependent on 
the mass of muscle remaining. Ailopurinol has the added benefit 
of being an exceptionally well tolerated drug (Bundles ejt , 1963)
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since toxic reactions , usually mild cutaneous appearances which 
quickly subside when treatment is discontinued, are very rare, 
occurring only in patients with severe gout or impaired renal 
function. Sublingual PA3, NA3 and placebo tablets were administered 
to imperfectly diagnosed DMD patients (Golarz and Bourne, 1962; 
Bourne and Golarz, 1962) but slight beneficial effects were 
observed only after 1 year and only with PA3. The ineffectiveness 
of NA3 may be explained by Gershon and Fox (1974) who found reduced 
phosphoribosylpyrophosphate (PRPP) values after oral nicotinic 
acid. The rate of ^  novo purine synthesis is, in part, determined 
by the PRPP concentration (Fox and Kelley, 1971). Bourne and 
Golarz (1962) found it necessary to use PA3 since the proliferating 
endomysium dephosphorylated the but not the 3*-adenylate, the 
latter then being converted on absorption to the active 5’-aden­
ylate. Various nucleotides and nucleosides given by intravenous 
infusion likewise had a slight beneficial effect (Thomson and 
Guest,. 1 9 6 3).
This study tests the hypothesis of a purine metabolic defect 
in DMD by a double-blind trial of ailopurinol, used to promote 
salvage and re-cycling of what purines are available, and of PA3 
and PA3 superimposed on ailopurinol. A separate study of the 
adenine nucleotide content of DMD muscle, before and after 
treatment with ailopurinol, compared with that of healthy controls, 
was also undertaken.
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CHAPTER II 
l'ŒTHODS AND MATERIALS
Pyrex borosilicate glassware and Grade A soda glass pipettes 
were used throughout; these were cleaned by steeping for at least 
a week in 30% AR nitric acid, repeated rinsing in glass-distilled 
water then drying in covered beakers at 123^0 or for pipettes, by 
AR acetone and suction. The silica photometric cells, of 1 cm 
light path, were cleaned by repeated rinsing in distilled water 
when re-used on the same day, with immersion in nitric acid 
overnight. Detergents or chroraate, giving ions liable to firm 
adsorption on glass surfaces, were avoided.
Serum and plasma assays
Serum and plasma enzyme activities were continuously measured 
as linear absorbance changes against time, using a Unicam SP 800 
flat-bed recording double-beam spectrophotometer with fixed 
wavelength attachment (SP 820), automatic re-cycling cell changer 
(SP 8 3 0) and programme controller (SP 823), 4 reactions could be
followed simultaneously against 4 blanks in the constant temper­
ature water-jacketed cell housing (SP 8?4), thermostatically 
controlled by circulated water from a constant-temperature bath 
regulated by a Gircotherm turbine-heater worlcing against a cooling 
coil bearing a slow current from the cold-water rising main.
Whole blood was taken from an antecubital vein using a 
inch 21-gauge needle and sterile disposable syringe, isopropanol 
skin toilet, minimal venous stasis and gentle handling to avoid
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haemolysis. All venepunctures vme performed by Dr. W.H.S. Thomson. 
The blood was left to clot at room temperature for up to an hour 
in a clean dry glass container. Serum was used throughout except 
later in a separation of erythrocytes (rbcs) from leucocytes and 
platelets (wbcs). Serum or plasma was separated by centrifugation 
at 2,000g, and again at 3,200g to remove the last blood cells.
These procedures were always carried out in subdued light as direct 
sunlight, even for short periods, can cause a loss of up to 23% 
of the CPK activity (Thomson, 1969b). Where necessary distribution 
before clotting, into stoppered graduated Pyrex tubes, was direct 
from the syringe or by a marked wide-bore Pasteur pipette.
Treatment of blood and serum specimens included incubation 
for 24 hours at 23*0.1°C in a water bath and at 1.3°C-0.1 in a 
23% ethylene glycol bath, using a Grant CCK cooling coil and 2,3 
cm expanded polyurethane insulation, or successively for 1 or 6 
hours at 1.3^0 then at 23°C to complete the 24 hour period. Certain 
clotted or heparinised specimens were vortex mixed (Whirlimixer) 
for 60 seconds for mechanical haemolysis after 24 hours at 1,3°C, 
to increase rbc fragility. Serum was also stored in a cold room 
(24 hour range -3 to +8°C, mean 4°C) or deep-frozen at -21.3°C.
Subjects were normal healthy adult males and females with no 
family history of DMD, DMD patients, female DMD carriers and other 
females from DMD pedigrees, as well as patients with the similar 
but far milder X-linked BMD and female BMD carriers. Classically 
affected male relatives of carriers of DMD and BMD are denoned by;
B, son; b, brother; mb, mother’s brother; ss, sister’s son; mss, 
mother’s sister’s son; and in BMD where affected males may reproduce 
unlike DMD, additionally by; f, father; and mf, mother's father.
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Cases of myocardial infarction and viral hepatitis A were also 
included.
The normal ranges of some serum enzymes were ascertained in 
July and again in November of 1973, using subjects in good health 
and active daily employment, and with DMD free pedigrees. On each 
occasion 24 males (aged 18.14 to 61.92 years) and 2Ai- females (aged 
1 7 .4 1 to 6 5 .3 6 years) were bled, many individual being common to 
both series. In July, blood specimens were taken at intervals 
over 2 successive days from subjects randomly divided in 2 equal 
groups. In November all subjects were bled at intervals on the 
same day.
Rbcs and wbcs were separated in blood from 3 healthy subjects, 
4 0 -3 0 ml blood was taken and divided between 4 glass vials coated 
inside with ion-free heparin (Evans "Pullarin”) and promptly mixed 
by gentle rotation before combining into 2 equal volumes of 
heparinised blood. These were centrifuged for I3 minutes at 400g 
and the resulting cloudy wbc-rich supernatants were pipetted into 
2 other tubes and centrifuged at 3,200g for 3 minutes to give a 
pellet of wbcs in clear plasma. This plasma was then carefully 
flushed through the respective packed rbcs and the whole process 
repeated 3 or 6 times. After the last spin 1 of the supernatants 
was restored to its packed rbcs (the other rbcs were discarded) 
and this rbc-rich suspension was well mixed and divided into 3 
portions - for plasma assay forthwith, after chilling for 24 hours 
at 1,5°C and after cell disruption (Whirlimixer) for 60 seconds 
following 24 hours at 1.3°C. A portion of the other supernatant 
was retained for assay forthwith, and the remainder was flushed 
through all the wbcs. As most of the wbcs had adhered to each
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other, making uniform dispersion impossible without causing cell 
damage, the whole was chilled at 1.3^0 for 24 hours, then centr­
ifuged at 3,200g to allow removal of an aliquot of cell free plasma 
before cell disruption (as before). The necessary corrections of 
the results were made in respect of the same number of wbcs in 
different knovm volumes of plasma.
The effect of exercise was studied in a healthy male. He was 
bled at 10am and the 3x2 ml portions of clotted blood taken had 
serum enzyme assays performed forthwith, after 24 hours at 1.3°C 
and also on cell disruption after this chilling. That same 
evening the subject undertook 2 hours of continuous severe physical 
exertion. Venepunctures were performed at the same time on the 
following 3 consecutive mornings and the specimens obtained were 
likewise divided and treated before serum assay.
Creatine phosphokinase (ATP : creatine phosphotransferase,
E.G. 2.7.3*2.; CPK) was measured by the method of Oliver (1933), 
modified by Rosalki (1967):-
ADP + CP CPK. creatine + ATP
 ------"7
ATP + glucose HK  ^ ADP + G-6-P
G-6-P + KADP G-6-PPH^ 6-PG + NADPH
CPK acts in its optimal direction at near-physiological pH, and, 
with HK, G-6-PDH, ADP and NADP in excess, is rate limiting for the 
production of indicator NADPH. CPK activity was measured by rate 
of increase in absorbance at 340 nm, linear during the 13 minute
period of observation. 2 reconstituted commercial kits were used;
that of Boehringer Mannheim GmbH (The Boehringer Corporation 
(London) Ltd.) (CPK-Bg), with glutathione as CPK activator and
10 mM AMP to inhibit adenylate kinase (ATP : AMP phosphotransferase,
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E.G. 2,7*4*3.j AK) and that of J.T. Baker Cemicals B.V. Deventer, 
Netherlands (Diamed Diagnostics,, Liverpool) (GPK~Bk), with 
dithiothreitol and 11.3 mM AMP. AK is not completely inhibited 
by the addition of AMP to the CPK assay mixture and so may falsely 
elevate CPK activity by supplying ATP in the presence of excess 
ADP:-
2 ADP AK ^ AMP + ATP 
This increment (AKI) was measured using the Baker kit which has 
the CP separate, allowing its substitution with saline so that 
the actual CPK activity (nett CPK-Bk) could be obtained by subtr­
acting AKI from each CPK-Bk assay. Activity, expressed as Inter­
national Units per litre at 23^0, was measured against air using 
0.1 ml serum to give a final volume of 2.72 ml (CPK-Bg) or 2.3 ml 
(CPK-Bk and AKI). CPK was also measured using the Boehringer and 
Baker single-assay vials. Test concentrations were the same as 
the multiple-assay kits of both systems. The Baker procedure was 
unchanged but with the Boehringer kit 0,1 ml serum was added to 
a vial whose contents had previously been dissolved in 2,3 ml of 
prepared buffer, the whole was then transferred to a cuvette for 
assay.
Aldolase (fructose-1,6-diphosphate : D-glyceraldehyde-3- 
phosphate-lyase, E.G. 4*1.2.7.; ALD) v/as measured by the slightly 
modified method of Ludvigsen (1963)î-
F-l,6-P ALD\ DHAP + GA-3-P
GA-3-P TIM) DHAP
2 DHAP + 2 NADH GDH^ 2 glycerophosphate
+ 2 NAD
With ALD rate limiting for the disappearance of indicator NADH, 
since TIM, GDH, F-l,6-P and NADH are in excess, ALD activity was
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measured by a linear decrease in absorbance against time at 340  
nm for 20 minutes. In the Boehringer kit 0,2 ml serum gave a 
final volume of 2.76 ml and activity, expressed as IU/1 at 25°C, 
was measured at 37°C against a blank of 0.2 ml serum in saline.
Lactate dehydrogenase (L-lactate : NAD oxidoreductase, E.G. 
1.1.1.27.; LDH) was measured by the method of Wroblewski and 
LaDue (1953):-
pyruvate + NADH LDH y lactate + NAD 
LDH acts in its optimal direction and activity was measured by the 
disappearance of indicator NADH, using excess pyruvate and NADH, 
as a linear decrease in absorbance against time at 340 nm for 10 
minutes. The Boehringer "optimized" kit was used, with 0.1 ml 
serum added to give a final volume of 3.13 ml with activity, 
expressed as IU/1 at 25°C, measured against air. LDH was also 
measured using the Boehringer single-assay vial. The test 
concentration remained the same, and 0.1 ml serum was added to 
the vial with its contents already dissolved in 2.5 ml of buffer.
The whole was then transferred at once to a cuvette for assay.
Aspartate aminotransferase, formerly glutamic-oxaloacetic 
transaminase, (L-aspartate : 2-oxoglutarate aminotransferase, E.G. 
2.6.1.1.; GOT) measurement was based on the method of Karmen (1933) 
aspartate + 2-oxoglutarate GOT ^ glutamate + oxaloacetate 
oxaloacetate -t* NADH MDH^ malate + NAD 
GOT activity was measured by the disappearance of indicator NADH, 
in the presence of excess aspartate, 2-oxoglutarate, NADH and MDH, 
as a linear decrease in absorbance against time at 340 nm for 10 
minutes. The Boehringer "optimized" kit was used, with 0.5 ml 
serum giving a final volume of 3.7 ml with GOT activity, measured
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against air, expressed as IU/1- at 25°C.
Alanine aminotransferase, formerly glutamic-pyruvic transaminase 
(L-alanine : 2-oxoglutarate aminotransferase, E.G. 2.6.1.2.; GPT) 
was measured by the method of Wrôblewski and LaDue (1956):- 
alanine + 2-oxoglutarate GPT ^ glutamate + pyruvate 
pyruvate + NADH LDH^ lactate + NAD
GPT activity was measured by the disappearance of indicator NADH, 
with alanine, 2-oxoglutarate, NADH and LDH in excess, as a linear 
decrease in absorbance against time at 340 nm for 10 minutes.
The single-assay vial Boehringer "optimized" kit was used, with 
0.5 ml serum added to the vial, the contents of which had already 
been dissolved in 3.0 ml buffer, and the whole v/as transferred 
immediately to a cuvette for measurement of activity against air 
expressed as IU/1 at 25°C. GOT activity was also measured using 
single-assay vials, by the same procedure.
(f-glutamyl transferase (amino acid : h-L-glutamyl transferase, 
B.C. 2.3.2.2.; Y-GT) measurement was based on the method of Szasz 
(1969):-
glycylglycine + L-y-glutamyl-p-nitroaniline
y-GT) glutamylglycylglycine + p-nitroaniline 
#-GT activity was measured by the increasing appearance of coloured 
p-nitroaniline, with glycylglycine and ÿ-oL-glutamyl-p-nitroaniline 
in excess, as a linear increase in absorbance against time at 405 
nm for 10 minutes. The Boehringer single-assay vial was used, 
with 0,2 ml serum added to the vial, the contents of which had 
already been dissolved in 3.0 ml buffer, and the whole was 
transferred at once to a cuvette for measurement of activity, 
against air expressed as IU/1 at 25^0.
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Alkaline phosphatase (orthophosphoric monoester phosphohydrolase, 
E.C. 3.1 .3 .1 .; Aik P) was measured by the method of Bessey _et al.
(1946):-
p-nitrophenylphosphate Aik p-nitrophenol + Pi 
Aik P activity was measured by the increasing appearance of coloured 
p-nitrophenol, with p-nitrophenolphosphate in excess, as a linear 
increase in absorbance against time at 403 nm for 10 minutes.
The Boehringer kit was used with 0.03 ml serum in 3.0 ml of buffered 
substrate; activity, measured against air, was expressed as IU/1 
at 23°C.
Pyruvate kinase (ATP : puruvate phosphotransferase, E.C.
2 .7 .1 .4 0 .; PK) measurement was based on the method of Beisenherz
et (1933):-
ADP + PEP PK  ^ ATP + pyruvate
pyruvate + NADH LDH y lactate + NAD
With PK rate limiting for the disappearance of indicator NADH,
since PEP, ADP, NADH and LDH are in excess, activity was measured
by a linear decrease in absorbance against time at 340 nm for 10
before
minutes, self-corrected by reading for 10 minutes^adding the ADP 
to start the PK reaction. The Boehringer kit was used, with a 
test concentration of 1.0 mM PEP and 0.3 ml serum added to give 
a final volume of 3.23 ml. PK activity was expressed as IU/1 at 
23^0, and measured against air. To estimate the contribution 
made by each isoenzyme (i) liver and erythrocyte PK was inhibited 
(Seubert ^  , 1967; Llorente _et , 1970; Harano et , 1973)
by adding 2.0 mM alanine to the reaction mix to give PK-Ala, (ii) 
the muscle form, being isosteric, had adequate activity at 0.2 mM 
PEP giving PK-M, unlike the liver form where allosterism and 
sigmoid kinetics gave very little activity below 0.3 mM PEP
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(Tanaka ^  al. , 1967a; Llorente ^  , 1970; Harano ^  al., 1973),
and (ill) both forms of PK were measured at 2.0 mM PEP to give 
PK-LM, From PK and PK-Ala the percentage inhibition by alanine 
was calculated; likewise the ratio of PK-M to PK-LM. The alanine 
was added to the standard kit in 0.01 ml and different PEP solutions 
(monosodium salt, Boehringer) were added to otherwise unchanged 
assay conditions. The allosteric properties of liver and erythr­
ocyte PK are lost on chilling but recover rapidly at ambient 
temperatures (Llorente et , 1970; Harano e^ , 1975), therefore 
all frozen or chilled sera were left at room temperature for at 
least 2 hours before assay.
Glucose was measured by the method of Schmidt (I96I);- 
glucose HK y G-6-P
G-6-P + NADP G-6-PDH ^ 6-PG + NADPH
Glucose concentration, expressed as mg/100 ml, was measured by 
the increase in absorption at 340 nm (Unicam SP 500 Series 2 
spectrophotometer) by NADPH, formed in the presence of excess HK, 
G-6-PDH and NADP. The Boehringer kit v/as used with 0.2 ml of a 
1:10 dilution of serum in saline giving a final volume of 2.90 ml 
The reaction was started by adding 0.02 ml of mixed enzymes and 
followed to the end point, usually within 10 minutes.
Sodium (Na^) and potassium (k"**) were measured on an Instrumen­
tation Laboratory 143 flame photometer, with inbuilt lithium 
standard, digital read-out and requiring only 0.1 ml serum.
Values are expressed as mequiv/1 and the analyses were carried 
out by the University Department of Chemical Pathology, Royal 
Hospital for Sick Children,. Yorkhill, Glasgow.
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Uric, acid was measured by the method of Kageyama (1971):- 
uric acid uricase  ^ allantoin + CO^ +
+ methanol catalase ^ + formaldehyde
formaldehyde + acetylacetone + NH^
  ^ 3,3-diacetyl-1,4-dihydroxylutidine
Uric acid concentration is directly measured as mg/100 ml by 
increased absorbance of indicator diacetyl-dihydroxylutidine with 
uricase, catalase, methanol, acetylacetone and ammonia present 
in excess. The Boehringer Urica-quant kit was used with 0*5 ml 
serum added to a 5-0 ml reagent volume and incubated at 37°C for 
60 minutes before measuring the increase in absorbance at 410 nm 
(Unicam SP 500 Series 2 spectrophotometer). This method was 
chosen as others, which do not use the very specific uricase, are 
not so precise (Muller ^  , 1974) and are prone to serious
interference with occasional false elevations (Lum and Gambino, 
1973). Uricase was first used by Kalchar (1947) and later by 
Praetorius and Poulsen (1953) whereby uric acid was determined, 
directly at 290 nm, by the decrease in absorbance after uricase 
action. The Kageyama (1971) method, with uric acid breakdown 
coupled to the formation of a coloured product, excludes 
deproteinisation and is therefore much simpler; it ia also free 
from turbidity errors that may occur when a wavelength in the 
ultra-violet range is used.
24 hour urinary outputs
24 hour urine collections were arranged at home between 8 am 
Sunday and 8 am Monday using a polythene funnel and a 2.5 litre 
(Winchester) amber bottle containing 4 ml toluene (AR) as a 
presrvative and 10 ml saturated aqueous lithium carbonate (AR)
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to prevent urate precipitation, so enabling the urine to be stored 
at room temperature for up to 3 days before analysis (Chalmers 
and Watts, 1968; Liddle et , 1939).
After 10 fold dilution with distilled water, urinary uric acid 
was measured as serum, and output expressed in mg/24 hours.
Urinary creatinine was measured by the method of Folin and Wu 
(1 91 9) based on the Jaffe reaction (creatinine/alkaline picrate) 
and adapted to Auto Analyser; output was expressed in mg/24 hours. 
The determinations were routinely made by the Biochemistry Depart­
ment, Glasgow Royal Infirmary.
Clinical design of double-blind trial
The effects of ailopurinol and later, sublingual procaine 
adenylates, were tested by double-blind techniques. 16 boys 
(aged 3 .3 9  to 1 4 .2 9 years) took part in the trial; 9 were ambulant 
and 7 confined to the wheelchair. All had clinically classical 
DMD confirmed by grossly elevated serum enzyme values, notably of 
CPK, and additionally in all but 3 by characteristic histology at 
muscle biopsy and/or genetically, with brothers, maternal uncles
or mothers carrying the gene.
In each patient the maximum height in ora was found to which
he could, using one and/or both hands, in a single continued
exhaustive attempt, raise the mercury in a laboratory manometer 
by rapidly pumping air from a small rubber hand-bulb into a 500 ml 
resevoir connected to the manometer. In addition, each ambulant 
patient was timed (in seconds) ascending the same flight of 10 
stairs, as fast as possible.
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Clinical status was measured by Table XIX. Repeated examination 
of the patients gave this 16 point scale of observed disabilities, 
beginning with the worst and ending with the least. Each patient 
was placed on the scale at the point of his maximum capability, 
confirming always that he could perform every action up to and 
including this point, but none beyond it. For each patient a 
change in position on the scale merely indicated an improvement 
(+) or no improvement (0) for statistical purposes only and could 
not be used to quantify the degree of physical improvement,
EGG leads I, II, III, V4R, VI and V6 were recorded in all patients 
and also aVR, aVL and aVF in the older children (Mrs. McLean,
Knightswood Hospital, Glasgow).
Ailopurinol tablets (100 mg), commercial but unmarked, were 
allocated at random to 8 of 16 numbered bottles, and inert matching 
placebo tablets to the rest. Allocations were carried out by the 
Wellcome Foundation Ltd., who provided the tablets and kept the 
key to the numbering. Procaine adenylate tablets were prepared 
using the modified procedure of Ruskin (1963). To 46.6 g of 
powdered procaine base (Sigma (London) Chemical Co. Ltd.) suspended 
in 900 ml distilled water at room temperature was added, with 
stirring, an equimolar amount (100 g) of ATP (Cambrian Chemicals 
Ltd,) in successive portions. The pale pink opalescent solution 
quickly obtained was filtered and lyophilised in an oil pump vacuum 
against EtOH/solid CO^ to a pale pink microcrystalline solid, m.pt. 
130-140^0 (decomp.). This was ground and dried ^  vacuo to give 
procaine adenosine-5 *— triphosphate (PA5) sis an almost colourless 
powder. In the same way procaine adenosane-3’ -monophosphate (PA3) 
was obtained as an exceedingly hygroscopic powder, m.pt, 88-93°C
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from equimolar amounts of procaine base and adenosine-3’-monophos- 
phoric acid (BDH Chemicals Ltd.), These procedures were carried 
out by Dr. W.H.S. Thomson.
Atomic absorption spectrophotometry (Mr. A.G. Hill, BDH) showed 
less than 1, 1, 3 and 0,5 parts per million of barium, cadmium, 
lead and arsenic respectively in both preparations, and semi- 
quantitative arc emission spectrography likewise confirmed the 
absence of toxic elements.
Sub-lingual tablets, peppermint flavoured and with a dissolution 
time of 2 0 -3 0 minutes, each contained 150 mg PA3 or PA5 (about 100 
mg adenosine phosphate) and were prepared by Arthur Cox and Co., 
Brighton. In matching placebo tablets lactose replaced PA3 and 
PA5, with a small amount of anhydrous citric acid and "Bitrex" 
solution added to give a sourness and bitterness matching that of 
the active tablets. This nasty taste could be somewhat masked by 
peppermint sweets, though most patients soon became used to it.
PA3 tablets were allocated at random to 4 of 8 numbered bottles, 
and placebo tablets to the rest; this was repeated in 8 more bottles 
for PA5. Allocations were made by the pharmacist at Knightsv/ood 
Hospital, Glasgow, who kept the key to the numbering.
Patients were divided into 4 groups and examined before noon 
on the same day each week for 18 consecutive weeks. The first 
6 weeks (period A), in which nothing was given, was used to assess 
clinical status of the patients and to determine the mean of 
enzyme activities and metabolite values. For the next 6 weeks 
(period B) each patient, irrespective of age or weight, took one
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tablet dally from the ailopurinol/placebo bottle allocated to him.
The same dose was given to every patient as the preparation of a 
multiplicity of tablets precisely correct for each individual 
would have made the conduct of a double-blind procedure impossible. 
Since clinical change was not quantified, but measured as improvement 
(+) or no improvement (0), there was no threshold below which 
ailopurinol would not have an effect. Variations in dose with 
respect to age or weight randomly affected both groups, and were 
without statistical consequences. The contents of the bottles 
were revealed at the end of period B and for the last 6 weeks 
period C all patients took one unmarked ailopurinol tablet daily; 
in addition, those who already had ailopurinol in period B received 
one of the PA5/placebo bottles and those who were on the placebo 
received one of the PA3/placebo bottles. Each patient took 4 
sub-lingual tablets daily during period C after which the contents 
of the bottles were again revealed.
At weekly examination, venepuncture for serum enzymes (CPK-Bk, 
AKI, ALD, GOT and &-GT) and urate was followed by testing perfor­
mance using manometry and stairs. The 24 hour urine collection 
for urate and creatinine output was also received. After each 6 
week period clinical status was assessed in terms of the scale in 
Table XIX, The activity of serum CPK-Bk in DMD patients is so 
high that dilution of the serum with saline is necessary, and, since 
activity may vary considerably with the degree of dilution 
(Thomson, 1969b; Snehalatha ^  , 1973) repeated estimations
in each individual were always carried out at the same dilution.
The ECG was taken at the end of each period.
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Assay of metabolites in muscle
The amounts of ATP, ADP, AMP, CP and G-6-P were determined in 
muscle of a) 5 DMD patients (aged 3.67 to 10.lA years) immediately 
before and, in 4 of these 3, 6 months after taking allopurinol 
daily, b) 3 DMD patients (aged 4.37 to 9»46 ÿears) after daily 
allopurinol for approximately a year, and c) 3 healthy male controls 
(aged 1 2 .3 1 to 3 6 .3 2 years) undergoing surgical repair.
DMD patients (all ambulant) were admitted to hospital at 9 am, 
no premedication was given and the subjects were anaesthetised 
with N^O/O^/halothane. At open biopsy 1-2 g of muscle v/as quickly 
dissected from the vastus lateralis (Dr. Alex McQueen, Department 
of Dermatology, Glasgow University). Within 13-30 seconds the 
tissue was freeze-clamped and immersed in liquid in a Dewar 
flask. Less than 30 minutes later in the laboratory the specimen 
was rapidly weighed and powdered under liquid in a pre-cooled 
mortar and pestle. An aliquot (0,3 to 0*9 g) of powdered muscle 
was taken, weighed and kept at -21.3°C until the non-collagen 
nitrogen (NON) estimation could be carried out,
3 .0  ml 6% perchloric acid was added in 1 ml lots to the 
remaining muscle powder under liquid in the mortar and the whole 
ground up together. The was then allowed to evaporate, and the 
powdered perchloric acid/tissue immediately transferred to a large 
tube and left to thaw on ice; protein precipitation would occur 
simultaneously with tissue warming as perchloric acid thaws first. 
The resulting preparation was finely homogenised (Ultra-Turrax) 
on ice for 30 seconds, centrifuged at 3,200 g for 10. minutes. After 
pipetting off the supernatant the pellet was resuspended in 3.0 ml
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5% perchloric acid and recentrifuged. The 2 supernatants were 
combined, filtered, and two 2 ml portions neutralised for duplicate 
determination (pH 6.93-7.03 by 10 and 0.1 M KOH using a Pye 
Dynacap pH meter and glass electrode). The exact volume of KOH 
added was noted. This neutralised extract was left on ice for 
10 minutes, decanted from the sediment of KCIO^ and analysed 
forthwith.
The following assay conditions were based on those used by 
Stengel-Rutkowski and Barthelmai (1973) and Bergmeyer (1963); and 
G-6-P, ATP and CP were measured sequentially by addition of the 
appropriate substrates and enzymes to the test mixture in a cuvette
Test concentrations:- 
Triethanolamine hydrochloride buffer, 90 mM, pH 7.6 
Diaminoethanetetra-acetic acid, disodium salt (EDTA), 9 mM 
Mg SO^, 12,3 mM
Nicotinamide adenine dinucleotide phosphate, oxidised form, 
disodium salt (NADP), 0.4 mM 
D-glucose, 1.3 mM
Adenosine diphosphate, disodium salt (ADP), 0,4 mM (ATP contami- 
nation<l%)
Glucose-6-phosphate dehydrogenase, grade I from yeast (G-6-PDH), 
0.14 lU
Hexokinase, from yeast (HK), 3.6 lU
Creatine phosphoklnase, from rabbit muscle (CPK), 1.8 lU 
All biochemicals were supplied by Boehringer Mannheim GmbH,
Principle of the assays;-
CP + ADP CPK  ^ creatine + ATP 
ATP + glucose HK  ^ ADP + G-6-P
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G-6-P + m D P  G-6-PDH^ 6-PG + NAD PH
In the presence of sufficient NADP, G-6-PDH reacts quantitatively 
with G-6-P to form indicator NADPH. The addition of HK ensures 
phosphorylation of added glucose, using the ATP of the sample, to 
G-6-P which is then oxidised, producing indicator NADPH, If ADP 
and GPK are then added all 3 coupled reactions proceed quantitatively 
allowing the assay of CP,
The following were therefore pipetted into a cuvette
Solution C one. 0 f 
stock soln.
V olume 
(ml)
Buffer 0.12 M 2.3
EDTA 0.13 M 0.2
Mg SO^ 0.21 M 0.2
NADP 12.3 mM 0.1
Sample 0.1
G-6-PDH 7 lU/ml 0.02
Glucose 22.0 mM 0,2
HK 280 lU/ml 0.02
ADP 27*6 mM 0.03
CPK 90 lU/ml 0.02
Absorbance. A-
Test Volume 3*12 ml 
AA,A^-A^d. i. 'G-6-P
A,
Test Volume 3*34 ml : A,
" ^^ATP
A,
Test Volume 3*41 ml : A.
^6”% “ ^^CP
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The initial absorbance was read, before any adition of enzymes, 
for a period of 3-5 minutes (A^), With G-6-PDH added the change 
in absorbance was followed until the reaction stopped (A^). The 
difference between A^ and A^ (AAg_^_p) was due to the G-6-P content 
of the sample. If the G-6-PDH preparation had been contaminated 
with PGI the result would be an estimation of the total hexose 
monophosphate present and not just G-6-P. This was not the case, 
however, as a reaction did occur when, after reading A^, PGI was 
added. This indicated that no PGI was originally present and that 
A^-Ai was in fact a measure of G-6-P only.
A^ v/as obtained within 30 seconds of the addition of glucose, 
and HK, to start the ATP reaction, was then quickly added. These 
2 precations prevent any significant reaction of ATP with the HK 
contaminating the G-6-PDH preparation; for the same reason glucose 
was not added until after the initial reaction was complete. The 
absorbance was followed until there was no further reaction of 
ATP (A^), and the difference between and A^ (AA^ g^ p) gave a 
measure of the ATP present. ADP was added to the test mix and, 
after the contaminating ATP had reacted, the absorbance (A^) was 
noted before the final addition, that of GPK, was made. Again the 
reaction v/as followed to completion (A^) and the difference between 
A^ and A^ (AA^p) measured the CP content of the sample.
«Acl A M P  Maas-ure-t/ .
Test concentrations;- 
Triethanolamine hydrochloride buffer, 90 mM, pH 7.6 
EDTA, 9 mM 
MgSO., 12.5 mM
Nicotinamide adenine dinucleotide, reduced form, disodium salt 
(NADH), 0.4 mM
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Phosphoenol pyruvate, monosodium salt (PEP), 12.5 mM 
Lactate dehydrogenase, from rabbit muscle (LDH), 3.6 lU 
Pyruvate kinase, from rabbit muscle (PK), 1.2 lU 
Adenylate kinase, from rabbit muscle (AK), I .4 lU 
All biochemicals were supplied by Boehringer Mannheim GmbH.
Principle of the assays;-
AMP + ATP AK 
ADP + PEP PK
2 ADP
ATP + pyruvate
pyruvate + NADH LDH^ lactate + NAD 
In the presence of sufficient PEP, PK reacts with ADP to form 
pyruvate which, with excess NADH and LDH, quantitatively diminishes 
the amount of indicator NADH. If ATP and AK are then added in 
excess the 3 coupled reactions will proceed sequentially allowing 
the assay of AMP,
The follov/ing were therefore pipetted into a cuvette:-
Solution Cone, of 
stock soln.
Volume
(ml)
Buffer 0,12 M 2.5
EDTA 0.15 M 0.2
MgSO^ 0.21 M 0.2
PEP 0.21 M 0.2
NADH 13.5 mM 0.1
LDH 180 lU/ml 0.02
Sample 0.1
PK 60 lU/ml 0.02
Test Volume 3.34 : A.
A2-A1 = a a ^^p
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AK 70 lU/ml 0.02
Test Volume 3*36 ml : A^
S " ^ 2  “ ^ ^AMP
The indicator reaction with LDH was allowed to settle for 3-3 
minutes and, after the absorbance was read (A^), PK was added to 
start the ADP reaction which was then followed to completion (A^). 
The difference between A^ and A^ (AA^^p) was due to the ADP content 
of the sample. AK was added and the change in absorbance was 
followed until the AMP reaction stopped, when the difference between 
A^ and A^ (AA^^p) measured the AMP present in the sample.
All these estimations of muscle metabolite contents were made, 
in duplicate, on a Unicam SP 500 Series 2 spectrophotometer at
340 nm against the same reaction mix with saline replacing the 
sample. The results are expressed in moles x 10"*^/g of muscle 
(wet weight) and moles x 10~^/g of non-collagen nitrogen (NON).
In the calculation of these results the following formula was 
used;-
6A X V„ X Vp X V^
 _____— ____d  = moles X lO" /g of muscle (wet weight)
E X d X V^ X V^ X V^
Where:-
= volume in cuvette after the addition of enzyme to start the
reaction (test volume, ml)
= weight of the muscle sample (g)
Vp = Vi + total weight of perchloric acid used for the deprotein-
isation (g)
V^ . = volume of deproteinised extract before neutralisation (ml)
V^ = volume of deproteinised extract after neutralisation (ml)
(i.e. V^ + volume of KOH required for neutralisation)
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= volume of extract added to the cuvette (ml)
E = extinction coefficient of NADH and NADPH; E = 6.22 cm^/mole x 10~^
d = light path (1 cm)
The AMP calculation was altered to take into account the 
oxidation of 2 moles of indicator NADH by 1 mole of AMP.
Though the absorbance usually remained constant after completion 
of a reaction, there was occasionally a small progressive change.
This drift, which appeared always to be linear with time, was 
assumed to be superimposed throughout the whole reaction, and was 
corrected by extrapolating to the start of the reaction. To ensure 
the greatest accuracy the plot was estimated from the regression 
line, calculated by the method of least squares. The drift 
was found only in the assay of ATP and CP, and may be explained 
by contamination of both HK and GPK by AK. A small amount of AK
could cause the ADP present to dismute to AMP and ATP, the latter
then being introduced to the coupled reactions to give a small but 
steady formation of NADPH, linear with time and actually measuring 
the slight activity of AK. No other reasons are apparent.
To determine the NGN content the powdered frozen muscle set 
aside was removed from the deep-freeze and allowed to thaw. The 
sample was homogenised (Ultra-Turrax) in a knownvolume of distilled 
waiter (about 10% w/v). 1 volume of this homogenate was added to
10 volumes of 0.05 M WaOH, stoppered, mixed and allowed to stand 
for 18 hours at room temperature before filtration (Whatman No. 1 
paper) to give the alkali digest, according to the method of 
Lilienthal et al. (1950). The nitrogen content of this digest 
was estimated, (Miss Moira Young, Department of Animal Husbandry,
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Glasgow University) by micro-Kjeldahl digest and titration, since 
colouriraetry (Messier) proved unsatisfactory. It is expressed as 
mg/g of muscle (wet weight).
Statistics
For brevity, statistical significance may be denoted by 
*(P<0.05), **(P<0.01) and ^^(P<0.001), MS denoting no significance 
Unless otherwise stated significant differences between means were 
estimated using Student's "t" test.
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CHAPTER III
SERUM ENZYMES AND DMD CARRIER DETECTION ; RESULTS AMD DISCUSSION 
Serum enzyme assays with commercial kits
Owing to increasing diversity of serum enzyme assays in 
diagnosis, many laboratories now depend on reconstituted commercial 
kits. Those measuring reaction rates spectrophotometrically at 
340 nm may give erroneous results. Occasional omissions, such as 
cofactors, are immediately evident; but unsuspected contamination, 
apparently by a small quantity of the very enzyme to be measured, 
is increasingly common, though far less obvious, and may be due 
to its presence in accessory indicator enzymes prepared from the 
same parent tissue.
Contamination blank values (Table I) were obtained, as perfectly 
linear readings over 20 minutes, when normal saline was used instead 
of serum in freshly prepared multiple-assay kits from a well-known 
manufacturer (Boehringer Mannheim GmbH). In the case of CPK, 
however, the blank value for a particular kit, read in quadruplicate 
weekly for 4 weeks storage at 4^C, did remain constant at 8.16, so 
that subtraction of this blank from values using serum gave very 
close correlation (CPK-Bg, Table VII) with those obtained from the 
same serum using the J.T, Baker multiple-assay vial (CPK-Bk), 
which had no blank value at all (though that of their single-assay 
vial ranged from nil to 2.04). Thus where specimens go to the same 
laboratory performing frequent CPK assays, a simple correction 
gives dependable results. This correction was made throughout the 
work reported here,
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Table I opposite
Contamination blank values, expressed as i.u./l at 25°C, 
obtained when saline was substituted for serum in 
commercial niultiple-assay kits used for the determination 
of serum enzyme activities.
Table II opposite
Contamination blank values, expressed as i.u./l at 25°C, 
obtained when saline v/as substituted for serum in 
commercial single-assay vials used for the determination 
of serum enzyme activities.
Table III opposite
Normal ranges in serum of enzymes (in i.u./l at 25°C) 
and of electrolytes (in mequiv/1) determined previously 
by other workers.
TABLE I
CONTAMINATION BLANK VALUES (Multiple-assay kits) 
Assay Catalogue No. Contamination
CPK-Bg 13926 11.66, 
8.46,
9.33, 3.23 (3 
6.71 (2 kits,
kits, same 
same batch
batch 
no. )
ALD 13974 0.43, 0.39 (2 kits. same batch no. )
GOT 13923 2.14
GPT 13923 1.01
LDH 13977 Nil
PK 13983 Fil
TABLE II
CONTAMINATION BLANK VALUES (Single-assay vials, boxes of 20) 
Assay Catalogue No* Mean Recorded range Mean ± 2 S.D.
CPK-Bg 13970 2.13 0 .4 2 - 4.18
3.08 1.25 - 6.06
GOT 13364 1.45 0.51 - 2.23
GPT 15563 1.71 1.18 - 2.70
LDH 13561 7.55 2.99 23.43
TABLE III
NORMAL RANGES
Assay Normal males Normal females
Na+ 135.10 - 143.33 135.20 1 4 4.44
K+ 3.35 - 4.61 3.71 - 4 .7 2
ALD 1.07 - 2.34 0.81 •m 2 .2 7
LDH 95.17 - 166.13 80.16 — 178 .26
GOT 6.90 - 13.47 6.78 12.61
GPT 3.12 - 23.36 4.40 - 1 5 .9 5
y-GT 4.20 - 31.19 2.73 16.97
Aik P 63 — 160 41 — 154
0 - 4.30
0.96 - 3.21
0 .7 1 - 2.16
0.94 - 2.48
0 - 17.36
\ di 
/ b£
fferent 
atch nos.
(Hausamen et al.,1967)
4-Yo.
In small laboratories where CPK Is rarely requested, however, 
boxes of 20 lyophilised single-assay vials (Boehringer) are used 
instead of raultiple-assay kits. Since a saline blank in such a 
vial distorts conditions for subsequent serum assay, it might be 
assumed no blank is necessary, or that the blank value is the same 
in all vials from the same box and with the same batch number. 
Individual blank values, which varied widely, were nevertheless 
obtained (as above) from each single-assay vial in complete boxes 
of 20 (Table II), and these varying values are greatly multiplied 
if diluted serum is used. In GOT and GPT the contamination is 
small, with little variation between vials, and presents no 
problem; but blank values from the inexplicable LDH vials, which 
contain only pyruvate, NADH and phosphate buffer, vary by as many 
as 20 units and might easily influence diagnosis in the anginal 
infarct seen too late for other enzymes. In CPK, however, even 
a few units above or below the female upper limit (Table IV) may 
confirm or deny a high risk of the carrier state for females in 
pedigrees of DMD; so that an unluckly CPK vial that adds or subtracts 
a random gratuitous 6 units or so might decide a needless abstinence 
from reproduction, or worse, the appearance of dystrophic offspring 
in families falsely reassured. In such circumstances the single- 
assay vials should be avoided and, since CPK survives overnight 
posting in a filled tube of clotted blood (Sweetin and Thomson,
1973a), these specimens should be sent to a suitable laboratory 
where the workload justifies use of multiple-assay kits in which 
a constant blank value is readily determined.
Comparative studies of pyruvate kinase and creatine phosphokinase
Table III quotes normal ranges used in this work. Normal values
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in healthy adults (Table IV) show that in both sexes PK and PK-LM, 
each measuring the combined liver and muscle isoenzymes, are very 
similar since a PEP concentration greater than 1 mM affects each 
form only slightly (Tanaka et , 196?a). Similarly PK-Ala (liver 
form inhibited) closely corresponds with PK-M (liver form not active) 
CPK-Bk appears much more sensitive than CPK-Bg, probably due to 
dithiothreitol in the Baker kit being a better CPK activator than 
the glutathione of Boehringer (Warren, 1972; Miyada _et , 1975). 
Further, the female normal range for CPK-Bk was estimated in July 
and again in November; 7 subjects were common to both series and 
17 were not. For those 17, although the means were not signifi­
cantly different betv/een series the variances were**, and in the 
paired observations there v/as a significant correlation* between 
the mean value of, and the signed difference between, July and 
November as tested by non-parametric rank correlation. The 
interpretation of this data is that females with CPK above the 
mean do tend to have higher values in summer than in winter, 
whereas those below the mean tend to have lower values then. A 
similar but opposite finding in males was found not significant.
Such markedly seasonal sex differences are difficult to explain 
and provide yet another complication in the detection of DMD 
carriers. Normal AKI is small in both sexes.
Significant sex differences (Table V) occur only in values of 
serum enzymes originating in muscle (PK-Ala, PK-M, % alanine 
inhibition), with very large increases in male CPK, particularly 
in November. In females arranged in 3 groups according to the 
stage of their menstrual cycle (Table VI) the means for post­
menopausal women were higher than the others, though not signifi­
cantly so, perhaps due to the known decline of ovarian oestrogens.
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Table IV opposite
Levels of serum enzymes (in i.u. /I at 23°G) determined 
in 24 normal males (aged 18 to 62 years) and 24 normal 
females (aged 1? to 66 years).
TABLE IV 
NORMAL VALUES
Sex Assay Mean Standard Recorded range Mean ± 2 S.D.
Male PK
PK-LM
PK-Ala 
PK-M
% alanine inhibn.
Ratio PK-M/PK-LM
CPK-Bg (July).
CPK-Bk (July)
CPK-Bk (Nov.)
AKI (Nov.)
Nett CPK-Bk (Nov.) 47.02
17.55
deviation
4.09 9.37 - 2 5 .1 9 9.36 2 5 .7 3
18.62 4.48 10.24 - 2 7 .8 0 9 .66 - 2 7 .5 8
11.69 2 .8 1 6.-38 - 1 8 .2 9 6 .0 6 M3 1 7 .3 1
10.43 2.76 4 .6 0  - 1 5 .6 8 4 .9 1 - 1 5 .9 5
33.19 5.68 22.83 - 4 3 .4 9 21.83 4 4 .5 5
0.56 0.07 0.44 “ 0 .6 9 0.43 - 0 ,6 9
35.97 1 4 .0 1 17.78 - 6 9 .6 8 7 .9 5 - 6 3 .9 9
44.54 16.31 2 1 .4 6 — 8 1 .4 0 1 1 .9 2 77.16
47.46 22.02 20.23 - 96.45 3 .4 2 » 9 1 .5 1
0.44 0.46 0 1.73 0 1.36
22.00 1 8 .5 0 - 96.20 3 .0 1 9 1 .0 4
PK 1 5 .5 3 3 .1 9 9 .4 1 1 9 .4 4 9.16 ■— 2 1 .9 0
PK-LM 1 6 .4 2 3.42 9 .7 2 — 2 4 .1 4 9 .5 8 — 2 3 .2 6
PK-Ala 9 .4 5 1 .9 9 5 .4 3 1 3 .4 8 5 .4 8 1 3 .4 3
PK-M 8.64 1 .8 5 4 .8 1 — 1 3 .5 9 4 .9 4 — 1 2 .3 4
% alanine inhibn. 38.72 8 .0 3 2 5 .0 0 nn 5 4 .2 7 22.65 5 4 .7 9
Ratio PK-M/PK-LM 0 .5 3 0.08 0.34 — 0.66 0.36 — 0 .6 9
CPK-Bg (July) 2 1 .0 9 1 0 .7 2 1 .1 7 — 45.48 0 - 4 2 .5 2
CPK-Bk (July) 2 7 .3 7 1 1 .9 0 3 .7 0 CBi 53.28 3 .5 7 5 1 .1 7
CPK-Bk (Nov. ) 2 4 .0 6 6 .2 7 1 4 .5 5 “ 3 4 .2 9 1 1 .5 2 — 36.60
AKI (Nov.) 0 .5 3 0.56 0 1.48 0 !• 66
Nett CPK-Bk (Nov.) 2 3 .5 3 6.38 1 4 .3 1 - 3 4 .0 4 1 0 .7 7 — 36.29
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Table V opposite
Percentage differences in mean serum enzyme activities 
between the normal males and normal females shown in 
Table IV. In each case the difference is shown as a 
percentage of the level in females.
Table VI opposite
Comparisons of the mean serum enzyme activities (in i.u./l 
at 25°C) of the normal females shown in Table IV grouped 
according to the stage of their menstrual cycles.
TABLE V
% DIFFERENCES OF MALE FROM FEMALE MEANS
PK
PK-LM
PK-Ala
PK-M
% alanine inhibn. 
Ratio PK-M/PK-LM
CPK-Bg (July)
CPK-Bk (July) 
CPK-Bk (Nov.)
AKI (Nov.)
Nett CPK-Bk (Nov.)
+12.40
+1 3 .3 9
+23.63 ** 
+20.-65 *
-1 4 .2 8 ** 
+5 .6 6
+70.-56 ***
+62.75 *** 
+97.53 ***
- 22.22 
+9 9 .7 9 ***
TABLE VI
MENSTRUAL CYCLE AND MEANS IN NORMAL FEMALES
Stage of cycle Number PK PK-LM PK-Ala PK-M
1- 14 days 14 1 5 .1 8 15 .-71 9 .5 0 8 .7 3
15" 28 days 4 1 4 .9 4 16.38 8 .4 2 8.02
Post-menopausal 6 1 3 .7 4 18.10 1 0 .0 5 8.85
% alanine Ratio CPK-Bg CPK-Bk
inhibn. PK-M/PK-LM (July) (July)
1- 14 days 14 36.88 0 .5 5 1 9 .3 9 2 5 .5 3
15- 28 days 4 4 2 .7 4 0 .5 0 1 8 .5 9 24.67
Post menopausal 6 4 0 .3 3 0 .4 9 26.72 33.46
CPK-Bk AKI Nett CPK--Bk
(Nov.) (Nov.) (Nov.)
1- 14 days 9 2 4 .0 6 0 .5 2 2 3 .5 4
15- 28 days 7 23.65 0.56 2 3 .0 8
Post-menopausal 8 2 4 .4 2 0 .5 2 2 3 .9 0
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Sweetin and Thomson (1973a) did, in fact, find this difference 
significant for certain enzymes, and dearth of these hormones in 
males, together with the larger muscle bulk, may explain the sex 
differences noted. All modalities of PK correlate very highly in 
males (Table VII) but slightly less well in females. The modest 
correlations in males between CPK and PK, better with PK-Ala and 
PK-M than PK and PK-LM, are absent in females except of lov/ 
significance only with the 2 muscle forms; and the more sensitive 
CPK-Bk usually gave a higher correlation. No correlation between 
GPK and AKI could be found in normal subjects.
No relation between age and any serum enzyme value was found 
in either sex (Table VEH) but a small decline of AKI with time of 
day (Table IX) did occur in males. A similar decline of AKI in 
females conflicts with the findings of Juchems e^ (1968) who 
reported that AKI (not inhibited by AMP, however) tended to increase 
at night. CPK in females showed a highly significant increase 
with time of day on one occasion in July, and, though the changes 
mentioned may have masked a similar relationship in November, these 
observations tend to confirm late afternoon as the most informative 
time for carrier detection (Thomson, I968). Further, the decline 
with time of day of female % alanine inhibition indicates an 
increasing proportion of muscle PK,
In normal serum stored for 24 hours the activity of all PK 
modalities declined very rapidly at 23^0 (Table X) and only a 
little less rapidly at 4°G. After only 24 hours at these temper­
atures PK and PK-LM declined to only a fraction of their original 
value. Since PK-Ala and PK-M did not decrease so far, the liver 
isoenzyme may be the more labile; and this difference in stability
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Table VII opposite
Correlation matrices between activities of different 
serum enzymes in the groups of normal males and females 
shown in Table IV. This Table is in two halves, an 
upper and a lower, as indicated. The groups in the two 
halves were not identical though some males were common 
to both male groups and some females were common to both 
female groups.
TABLE VII
CORRELATION MATRICES
PK PK-LM PK-Ala PK-M CPK-Bg
Males (22 df)
PK-LM 0.9699***
PK-Ala 0.9263*** 0 .9004***
PK-M 0 .9006*** 0.8933*** 0 .9186***
CPK-Bg (July) 0.3 19 7** 0 .30 3 8** 0 .3 7 1 1** 0.6273***
CPK-Bk (July) 0.3823** 0,5825** 0.6115*** 0.6436*** 0.9720***
Females (22 df)
PK-LM 0 .9450***
PK-Ala 0.7993*** 0.7386***
PK-M 0 .8203*** 0 .7886*** 0 .7991***
CPK-Bg (July) 0 .2 1 3 1 0.2136 0.3758* 0.3768*
CPK-Bk (July) 0 .2 2 3 9 0.2185 0.3515* 0.3919* O.986O***
CPK-Bk (Nov.) AKI (Nov.)
Males (22 df)
AKI (Nov.) 0 .0 4 4 2
Nett CPK-Bk 0.9998*** 0.0233
(Nov. ).
Females (22 df)
AKI (Nov.) -0 .1 5 2 0
Nett CPK-Bk 0.9962*** -0.2371
(Nov.)
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Table VIII opposite
Regressions of serum enzyme activities (E) in i.u./l at 
25°C, on age (A) in years, in the 24 normal males and 
24 normal females shown in Table IV.
TABLE VIII
REGRESSIONS OF SERUM ENZYME VALUES (E) ON AGE (A) (n=24; 22 df)
Maies
PK
PK-LM
PK-Ala
PK-M
% alanine inhibn. 
Ratio PK-M/PK-LM
CPK-Bg (July)
CPK-Bk (July) 
CPK-Bk (Nov.)
AKI (Nov,)
Nett CHI-Bk (Nov.)
Females
PK
PK-LM
PK-Ala
PK-M
% alanine inhibn. 
Ratio PK-PI/PK-LM
CPK-Bg (July)
CPK-Bk (July) 
CPK-Bk (Nov.)
AKI (Nov.)
E = 0.1865 " 5.1296xl0“fA
E = 0.1977 - 5.3907x10~^A
E = 0.1304 - 5.1410x10‘"!’'A
E = 0.1211 - 3.9063x10" 'a
E = 29.9791 + 8.8760x10"^A
E = 0.6217 - 1.7176x10"^A
E = 0.1101 + 3.6636x10 " \
E = 0.1332 + 7.5729x10“J^ A
E = 0.1832 + 2.2934x10"^A
E = 0.0022 - 1.0290xl0"&
E = 0.1810 + 2.3983xlO"^A
E = 0.1302 - 4 .0260x10"&
E = 0.1300 + 1.7666x10 ""A
E = 0.0943 - 9.4320x10 " &
E = 0.0862 - 8.7190x10"^A
E = 36.0262 + 6.6984xlO"&
E = 0.5894 - 1.3900x10"-^A
E 0 .0 2 7 8 + 1.1070x10"^A
E = 0.0312 + 1.4864x10 " &
E = 0.1002 - 6.3990x10"^A
E = 0.0015 + 1,5910x10"^A
Nett CPK-Bk (Nov.) E = O.O988 - 7-9910x10"^A
=0.9365)
=0 .8974)
=1.3969)
=1.6630)
=1.1257)
=1 .9 571)
t=0.5379)
=0.8148)
=0.1883)
=0.4063)
=0.1969)
=0.0765)
=0 .3 1 3 0)
=0.2878)
=0.2 8 5 6)
=0 .4 8 5 2)
=1.1651)
t=1.8782)
=1 .9284)
=0.1335)
=0 .3 7 2 4)
=0.1639)
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Table IX opposite
Regressions of serum enzyme activities (E) in i.u./l at 
25^0 on time of day (T) expressed as minutes after 9.00 a.m. 
in groups of 12 and 24 normal males. For all enzymes 
except CPK-Bk (Nov.), AKI (Nov.) and Nett CPK-Bk (Nov.) 
regressions are shown for two experiments carried out on 
different groups and different days.
TABLE IX
REGRESSIONS OF SERUM ENZYME VALUES (E) 
ON TIME OF DAY (T MINS AFTER 9AM)
Males (n=12; 10 df) 
PK
PK-LM
PK-Ala
PK-M
E = 0 .1 8 1 3 + 0.0851x10
E = 0.1446 + 0.3284x10
E = 0.1938 + 0.0710x10
E = 0 .1 4 5 5 + 0.5670x10
E = O.I2O7 + 0.0422x10 
E = 0 .0 8 2 1 + 0.4296x10
% alanine inhibn. 
Ratio PK-M/PK-LM 
CPK-Bg (July) 
CPK-Bk (July)
E = 0 .1 0 6 2 + 0.1290x10
E = 0 .0 8 9 1 + 0.0346x10
E = 34.1783 " 1.5044x10 
E = 2 7 .9 5 9 4 + 1.9892x10
E = 0 .5 5 0 9 + 0.4084x10'
E = 0 .6 0 2 5 - 1.9310x10'
E = 0 .1 3 1 4 + 0.2109x10
E = 0.0881 + 0 .9319x10
E = 0 .1 8 3 2 + 0 .7257x10  
E = 0.1264 + 1.3946x10
-4
~4
-4
-4
-4
■4
•4,.
“4T
'3
-2
-4
"4
-4
-4
Males (n=24; 22 df)
CPK-Bk (Nov.) E = 0.1800 + 0.4627x10
AKI (Nov.) E = 0 .0 0 3 4 - 0,0607x10
Nett CPK-Bk (Nov.) E = 0.1766 + 0.5235x10
- 4
•4
"4
T
=0.0991)
=0.4518)
=0 .0708)
=0.7874)
=0.0636)
=0.7627)
=0 .2 07 5)
=0.0750)
=0 .0041)
=0 .0499)
=0.0080)
=0.0514)
=0.1870)
=1.0614)
=0 .4 8 7 5)
=1.1669)
t=0.3348)
t=2.3514 *) 
t=0.3801)
Continued,,.
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Table IX (Continued) opposite
Regressions of serum enzyme activities (E) in i.u./l at 
25^C on time of day (T) expressed as minutes after 9.00 a.m. 
in groups of 12 and 24 normal females. For all enzymes 
except CPK-Bk (Nov.), AKI (Nov.) and Nett CPK-Bk (Nov.) 
regressions are shown for two experiments carried out
on different groups and different days.
TABLE IX (Continued)
Females (n-12; 10 df) 
PK E
E
PK-LM
PK-Ala
PK-H
% alanine inhibn.. 
Ratio PK-IVPK-LM 
CPK-Bg- (July) 
CPK-Bk (July)
E
E
E
E
E
E
E
E
E
E
E
E
E
E
Females (n=24; 22 df)
CPK-Bk (Nov.) E =
AKI (Nov.) E =
Nett CPK-Bk (Nov.) E =
0.1547 + 0.4118x10'jj'T 
0.1501 + 0.0907xl0“'^ T
0.1555 + 0.70?9x10“!^ T 
0.1586 + 0.1858x10"'^ !
0.0882 + 0,0624x 10"!‘'T 
0.0746 + 0.6750xl0"^T
0.0745 *»• 0.l652xl0"|‘T 
0.0816 + 0.2126xl0"^T
54.5924 + 1.126lxl0"pT 
49.5600 - 5.8809x10 T
0.5847 - 2.8099xl0"J‘'T 
0.5181 + 0.7217x10"^T
0.0760 » 0.2506xl0"fT 
0.0042 + 2.8729x10~^T
0.1159 - 0.2942xl0”fT 
0.0268 + 5.5146x10"^T
0 .1 0 0 4 - 0.1100xl0“^T
0 .0 0 4 1 - 0.0759xl0"S 
0 .0 9 6 5 - 0.0561x10" ""T
t=0.5572)
t=0.l629)
t=0.9492)
t=0.2925)
t=0.1467)
t=1.7977)
t=0.5950)
t=0.6658)
t=0.8410) 
t=2.9519 *)
t=1.5648)
t=0.4894)
t=0.2594) 
t=4.9657 ***)
t=0.5675) 
t=4.5056 **)
t=0.5015)
t=2.5722 *) 
t=0.0971)
also explains the decrease in % alanine inhibition and the corres­
ponding increase in ratio PK-M/PK-LM. Even at -21.5°C much PK 
activity may be lost after 4 weeks, whereas CPK was comparatively 
stable in the same circumstances (Table XI) and only after 13 weeks 
at -21.5*^0 did its activity decline appreciably in both CPK-Bg and ‘ 
CPK-Bk. Storage for 24 hours at 25°C gave a small reduction in 
CPK activity, allowing overnight mailing of serum before assay, 
though prompt analysis is always preferable, PK, however, is not 
at all suitable for overnight posting, since a large loss of 
activity could bring an otherwise abnormal carrier within the 
normal range, or, as with 3 and 4 in Table X the % alanine inhi­
bition could become spuriously abnormal.
In whole blood stored at 23°C for 24 hours CPK survives well 
(allowing overnight mailing) and may even increase slightly (Table 
XII), especially after chilling for an hour, as if there was slight 
efflux from blood cells containing more CPK than serum. The frank 
efflux of LDH after 24 hours at 23°C usually increased very markedly 
with chilling, though in DMD patient 11 a decrease in serum activity 
after 25^C for 24 hours (with or without a preliminary hour at 1.5^C), 
suggested movement into blood cells from an elevated serum value; 
efflux occurred only after prolonged chilling. In other subjects 
efflux was slight (3 and 9), moderate, or gross (1, 6 and 10) and 
apparently quite individual and independent of sex or health, PK 
efflux was mainly type L, as indicated by the changes in % alanine 
inhibition and ratio M/LM, and was of similar degree to that of 
LDH.
In contrast to LDH (Table XII) PK generally decreased after 
24 hours at 2 5°C, the loss of activity due to its instability
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Table X opposite
Activity of pyruvate kinase (in i.u./l at 25^C) in serum 
separated from clotted blood of 2 normal males and 2 
normail females. In each case the blood was centrifuged 
one hour after being withdrawn. The enzyme activity in 
the serum was then assayed
(a) immediately
0
(b) after storage at 25 C for 24 hours
(c) after storage at 4^0 for 24 hours
(d) after storage at 4^0 for 1 week
(e) after storage at -21.5°C for 24 hours
(f) after storage at -21.5°C for 1 week
(g) after storage at -21.5^0 for 4 weeks.
TABLE X
ENZYME STABILITIES IN STORED NORMAL SERA ~ PYRUVATE KINASE
Procedures: (a) Forthwith (b) 24 hours at 25°C
(g ) 24 hours at 4^0 (d) 1 week at 4°G
(e) 24 hours at -21.5°C (f) 1 week at -21.5°C
(g) 4 weeks at -21.5°G
% inhn « % alanine inhibition; Ratio - Ratio PK-M/PK-LM.
Number Sex Age 
(yrs)
1 M 20.06
M 22.63
Assay (a) (b) (c) (d)
PK 1 7 .0 3 1 3 .1 7 1 3 .0 6 7 .3 2
PK-LM 20.76 1 3 .2 7 1 4 .2 1 7.73
PK-Ala 12.33 1 0 .4 5 10.24 7.00
PK-M 10,66 8 .1 5 9 .2 0 5 .2 3
% inhn 2 7 .6 20.6 21.6 4 .3
Ratio 0 .5 1 0 .6 1 0.65 0,68
(e) (f) (s)
PK 1 6 .5 1 1 4 .5 2 1 3 .7 9
PK-LM 1 7 .4 5 1 6 .4 1 1 5 .4 7
PK-Ala 1 1 .5 0 10.35 9 .5 1
PK-M 1 0 .1 4 8 .1 5 9 .7 2
% inhn 3 0 .1 28.8 • 3 1 .1
Ratio 0.58 0 .5 0 0.63
(a) (b) (c) (d)
PK 1 5 .4 7 12.02 12.22 7 .5 2
PK-LM 1 7 .9 7 1 2 .5 7 13.06 8 .4 7
PK-Ala 1 1 .7 0 9 .4 1 8.88 6 .48
PK-M 9.82 8 .5 7 8 .4 7 5 .9 6
% inlin 2 4 .3 2 1 .7 2 6 .7 1 3 .9
Ratio 0.55 0.67 0 .6 5 0 .7 0
(e) (f) (g)
PK 16.20 1 4 .5 3 1 1 .7 0
PK-LM 1 6 .0 9 1 6 .0 9 12.65
PK-Ala 10.35 8.78 8.99
PK-M 8.99 7 .9 4 8.67
% inlin 36.1 39.6 2 3 .2
Ratio 0.56 0 .4 9 0 .6 9
Continued
TABLE X (Continued) 
Number Sex 
3 F
Age
(yrs)
F
Assay (a) (b) (c) (d)
PK 1 4 .1 1 1 0 .3 5 1 1 .3 9 4 .9 1
PK-LM 16.83 10.97 1 3 .7 9 4 .3 9
PK-Ala 1 0 .4 7 8 .1 5 7 .3 2 3 .4 3
PK-M 8.78 6 .9 0 6 • 06 3 .0 3
% inhn 2 3 .6 21.2 3 5 .8 2 9 .8
Ratio 0 .3 2 0 .6 2 0.44 0 .6 9
(e) (f) (s )
PK 13.38 1 2 .3 3 1 0 .9 7
PK-LM 1 5 .8 8 1 3 .6 9 1 2 .8 3
PK-Ala 9.61 9 .3 0 6 .6 9
PK-M 9 .0 9 7.73 6 .3 8
% inhn 2 8 .1 2 4.6 3 9 .1
Ratio 0 .5 7 0.36 0 .3 1
(a) (b) (c) (d)
PK 1 5 .4 7 1 0 .8 7 11.60 6.58
PK-LM 1 7 .0 3 1 1 .7 0 13.48 5 .8 3
PK-Ala 11.60 9 .0 9 8 .9 9 5 .4 3
PK-M 9 .9 3 7 .7 3 7.63 3.87
% inhn 2 5 .0 16.3 2 2 .3 1 7 .5
Ratio 0 .5 8 0,66 0.37 0.66
(e) (f) (s )
PK 1 3 .7 9 1 3 .6 9 1 1 .9 1
PK-LM 1 6 .6 2 14.63 12.33
PK-Ala 1 0 .0 3 1 0 .5 5 8 .4 7
PK-M 9 .3 0 8 .0 3 3 .0 2
% inhn 2 7 .3 2 2 .9 2 8 .9
Ratio 0.36 0 .5 5 0 .4 1
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Table XI opposite
Activity of creatine phosphokinase (in i.u./l at 23°C) in 
serum separated from the clotted blood of 5 normal males 
and 3 normal females. In each case the blood was 
centrifuged one hour after being withdrawn. The enzyme 
activity in the serum was then assayed
(a) immediately
(b) after storage at 25 for 24 hours
(c) after storage at 1.5% for 24 hours
(d) after storage at -21.5% for 24 hours
(e) after storage at -21.5°G for 1 week
(f) after storage at -21.5% for 4 weeks
(g) after storage at -21.5% for 15 weeks
TABLE XI
ENZYME STABILITIES IN STORED NORMAL SERA - CREATINE PHOSPHOKINASE
Procedures: (a) Forthwith (b) 24 hours at 25^C
(c) 24 hours at 1.5% (d) 24 hours at -21.5%
(e) 1 week at -21.5°C (f) 4 weeks at -21,5°C
(s) 13 weeks at -21,5%
Each value given is the mean of tv/o estimations.
Number Sex Age Assay (a) (b) (c)
(yrs)
1 M 2 0 .4 1 CPK-Bg 4 4 .6 1 43.00 4 0 .8 2
CPK-Bk 5 6 .2 4 5 4 .5 1 5 4 .2 7
(d) (e) (f) (g)
CPK-Bg 4 2 .7 1 4 2 .8 6 44 .*46 43.00
CPK-Bk 5 5 .1 3 54.76 5 2 .4 2 4 9 .4 6
(a) (b) (c)
2 M 2 1 .5 4 CPK-Bg 2 7 .8 4 2 5 .6 6 2 6 .5 3
CPK-Bk 34.16 3 2 .1 9 34.16
(d) (e) (f) (g)
CPK-Bg 23.76 22,74 2 4 .3 4 2 4 .7 8
CPK-Bk 3 2 .6 8 3 2 .9 2 3 3 .4 2 3 0 .0 9
(a) (b) (c)
3 M. 2 3 .1 5 CPK-Bg 23.61 22.16 2 1 .7 2
CPK-Bk 3 0 .3 4 2 8 .2 4 2 7 .7 5
(d) (e) (f) (g)
CPK-Bg 22.16 22.01 2 2 .7 4 18.37
CPK-Bk 2 9 .9 7 29.48 2 9 .4 8 2 5 .2 8
Continued
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TABLE XI (Continued)
Number Sex Age Assay (a) (b) (c)
(yrs)
4 F 21.85 CPK-Bg 26,24 23.32 22.89
CPK-Bk 30.71 29.11 29.11
(d) (e) (f) (g)
CPK-Bg 23.61 24.05 21.43 21.28
CPK-Bk 31.94 28.00 .26.89 27.26
(a) (b) (c)
5 F 27.35 CPK-Bg 13.99 12.24 12.10
CPK-Bk 15.05 14.80 15.42
(d) (e) (f) (s)
CPK-Bg 11.37 10.79 10.64 9.77
CPK-Bk 14.68 14.80 14.92 13.69
(a) (b) (c)
6 F 40.28 CPK-Bg 28.13 27.84 28.57
CPK-Bk 36.75 33.30 33.92
(d) (e) (f) (g)
CPK-Bg 26.97 25.66 24.78 24.78
CPK-Bk 33.35 34.29 32.68 32.56
Table XII opposite
Enzyme activities (in i.u./l at 25°C) in serum separated 
from the clotted blood of 6 healthy subjects (3 male and 
3 female), 3 (female) DMD carriers and 2 (male) DMD 
patients. The blood was subjected to the following 
treatments
(a) allowed to clot at room temperature for one hour 
before centrifugation
(b) stored at 25°C for 24 hours before centrifugation
(c) stored at 1.5% for 1 hour then 2 5 %  for 23 hours 
before centrifugation
(d) stored at 1.5% for 6 hours then 25%  for 18 hours 
before centrifugation
(e) stored at 1.5% for 24 hours before centrifugation 
In each case the enzyme activities of the serum were 
assayed immediately on separation.
TABLE XII
EFFECTS OF CHILLING CLOTTED BLOOD FROM HEALTHY SUBJECTS, 
DMD CARRIERS AND PATIENTS
Procedures: (a) Forthwith (b) 24 hours at 2 5 %
(c) 1 hour at 1,5°C, 23 hours at 25^0
(d) 6 hours at 1.5%> 18 hours at 2 5 %
(e) 24 hours at 1,5%
Assay (a) (b) (c) (d) (e)
No. 1 
Normal
20.94
male
years PK
PK-LM
40.65
42.95
38.35
35.53
65.00
69.60
106.6 
125.0
183.4
2 1 5 .8
PK-Ala
PK-M
31.98
27.48
31.14
24.45
40.55
34.90
58.10
49.12
59.04
6o, 61
% inhn 
Ratio
21.3
0.64
18.8
0.69
37.6
0.50
45.5
0.39
67.8
0.28
CPK-Bg
LDH
221.1
216.1
191.5
226.4
205.5
268.9
202.0
547.9
204.4
549.4
No. 1 20.96 years PK
PK-LM
29.37
30.20
29.37
29.37
38.35
40.96
61.76
69.60
123.8
152.7
PK-Ala
PK-M
24.24
2 0 .8 0
25.08
19.44
27.48
22.36
34.49
31.66
4 8 .2 8
4 2 .0 1
% inhn 
Ratio
17.4
0.69
14.6 
0.66
28.3
0.55
44.2
0.46
61,0
0 .2 8
CPK-Bg
LDH
62.10
140.3
75.22
1 7 1 .2
77*55
226.9
76.38
379.8
7 8 .1 3
3 1 5 .0
No. 2 
Normal
22.84
male
years PK
PK-LM
16.51
17.03
12.54
13.80
15.99
17.87
31.04
38.14
58.73
7 3 .9 9
PK-Ala
PK-M
10.73
10.45
8.67
7.63
10.24
8.99
16.41
14*94
2 0 .0 6
18.60
% inhn 
Ratio
33.5
0.61
30.8
0.57
35.9
0.50
47.1
0.39
65.8
0 .2 5
CPK-Bg
LDH
23.32
91.15
23.61
117.5
22.74
143.3
22.74
231.4
22.74
2 5 5 .7
No. 3 
Normal
23.72
male
years PK
PK-LM
18.81
19.33
17.66
18.18
19.44
18.50
19.44
20.17
21.01
2 2 .8 9
PK-Ala
PK-M
15.36
13.06
13.17
11.27
14.21
12.12
14.74
12.74
1 4 .0 0
10.76
% inhn 
Ratio
18.3
0.68
25.4
0.62
26.9 
0.66
24.2
0.63
33.3
0 .4 7
CPK-Bg
LDH
58.60
155.0
66. l8 
173,7
72.01
179.2
66.18 71.13 
172.7 172.7
Continued ...
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TABLE XII (Continued)
Assay (a) (h) (c) (d) (e)
No. 4 
Normal
27.26
female
years PK
PK-LM
1 5 .1 7
1 5 .0 6
1 0 .8 7
1 0 .1 4
1 3 .7 9
1 4 .0 0
16.83
21,21
3 2 .9 2
4 2 .9 5
PK-Ala
PK-M
8.56
5 .5 5
7.84
6 .2 7
8.88
7 .5 2
1 0 .2 4
8 .7 8
1 5 .0 5
1 2 .2 3
% inhn 
Ratio
36.5
0 .4 1
2 7 .9
0.62
3 5 .6
0 .5 4
39.1
0 .4 1
54.3
0.28
CPK-Bg
LDH
1 2 .5 4
83.05
1 5 .4 5
106.9
1 6 .9 1
1 2 7 .1
1 5 .4 5
165.1
1 5 .4 5
202.1
No. 5 
Normal
4 0 .1 4
female
years PK
PK-LM
1 5 .3 6
1 6 .0 9
1 3 .7 9
1 5 .9 9
1 5 .0 5
1 4 .4 2
1 4 .8 4
1 6 .7 2
1 9 .4 4
2 2 .1 5
PK-Ala
PK-M
1 1 .3 9
8 .9 9
10 .76
7 .7 3
10.03
8 .4 7
8 .5 7
8 .5 7
1 0 .8 7  
10,66
% inhn 
Ratio
2 5 .8
0.56
22.0
0 .4 8
3 3 .3
0 .5 9
4 2 .5
0 .5 1
4 4 .1
0,48
CPK-Bg
LDH
20.12
1 1 0 .9
21.87
1 3 3 .7
2 3 .0 3
1 9 9 .0
2 3 .0 3
1 5 2 .4
2 2 ,7 4
1 4 8 .9
No. 6 
Normal
5 9 .0 9
female
years PK
PK-LM
1 4 .3 2
1 5 .0 2
10.66
1 1 ,5 0
2 5 .0 8
2 9 .6 8
5 0 .9 4
66.88
1 3 1 .0
156.8
PK-Ala
PK-M
8 .1 5
6 .2 7
6 .2 7
5.85
10.87
1 1 .5 0
2 1 .9 5
2 0 .9 0
2 8 ,8 4
36.05
% inhn 
Ratio
43.1
0 .4 2
4 1 .2
0 .5 1
56.7
0 .3 9
5 6 .9
0 .3 1
7 8 .0
0 .2 3
CPK-Bg
LDH
1 1 .9 5
1 9 7 .5
1 1 .3 7
1 8 7 .4
12.24
2 4 5 .1
1 0 .9 3
3 9 3 .7
1 3 .1 2
483.1
No. 6 5 9 .1 5 years PK
PK-LM
2 0 .8 0
2 2 .9 9
10.66
12.65
2 8 .2 2
3 5 .4 3
6 9 .3 9
8 6 .5 3
112.8
1 4 2 .3
PK-Ala
PK-M
1 0 .0 3
8.67
6 .9 0
5 .8 5
1 3 .5 9
1 0 .5 6
2 6 .7 5
2 3 .2 0
3 1 .0 4
29.16
% inhn 
Ratio
5 1 .8
0.38
3 5 .3
0 .4 6
5 1 .2
0 .3 0
61.5
0 .2 7
7 2 .5
0.20
CPK-Bg
LDH
1 3 .1 2
2 3 0 .9
1 5 .1 6
2 0 9 .1
1 5 .4 5
3 0 0 .8
1 7 .4 9
4 5 7 .3
1 7 .4 9  
4 4 0 .6
No. 7 28.59 
DMD carrier ,
years
2s
PK
PK-LM
6 7 .7 2
6 8 .3 4
73.67
70 .85
8 2 .4 5
84.65
81.20
8 6 .5 3
85.57
9 8 .75
PK-Ala
PK-M
6 2 .0 7
5 2 .0 4
5 9 .2 5
52.67
6 3 .9 5
56.43
6 0 ,8 2  
5 3 .3 0
5 8 ,6 3
61.76
% inhn 
Ratio
8.3
0.76
1 9 .6
0 .7 4
2 2 .4
0.67
2 5 .1
0,62
3 1 .5
0.63
CPK-Bg
LDH
5 7 5 .5
258.3
5 7 4 .6
2 7 9 .5
6 2 7 .9
3 0 5 .4
5 9 9 .1
3 5 2 .5
600 .9
3 4 7 .9
M P Continued ..,
TABLE XII (Continued)
DMD carrier Is
No. 9 4 2 .5 4 years PK
DMD carrier 2b; 3s
No, 10 6.88 years
DMD patient 
(Ambulant)
No, 11 12 .3 6 years
DMD patient 
(Ambulant)
Assay (a) (b) (c) (d) (e)
PK
PK-LM
1 0 .9 7
1 1 .9 1
10.66 
12.44
1 3 .3 8
1 7 .5 6
1 9 .4 4
22.63
2 3 .7 7
2 7 .1 7
PK-Ala
PK-M
6 .4 8  
5 .9 6
6 .9 0  
6 .4 8
8 .7 8
8 .7 8
1 1 .2 9
8 .5 7
1 0 .1 9
9.67
% inhn 
Ratio
4 1 .0
0 .3 0
3 5 .3
0 .5 2
3 4 .4
0 .5 0
4 1 .9
0.38
5 7 .1
0 .3 6
CPK-Bg
LDH
11,66 
1 6 9 .6
1 1 .3 7
1 5 0 ,4
1 3 .1 2
1 9 9 .0
11,66
181.3
9 .9 1
164.1
PK-LM
2 3 .9 3
2 3 .3 0
1 8 .2 9
1 9 .0 2
2 2 .2 9  
2 3 .8 6
2 3 .6 9
2 3 .8 6
2 8 .7 4
3 4 .1 4
PK—Ala 
PK-M
1 7 .3 5
1 5 .3 6
1 3 .9 0
12 .23
16.55
1 4 .9 8
1 4 .8 1
1 4 .6 3
1 7 ,4 2
16.20
% inhn 
Ratio
2 7 .5
0.66
2 4 .0  
0 .6 4
2 5 .8
0.63
3 7 .5
0.61
3 9 .4
0 .4 7
CPK-Bg
LDH
1 4 1 .1
1 6 5 .1
1 4 2 .6
1 9 4 .5
1 5 1 .9
2 0 9 .7
1 4 6 .2
2 2 3 .3
1 4 5 .2
223.8
PK
PK-LM
5 3 5 .0
5 3 0 .9
5 3 3 .9
5 3 1 .9
5 5 2 .8
543.4
562.2
5 5 5 .9
5 4 3 .4
5 4 9 .7
PK-Ala
PK-M
4 9 1 .2
4 2 6 .4
4 8 1 .7
4 0 1 ,3
4 9 2 .2
428.5
476.5
420*1
4 2 8 .5
3 9 2 .9
% inhn 
Ratio
8.2
0.80
9 .8
0.75
11.0
0.79
1 5 .2
0.76
21.2
0 .7 1
CPK-Bg
LDH
3358
1291
3408
1377
3528
1493
3495
1681
3723
2350
PK
PK-LM
2 7 0 .6
264.9
2 5 6 .5
278.0
262.8
2 7 0 .7
2 8 1 .6
2 7 9 .0
2 9 8 .9
316.1
PK-Ala
PK-M
2 4 6 .1
1 9 0 .7
2 2 4 .7
2 0 4 .8
2 3 1 .9
1 9 8 .6
2 3 3 .6
1 9 9 .6
2 4 0 ,4
1 9 7 .0
% inhn 
Ratio
9 .1
0 .7 2
1 2 .4
0 .7 4
11.7
0 .7 3
1 7 .1
0 .7 2
1 9 .6
0.62
CPK-Bg
LDH
1673
7 0 3 .9
1759
650.7
1842 
6 6 0 .9
1768
7 2 9 .2
1803
830.7
apparently exceeding any prospective efflux. When chilled, PK 
and PK-LM showed larger increases than other PK modalities, since 
they both measure type M (muscle) and type L (liver and erythrocyte) 
PK. Although the liver and erythrocyte forms have identical 
electrophoretic properties (Etiemble and Biovin, 1976) they are 
kinetically different as liver isoenzyme is activated by fructose 
diphosphate but erythrocyte PK is not (Hess ^  , 1966; Tanaka
et al.) 1967b). Both behave identically, however, under the 
conditions of this assay. As expected, PK-Ala and PK-M show only 
modest increases at 1 . ,  and occasionally none at all of PK-Ala 
(3» 3, 7, 9, 10 and 11) and of PK-M only after prolonged chilling 
(5, 9 and 10). These differences in behavior between PK-Ala and 
PK-M, with the higher value of the former, suggest that PK-M should 
give a more accurate estimation of muscle PK since it shows the 
smallest increment of type L, and since the inhibition of liver 
PK by alanine is far from complete. This individual variation of 
efflux renders delayed assay of any PK modality valueless in DMD 
carrier detection, as for example in normal females 4 and 6 who 
show definite elevations after chilling for 24 hours. Assay of 
PK in serum separated forthwith is therefore obligatory.
Analysis of serum from normal male 1 at his first venepuncture 
gave abnormally high values for all enzymes, due no doubt to a 
vigorous soccer game the previous evening, since severe exercise 
is known to cause enzyme efflux (Griffiths, 1966a). In serum 
obtained a week later all values had returned to normal. In the 
original specimen, the fall in CPK by some 30 units after 24 hours 
at 25%  (20 units after chilling), suggests some movement into 
blood cells from the serum elevation.
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Of 11 known carriers examined (Table XIII, 1-11) 2 were obligate 
(5 and 11) but hitherto always undetectable, in accord with the 
natural distribution of carrier manifestation (Thomson _et al., 
1973b); and though 11 was doubtfully detected by a single, barely 
elevated finding (ratio 0 .7 0 with upper limit 0.69) all other 
readings in both were normal. CPK decisively detected all 9 
remaining DMD carriers (3 to 20 fold elevations), LDH only 3 clearly 
(less than 2 fold elevations) and 4 doubtfully, while PK detected 
3 clearly (about 2 to 6 fold elevations) and 4 very doubtfully, 
with elevations of only a unit or so. PK-LM, PK-M and PK-Ala gave 
similar results in the same individuals, with % alanine inhibition 
and ratio even less effective, detecting 7 (only 2 decisively) and 
3 (only 1 decisively) respectively. Of the 3 possible carriers, 
all values were normal except for the PK modalities in 12, each 
with elevations of only a few units.
Storage of clotted blood for 24 hours at 25°C (Table XIII) 
gave small changes in the already marked CPK elevations of known 
carriers but several marginal elevations of PK, PK-LM and ratio 
M/LM became normal, as did PK and PK-LM of possible carrier 12; 
while LDH behaved quite irregularly. Unlike normal females (Table 
VII), DMD carriers (Table XIII) showed a high correlation between 
serum PK and CPK, suggesting a higher content of muscle isoenzymes. 
LDH correlated only with CPK, though again not in normal, females 
(Sweetin and Thomson, 1973a) and perhaps for the same reason.
In male DMD patients (Table XIH) all values were grossly 
elevated throughout, again with high correlation between CPK and 
PK but of. LDH with neither. Further, the change in CPK after 24 
hours at 23°C (17 and 18) suggests its passage through the blood
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Table XIII opposite
Enzyme activities (in i.u./l at 23%) iu serum from 11 
known (female) DMD carriers, 3 possible (female) DMD 
carriers, 4 (male) DMD patients, 2 (female) BMD carriers 
and 1 (male) BMD patient. Serum was separated from aliquots 
of clotted blood after 1 hour at room temperature and 
(activities given in brackets) from further aliquots kept 
at 2 5 %  for 24 hours before separation.
TABLE XIII
CARRIERS AND PATIENTS: ENZYMES IN SERA FROM. CLOTTED BLOOD SPUN 
FORTHWITH AND (IN BRACKETS) AFTER 24 HOURS AT 2 3 %
Assays; (a) PK (b) PK-LM
(e) % alanine inhibn 
(g) CPK-Bg (h) LDH
(c.) PK-Ala (d) PK-M
(f) Ratio PK-M/PK-LM
No. Age Male
(yrs) relats.
Known DMD carriers 
1 16.38 lb
2 16.90 2b
3 2 1 .4 2 lb
4 28.39 2s
3 3 6 .9 8 2b; Is
6 3 9 .7 7 2ss
7 4 2 .3 1 2b; 3s
(a) (b) (c) (d)
3 1 ,04 3 3 .0 1 2 3 .9 2 2 2 .0 5
(31.25) (28.63) (26.34) (22.68)
(e) (f) (s) (h)
16.5 0.63 1 2 7 .4 132.7
(1 5.1 ) (0 .7 9) (1 3 2.7 ) (144.8)
(a) (b) % ) (d)
1 3 2 .6 1 3 4 .8 1 1 7 .6 106.3
(130.4) (138.3) (116.6) (106.9)
(e) (f) (g) (h)
11.3 0.79 4 7 3 .2 186.4
(10.6) (0.77) (472.3) (1 9 0.9)
(a) (b) (c) (d)
9 8 .4 4 1 0 4 .1 8 4 .0 2 73.87
(8 8.4 1 ) (1 0 4.7) (8 4.0 2) (70.83)
(0) (f) (g) (h)
1 4.6 0 .7 3 8 3 1 .9 3 3 0 .9
(3.0) (0.68) (7 4 3.2 ) (284.1)
(a) (b) (c) (d)
7 2 .7 3 7 1 .48 60,82 32.67
(73.67) (70.85) (39.23) (52.67)
(e) (f) (g) (h)
1 6 .4 0 .7 4 3 7 3 .3 2 3 8 ,3
(19.6) (0 .7 4) (374.6) (279.3)
(a) (b) (c) (d)
10,97 1 1 .9 1 6 .4 8 3 .9 6
(10.66) (12.44) (6 .90) (6 .4 8 )
(e) (f) (g) (h)
4 1 .0 0 .3 0 11.66 169.6
(33.3) (0 .5 2) (11.37) (1 3 0.4 )
(a) (b) (c) (d)
2 7 .6 9 27.38 21.63 1 2 .3 4
(2 7.0 7) (2 6 .44) (22.15) (1 8.9 2)
(e) (f) (g) (h)
2 1 .9 0 .4 6 1 7 6 .7 2 2 5 .9
(18.1) (O.7 2) (1 7 3.8 ) (318.5)
(a) (b) (c) (d)
2 2 .1 5 2 4 .0 4 1 8 .5 0 16.93
(21.33) (2 4.2 4) (17.33) (15.26)
(e) (f) (g) (h)
16.3 0 .7 0 1 3 3 .1 1 7 7 .7
(1 9.4 ) (0.63) (147.8) (169.1)
Continued ..
TABLE XIII (Continued)
No, Age Male
(yrs) relats.
Known DMD carriers 
8 4 6 .2 4 Is
9 5 2 .4 4 2s
10 5 5 .8 7 Is
11 5 5 .1 3 lb; 2s
(a) (b) (c) (d)
26.65 2 7 .6 9 18.39 1 7 .0 3
(21.11) (2 0.90) (15.26) (13.38)
(e) (f) (g) (h)
3 1 .0 0 .6 2 100.3 1 9 2 .4
(27.7) (0 .6 4) (94.17) (158.5)
(a) (b) (c) (d)
3 8 .4 6 4 1 .8 0 3 0 .2 0 2 7 .3 8
(34.69) (38.14) (2 9.2 6) (26.44)
(e) (f) (g) (h)
21.5 0.66 2 8 0 .5 2 3 3 .5
(15.7) (0.69) (2 7 7.8 ) (2 3 7.0 )
(a) (b) (c) (d)
2 3 .2 0 2 5 .1 9 1 5 ,5 7 1 5 .8 8
(21.53) (2 3 ,2 0) (15.57) (15.26)
(e) (f) (g) (b)
3 2 .9 0.62 2 0 4 .7 2 6 9 .4
(2 7.7 ) (0.66) (201.5) (269.9)
(a) (b) (c) (d)
1 3 ,6 9 1 4 .4 2 1 0 .1 4 1 0 ,1 4
(13.59) (1 3.7 9) (11.08) (9.8 2 )
(e) (f) (g) (b)
26.0 0 .7 0 2 6 .5 2 168.1
(18.5) (0.71) (29.45) (169.6)
'): PK/CPK:=0 .8312**;
CPK/LDS= '
PK/LDH= 0.4123;
0.7856**
Possible DMD carriers 
12 11.10 lb
13 36.05 Is
14 4 7 ,4 8 Is
(a)
22.68
(18.50)
(e)
2 4 .9
(14.8)
(a)
12.02
(12.33)
(e)
26.1
(29.7)
(a)
1 2 .9 6
(7 .5 2)
(e)
4^i-. 4
(27.8)
(b)
2 4 .9 8
(19.23)
(f)
0.66
(O.7 0 )
(b)
12.85
(1 4,2 1)
(f)
0.63
(0.45)
(b)
1 9 .75
(8.36)
(f)
0.34
(0 .3 5)
(c)
1 7 .0 3
(1 5,7 8)
(g)
3 2 .9 4
(33.82)
(c)
8.88
(8.67)
Ig)
2 5 .0 7
(30.03)
(c)
7.21
(5.43)
(g)
1 0 .5 0
(1 0 .5 0)
(d)
16.51
(13.38)
(h)
1 8 5 .8
(211.7)
(d)
8 .1 5
(6.38)
(b)
104*3
(1 4 2.8)
(d)
6 .6 9
(2.93)
(b)
1 3 2 .2
(136.7)
Continued , , .
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TABLE XIII(Continued)
No. Age Male
(yrs) relats.
(A = ambulant; W = wheelchair)
DMD patients 
15 6.83 Nil (A)
16 10.22 Nil (W)
17 12.36 2mb (A)
18 14.53 Nil (W)
(a) (b) (c) (d)
694.9 687.6 622.8 542.4
(662.3) (685.5) (600.9) (531.9)
(e) (f) (g) (h)
10.4 0.79 3504 612.7
(1.3) (0.78) (3528) (1337)
W) (b) (c) (d)
158.8 154.6 144.2 140.0
(185.0) (192.3) (179.7) (153.6)
(e) (f) (g) (h)
9.2 0.91 1673 805.2
(2.8) (0.80) (1668) (1529)
(a) (b) (a) (d)
270.7 264.9 246.1 190.7
(256.5) (278.0) (224.7) (204.8
(e) (f) (g) (h)
9.1 0.72 1673 703.9
(12.4) (0.74) (1759) (650.7)
(a) (b) (c) (d)
136.9 137.9 120,2 99.28
(135.9) (136.9) (123.3) (119.1)
(e) (f) (s) (h)
12.-2 0.72 1875 440.6
(9.2) (0.87) (1694) (379.8)
Correlations (2 df): PK/CPK= 0.9536*; PK/LDH= -0.0172
GPK/LDH= -0.2147
BMD carriers (a) (b) (c) (d)
19 18.23 2b 25.08 27.48 1 9 .1 2 17.77
(Known carrier) (21.11) (23.51) (16,93) (15.15)
(e) (f) (g) (h)
23.7 0.65 70.84 196.5
(19.8) (0.64) (69.39) (183.3)
(a) (b) (c) (d)
20 5 1 .7 7 2s 11.81 14.74 9.30 7.73
(Possible carrier) (10.87) (13.75) (7.11) (6.58)
(e) (f) ig) (h)
21.2 0.52 12.82 181.8
(34.6) (0.48) (16.33) (227.8)
BMD patient (a) (b) (c) (d)
21 10.05 lb (A) 597.7 620,7 543.4 458.8
(587.8) (608.2) (528.3) (471.8)
(e) (f) (g) (h)
9.1 0.74 3690 1003
(10.2) (0.78) (3612) (614.0)
Sic
cell membrane, but could equally be due to its adhesion to the cell 
wall. The slowly progressing BMD patient 21 had values similar 
to the youngest DMD patient 15 and, as before, CPK detected BMD 
carrier I9 more confidently than any other reading; on the other 
hand, possible BMD carrier 20 had normal CPK but slight abnormalities 
of % alanine inhibition and LDH,
A technical complexity arose in the assay of serum PK from 
whole blood kept at 2 5% ,  with or without prechilling for 1 or 6 
hours. A considerable reduction in the initial extinction of the 
test mix occurred, dependent on the length of incubation at 25%, 
and presumably caused by a fall in MADE concentration. This seemed 
due to a rise in serum pyruvate, which, in the presence of LDH, is 
rapidly converted to lactate at the expense of added NADH. The 
test mix absorbance in these circumstances would have lost a good 
deal of NADH even before recording could be started.
Contrary to earlier reports (Harano at ai^,1975; Alberts and 
Samaha, 1974) that PK is much more sensitive than CPK, this work 
has shown that CPK is superior. Not. only are its elevations in 
DMD patients and carriers much greater than those of PK but CPK 
is far more stable, allowing overnight posting of sera for CPK 
assay, but not for that of the labile PK. Moreover, the assay of 
PK is more time consuming and complex, as well as being prone to 
complications.
The work of Alberts and Samaha (1974) must come under criticism 
since they reported a striking superiority of PK in carrier detection 
without stating that their detection rate was only 58%, whereas 
Walton and Gardner-Medwin (1974) found that CPK usually gave
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around 70% detection and, in precisely defined circumstances, up 
to 86% (Thomson, 1969&) of carriers tested have been identified.
This contrasts very markedly with their recording a 19% detection 
rate for CPK. It must be assumed, therefore, that their method 
of assay, though nowhere defined, was one of the less sensitive 
of the many available. Harano et al. (1973) also failed to state 
their method of CPK assay and the use of an insensitive procedure 
might explain the inability to find a correlation with PK in DMD 
patients (Table XIII). Their finding that DMD serum contained 
virtually no liver isoenzyme (ratio M/LM of 0,99 and 0% alanine 
inhibition) is also surprising.
Nevertheless, despite all these imperfections, PK modalities 
did show abnormalities in carriers when CPK did not and, if assayed 
forthwith, PK may yet prove to be a valuable adjunct to CPK in DMD 
carrier detection.
Adenylate kinase increment in creatine phosphokinase assay and studies
of enzyme movements in blood cells
The changes in CPK-Bg noted previously were explained by a 
movement of the enzyme across blood cell membranes. It is, however, 
generally assumed that CPK is absent from rbcs (Pennington, 1974;
Blum and Brauman, 1975)» a belief stemming apparently from reports 
that CPK occurs in muscle and myocardium, with small amounts in 
brain and only traces elsewhere (Colombo £t , 1962; Schmidt,
1964; Dawson and Fine, 1967; Smith, 1972). Unfortunately, although 
the CPK content of blood cells was never actually investigated by 
any of these workers, Pennington (1974) and Blum and Brauman (1975) 
may have supposed that this had been done.
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Mueller et (1975) reported that Aik P, if present in 
abnormally high quantities, could depress CPK values. This, in 
conjunction with the action of rbc glutathione reductase to remove 
the CPK-Bg activator glutathione (Weidman, 1973), may further 
explain the CPK-Bg variations found. To clarify the situation a 
study of the behaviour cf clotted blood and serum in healthy subjects 
was carried out. CPK was assayed,using different activators, and 
also Aik P, and LDH to indicate the degree of mechanical haemolysis 
(Table XIV). Aik P was found normal in all subjects, but with 
little change after any procedure except a slight fall in activity 
on haemolysis, apparently indicating little or no blood cell Aik P. 
LDH as expected showed efflux into serum on chilling with additional 
large increases after haemolysis of the LDH-containing blood cells, 
CPK-Bg and CPK-Bk gave comparable results, except in 2 where CPK-Bk 
showed a much larger increase on haemolysis, perhaps due to the 
action of glutathione reductase masking a similar increase in 
CPK-Bg, Several subjects (1, 2, 3, 6, 7 and 8) showed a notable 
fall of CPK values in stored serum compared to the parent whole 
blood similarly treated. Storage as whole blood thus apparently 
preserves CPK-Bg and CPK-Bk, but storage as serum does not. That, 
blood cells are implicated is borne out by the increase in CPK 
activity after haemolysis. In unhaemolysed serum the type of 
activator had little effect on CPK values, nor were they influenced 
by those of Aik P, a finding confirmed by Wearne ^  (1975) and
Tsung (1976) although Wearne et ab. (1975) did find a "spurious 
CPK isoenzyme" on electrophoresis still active even when CP was 
omitted from the assay mix. This activity could only be due to 
AK converting excess ADP to AMP and ATP, of which the last then 
assayed as CPK to give an AK increment (AKI). Both CPK-Bg and 
CPK-Bk have added AMP to inhibit AK but apparently inhibition is
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Table XIV opposite
Enzyme activities (in i.u./l at 25%) in serum separated 
from the clotted blood of 9 healthy subjects ( 3 male 
and 6 female) after the following procedures
(a) separation after being allowed to clot at room tem­
perature for 1 hour
(b) separation after storage at 25^0 for 24 hours
(c) separation after storage at 1,5^G for 1 hour and 25^G
for 23 hours
(d) separation after storage at 1.5^C for 6 hours and 
25^0 for 18 hours
(e) separation after storage at 1.5°C for 24 hours
(f) separation after storage at 1.5°C for 24 hours and
subjection to 1 minute of vortex mixing to disrupt the 
blood cells
The additional activities given in brackets in columns
(b), (c), (d) and (e) are those of an aliquot of serum 
separated after blood was allowed to clot at room tem­
perature for 1 hour but before being subjected to the 
respective storage procedures. Each CPK activity given 
is the mean of two estimations.
TABLE XIV
BEHAViaR OF CLOTTED BLOOD AND (IN BRACKETS) SERUM FROM HEALTHY SUBJECTS
Procedures: (a) Forthwith (h) 24 hours at 25°C
(c) 1 hour at 1.5%, 23 hours at 25°C
(d) 6 hours at 1.5%, 18 hours at 25°C
(e) 24 hours at 1.5°C
(f) 24 hours at 1.5^C, 1 min. in vortex mixer to haemolyse
Each CPK value given is the mean of two estimations.
No, Age Assay 
(yrs)
Males (a) (h) (c) (d) (e) (f)
1 19*53 CPK-Bg 27.84 28.86 28.28 27.70 29.43 51.78
41.32 
105.3
224.8
47.67 
64.87
117.8 
322.1
33.38 
47.24 
43.23
415.8
Females
4 2 7 .3 3 CPK-Bg 1 3 .9 9 11.57 1 2 .9 7 1 3 .9 9 12.39 2 0 .9 9
32.07 
5 3 .4 6
40.67
8 4 .1 3
(a) (h) (c) (d) (e)
CPK--Bg 2 7 .84 28. 86 2 7. 9. 5
(2 5.66) (25. 66) (2 7 .26 ) (2 6.53)
CPK-*Bk 3 4 .16 3 4 .66 35. 27 3 5 .89 3 7 .49
(32. 1 9) (28. 9 8) (32. 56) (34. 16)
Alk P 128. 4 126. 4 128. 4 1 2 7.7 122. 1
(120. 8) (123. 8) (121. 4) (1 2 3.1)
LDH 106.3 1 5 9.5
CPK--Bg 44.61 4 6 .79 4 6 .79 4 4 .46 4 6 .21
(43. 00) (42. 56) (42. 56) (40. 8 2)
GPK--Bk 56. 24 54. 88 59.•46 57. 44 58. 58
(54. 5 1) (51. 68) (54. 27) (54.2 7 )
Alk P 120. 8 1 2 3.1 116. 5 118. 8 116. 8
(121. 4) (1 1 9.1) (122,4) (116. 2)
LDH 1 3 0.7 1 5 6.5
CPK-■Bg 2 3.61 2 5 .07 2 7.40 2 5.07 24. 18
(22. 24) (22.8 9 ) (20. 89) (21..72)
CPK.-Bk 3 0 .34 3 0 .09 33. 42 3 2 .31 3 4 .90
(28. 24) (28. 6 1) (28.48) (27. 75)
Aik P 4 6 .86 46. 53 4 8 .51 4 8 .84 48. 18
(46, 53) (45. 21) (47. 1 9) (4 4 .55)
LDH 1 2 9.1 236, 0
.- 9 . 9 9
(12, 2 4) (1 3.4 1) (1 3.32) (12. 10)
CPK.-Bk 1 5 ..05 1 4.80 18., 62 1 9.49 16, 16
(14. 80) (13. 6 9) (14.,9 2) (15.,4 2)
Aik P 6 2.04 5 9 .40 60. 06 58.,74 5 9.07
(59. 73) (57.,4 2 ) (6 0.7 2) (59. 73)
CPK.-Bg 28. 13 28.,28 28.,43 26. 53 28. 43
(2 7.84) (2 7.55) (26. 97) (28. 57)
CPK.-Bk 36.,75 3 5 .52 35..89 35. 77 33.,67
(33..3 0 ) (31.,82) (35.,0 3) (33.,9 2)
Aik P 100.,7 101.. 6 9 8.,01 9 6.,03 9 8.,67
(9 6.,69) (94.,38) (96.,0 3) (94.,0 5)
Continued
54a.
TABLE XIV (Continued)
No. Age Assay 
(yrs)
Females 
6 21.85
37.84
8 41.83
5 4 .6 5
(a) (b) (0 ) (d) (e) (f)
CPK-Bg 26.24 2 4 .0 5 2 4 .4 9 2 5 .2 2 26.09 3 4 .4 0
(2 3.3 2 ) (2 2.5 9) (22.74) (2 2.8 9)
CPK-Bk 3 0 .7 1 3 2 .4 4 2 9 .3 5 2 7 .6 3 33.67
(2 9.1 1) (28.49) (28.86) (2 9.1 1)
Aik P 81.18 8 6 .7 9 83.82 83.82 83.82 7 2 .2 7
(83.82) (82.50) (8 2.5 0) (8 1.1 9)
LDH 1 0 3 .8 176.7 6 9 4 .3
CPK-Bg 20.85 1 9 .5 3 1 9 .1 0 1 9 .8 2 18.95 33.06
(15.74) (16.62) (19.68) (17.93)
CPK-Bk 2 4 .5 4 2 4 .1 7 2 4 .5 4 2 4 .4 2 2 4 .3 0 4 1 .1 9
(20.72) (22.57) (2 2.0 8) (2 2.3 2 )
Aik P 1 0 1 .3 102.0 1 0 5 .3 101.0 1 0 3 .0 94.38
(103.0 ) (1 0 3.6 ) (1 0 4.6 ) (99.66)
LDH 108.8 1 3 1 .2 353.9
CPK-Bg 20.12 2 2 .3 0 22.74 2 3 .3 2 2 0 .5 5 2 7 .9 9
(18.66) (2 0.4 1) (19.53) (18.08)
CPK-Bk 2 4 .6 7 2 7 .8 7 2 8 .9 8 2 9 .7 2 2 8 .2 4 3 7 .3 7
(2 4 .3 0 ) (2 4.0 5) (24.67) (2 5.65)
Aik P 8 2 .1 7 8 6 .1 3 8 6 .1 3 8 7 .4 5 87.45 8 1 .8 4
(8 9 .4 5 ) (85.47) (87.12) (84.81)
LDH 6 2 .2 9 8 6 .0 9 2 1 8 .7
CPK-Bg 5 6 .4 1 4 9 .2 7 4 8 .6 9 5 1 .7 5 5 5 .5 4 60.35
(4 9 .4 2 ) (5 1.4 6) (50.87) (51.16)
CPK-Bk 67.46 6 2 .0 7 6 5 .4 9 6 8 .7 0 7 1 .7 8 83.50
(6 5.3 8 ) (65.00) (63.76) (67.97)
Aik P 1 1 2 .9 1 1 8 .4 1 1 7 .2 1 1 5 .2 1 1 9 .3 1 1 4 .8
(116.5) (118.5) (1 1 7.2 ) (113.5)
LDH 1 8 7 .9 2 7 1 .4 488.7
5k I
incomplete; in fact, Szasz. _el (1976a) later showed that with
10 mM AMP there was still 8% of AK activity remaining.
True CPK (nett CPK-Bk) was therefore measured by deducting 
this AKI (Table XV), allowing some clarification of the distribution 
and behaviour of CPK in serum and whole blood, particularly after 
haemolysis. Dithiothreitol was used as the CPK activator instead 
of glutathione vulnerable to erythrocyte glutathione reductase.
Any differences between CPK values in serum from treated whole 
blood and serum separated forthwith, must therefore arise from
blood cells. Thus after 24 hours at 2$°C the value of nett CPK-Bk
in whole blood changed only slightly in most subjects;
3 and 4 showed definite decreases however, though there was no 
comparative treatment of serum, and others (2, 8 and 10) and 
especially DMD patient 11, actually showed a reduction when 
compared with similarly treated serum. Thus blood cells may even 
have allowed uptake of CPK by passage through the intact cell 
membrane. The same treatment also caused slight rises in LDH and 
AKI in most, with a fall in glucose (Danowski, 1941; Eckel ^  ,
1 9 6 6) consumed to fuel the erythrocyte (NaK)-ATPase which retains
k'" and expells Na^ (Glynn, I9 6 8).
Marked increases in AKI and especially LDH occurred in whole
blood after 24 hours at 1.5% (Table XV), with AKI obviously a
major component of the apparent CPK efflux seen previously. The
sparing of glucose at 1,5% was due to failure of the temperature
dependent (NaK)-ATPase (Wood and Beutler, I967), with K^ rising 
+
as Na fell; these values remained unchanged when no blood cells 
were present. Nett CPK-Bk changed little on chilling of whole 
blood except for a slight rise in 4 and a more pronounced increase
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Table XV opposite
Enzyme activities (in i.u./l at 25^0), and concentrations 
of glucose (in mg/lOOml) and electrolytes (in mequiv/1), 
in serum separated from the clotted blood of 6 healthy 
subjects (2 male and 4 female), 3 (female) I)MD carriers,
3 (male) DMD patients, 1 (female) BMD carrier and 1 (male) 
BMD patient, after the following procedures
(a) separation after being allowed to clot at room tem­
perature for 1 hour
(b) separation after storage at 23°C for 24 hours
(c) separation after storage at 1,3°C for 24 hours
(d) separation after storage at 1.3°G for 24 hours and
subjection to 1 minute of vortex mixing to disrupt
the blood cells
The additional activities given in brackets in columns
(b) and (c) are those of an aliquot of serum separated 
after blood was allowed to clot at room temperature for 
1 hour but before being subjected to the respective storage 
procedures. Each CPK or AKI activity given is the mean 
of two estimations.
TABLE XV
BEHAVIOUR OF CLOTTED BLOOD ADD (IN BRACKETS) SERUM FROM 
HEALTHY SUBJECTS, CARRIERS AND PATIENTS
Procedures; (a) Forthwith (h) 24 hours at 25°C (c) 24 hours at 1.5°C
(d) 24 hours at 1.5^C, 1 min. in vortex mixer to haemolyse 
Each CPK and AKI value is the mean of two estimations.
No, Sex Age DMD Assay (a) (b) (c) (d)
(yrs)
1 M 20.72 Nil CPK-Bk 3 4 .4 1 3 5 .7 7 3 6 .5 1 4 5 .8 8
(3 3.4 2 ) (34.53)
AKI 0 .4 9 2 .9 6 3 .9 5 1 0 .9 8
(0.74) (0.49)
Nett CPK-Bk 3 3 .9 2 32.81 3 2 .5 6 3 4 .9 0
(52.68) (34.04)
LDH 1 1 2 .4 1 1 7 .0 1 7 2 .2 3 3 9 .8
(110.4) (1 1 5.5 )
Aik P 112.5 1 2 4 .4 1 1 1 .5 116.2
(II5 .2 ) (116.8)
Glucose 8 9 .5 4 3 6 .4 1 7 5 .5 7 72.36
(8 4.7 3) (8 6.7 9)
Na"*" 140 144 136 135
(1 4 1) (141)
K 4 .3 4 .4 9 .5 1 0 .5
(4.2) (4.3)
2 M 2 4 .1 4 Nil CPK-Bk 8 9 .1 7 8 5 .1 0 8 7 .4 4 9 7 .4 3
(86.83) (8 7.4 4 )
AKI 0 .9 9 1.36 0 .9 9 1 3 .9 4
(1.60) (0.74)
Nett CPK-Bk 88.18 8 3 .7 4 8 6 .4 6 8 3 .5 0
(8 5.2 2) (8 6 .7 0)
LDH 1 5 9 .5 1 7 4 .7 1 7 9 .3 4 2 1 .8
(167.7) (1 5 9.5)
Aik P 70.62 7 1 .9 4 7 0 .9 5 66.00
(71.28) (7 0.2 0)
Glucose 8 4 .0 4 18.32 7 5 .5 7 7 5 .8 0
(8 4.5 0) (84.04)
Na 143 144 137 135
(142) (1 4 2)
K 4 .3 4*4 9 .9 1 1 .3
(4.3) (4.3)
Continued ...
TABLE XV (Continued)
No. Sex Age DMD Assay (a) (b) (c) (d)
(yrs)
3 F 2 7 .6 8 Nil CPK-Bk 2 4 .1 7 18.75 2 1 .7 1 28.86
(1 9.4 9 )
AKI 1 .9 7 1.73 0 .7 4 1 1 .3 9
(0)
Nett CPK-Bk 22.20 1 7 .0 2 2 0 .9 7 1 7 .2 7
(1 9 .4 9 )
LDH 1 0 7 .9 113.4 1 8 2 .8 5 4 5 .9
(110.4)
Aik P 66.66 67.32 66.00 5 9 .0 7
(67.32)
Glucose 106.9 53.36 97 .55 8 9 .5 4
(108.5)
Na 143 144 134 132
(1 4 2)
K*** 3 . 9 3 .6 11.2 1 3 .0
(3.8)
4 F 40.62 Nil CPK-Bk 3 7 .2 3 3 4 .2 9 3 5 .2 7 5 0 .0 7
(31.57)
AKI 1.73 2.22 1 .7 3 1 5 .7 9
(0)
Nett CPK-Bk 3 3 .5 2 3 2 .0 7 33.55 3 4 .2 9
(31.57)
LDH 126.1 1 4 6.4 164 # 1 606.2
(1 2 9.1 )
Aik P 9 9 .0 0 9 8 .5 4 93.39 9 0 .4 2
(96.69)
Glucose 92 .97 39.16 81.75 77.73
(9 0.6 8)
Na"*" 141 144 137 134
(142)
K+ 4 .1 4.1 8.6 1 0 .3
(4.1)
5 F 4 2 .1 4 Nil CPK-Bk 28.61 2 8 .9 8 2 8 .8 6 3 3 .4 2
(26.52) (28.49)
AKI 0 .9 9 1 .4 8 1 .7 3 4 .9 5
(0) (0)
Nett CPK-Bk 27.63 2 7 .5 0 2 7 .1 3 2 8 .4 9
(26.52) (28.49)
LDH 66.8 3 84.06 9 0 .65 1 8 8 .9
(67.86) (61.76)
Aik P 8 1 .8 4 87.43 8 5 .8 0 86 .46
(86.46) (83.49)
Glucose 76.72 28.83 7 1 .2 2 6 3 .0 4
(7 5.3 4 ) (74.88)
Na'*' 142 144 136 133
(142) (1 4 2)
K'*’ 4 .4 4.7 10.4 1 3 .0
(4 .4 ) (4.3)
S U Continued ...
TABLE XV (Continued)
No. Sex Age DMD
(yrs)
6, F 49.43 Nil
Assay (a) (b) (c) (d)
CPK-Bk 13.42 1 4 .6 8 21.83 2 8 .2 4
(12.83) (14.55)
AKI 1.11 1 .9 7 7 .0 5 1 5 .3 4
(0) (0.37)
Nett CPK-Bk 14.31 1 2 .7 0 1 4 .8 0 1 2 .7 0
(12,83) (14.18)
LDH 1 1 9 .0 1 3 2 .9 3 1 1 .9 384.4
(121.0) (108.9)
Aik P 96.03 1 0 4 .9 9 8 .3 4 9 9 .9 9
(94.38) (98.01)
Glucose 94.58 4 6.94 8 4 .0 4 7 5 .1 1
+ (91.60) (95.26)
Na 139 140 132 128
4- (139) (138)
K 4*4 5 .6 12 ..2 1 4 .5
(4.3) (4.4)
CPK-Bk 413.2 4 0 3 .3 439.1 4 4 4 .0
(418.1) (433.5)
AKI 2.47 2 .3 4 4 .0 7 7 .8 9
(2 .9 6) (1.48)
Nett CPK-Bk 410.7 4 0 1 .0 435.0 436.1
(4 1 3.1 ) (432.0)
LDH 1 9 2 .4 2 3 0 .7 339»3 481.1
(2 1 9.0 ) (176.0)
Aik P 83.16 8 4 .4 8 79.53 7 7 .8 8
(7 8.5 4) (78.87)
Glucose 1 0 1 .7 3 1 .8 3 90 ,68 86.10
(101.3) (100.3)
Na 140 141 134 132
-1- (140) (139)
K 3.8 3.3 9 .3 10.0
(3.8) (3.8)
CPK-Bk 263.8 2 3 1 .7 2 7 2 .2 2 8 0 .7
(235.2) (267.4)
AKI 2 .5 9 2 .8 4 9 .1 3 2 3 .2 8
(0.99) (3.21)
Nett CPK-Bk 261.2 2 4 8 .9 263.1 2 3 5 .4
(2 5 4.2 ) (264.2)
LDH 1 5 0 .4 2 1 7 .8 3 9 2 .5 6 9 6 .8
(214.7) (I9 0.4 )
Aik P 112.3 1 0 7 .9 1 0 7 .3 9 7 .6 8
(105.9) (1 0 4.0 )
Na^ 142 146 134 129
(139) (I4 0)
K 4.3 . 4.5 1 1 .9 1 4 .4
(4.2) (4.3)
Glucose 9 4 .81 16.95 76.03 6 6 .8 7
(8 9.7 7) (8 1.9 8)
Continued ...
TABLE XV (Continued)
No. Sex Age DMD Assay (a)
(yrs)
9 F 4 7 .0 1 Is CPK-Bk 88.68
AKI 5 .4 5
Nett CPK-Bk 85.25
LDH 1 1 9 .5
Aik P 106.3
Glucose 8 8 .3 2
Na+ 138
K^ 3 .9
10 M 11.06 DMD CPK-Bk 2084
AKI 3 .2 1
Nett CPK-Bk 2081
LDH 8 3 0 .8
Aik P 2 3 7 .4
Glucose 84 .96
Na"*' 140
K"** 3.8
11 M 1 4 .0 3 DMD CPK-Bk 2163
AKI 1 .4 8
Nett CPK-Bk 2162
LDH 334.2
Aik P 2 3 0 .0
Glucose 95 .95
159
K'^  3.8
(b) (0) (d)
93.12 106.2
7 .4 0 1 7 .2 7
8 5 .7 2 8 8 .9 2
263.8 5 1 4 .5
1 0 1 .0 93 .7 2
80.84 7 0 .5 3
127 122
1 4 .4 1 8 .2
1962 2237 2193
(2039) (2 0 5 4)
3 .5 8 8.39 3 4 .2 9
(2 .5 9) (2.96)
1958 2229 2159
(2036) (205 1)
8 5 0 .8 1074 1550
(840.6) (845.7)
2 6 4 .0 280.5 260.7
(2 6 7.6 ) (2 69.6 )
2 5 .4 1 65.04 5 7 .9 4
(8 1.0 7) (8 4.2 1)
141 135 132
(139) (139)
4 . 2  9 .1 1 0 .6
(3.8) (3.8)
1935 2179 2160
(2165) (2189)
4 .8 1 1 1 .2 2 3 5 .6 4
(2.71) (2.54)
1930 2168 2124
(2162) (2187)
476.0 9 3 1 .8 1539
(481.1) (471.0)
2 3 8 .9 2 4 1 .2 2 1 1 .2
(2 4 0.6 ) (2 40.6 )
3 1 .8 3 7 9 .6 9 7 6 .7 2
(9 1.6 0) (9 2.5 2)
142 134 130
(1 41) (142)
4 . 1  11.4 1 3 .9
(3 .9) (3.8)
Continued ...
TABLE XV (Continued)
Ko.
12
13
Sex Age 
(yrs)
DMD Assay
M
F
15*3 0 DMD CPK-Bk 
AKI
Nett CPK-Bk
LDH 
Alk P
Glucose
Ha'*’
14 M
K+
BMD
1 8 .9 4 2b CPK-Bk 
AKI
Nett CPK-Bk
LDH 
Alk P
Glucose
Na+
K+
1 0 .7 7 BMD CPK-Bk 
AKI
Nett CPK-Bk
LDH 
Alk P
Glucose
Na+
K+
(a)
5 2 1 .7  
5 .9 2
5 1 5 .8
180.7
18-7.1
1 0 4 .0
139
3.7
67.59
3 .4 4
64.15
1 7 2 .2
76.56
80 .61
139
4.1 
2851
2 .7 1
2849
633.0
208.9
7 6 .5 0
138
4.2
(b) (c) (d)
738.8 753.6
3.35 10.61
735.4 7 4 3 .0
288.1
1 9 9 .7
69.31
4 .9 3
6 4 .3 8
2 4 5 .6
87.78
80.61
139
9 .6
2805
3 .7 0
2801
6 0 5 .7
2 2 5 .7
6 8 .7 0
133
7 .9
523 .6
1 8 8 .4
95 .26 8 7 .4 8
130 128
1 1 .7 1 2 .6
8 5 .7 2
21.-95
63.76
5 1 5 .5
7 2 .2 7
73.28
132
12.1
2807
1 9 .9 8
2787
8 2 0 .4
2 0 3 .0
6 2 .2 9  
131
9 .5
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in 10,. even when compared to simultaneously treated serum, and 
again in 12, though without a serum blank. Mechanical haemolysis 
after chilling then added the intact blood cell contents to serum, 
giving the expected further increase of AKI, LDH and k'*', and with 
carriers and dystrophic patients usually showing greater increases 
in these enzymes than normal individuals, perhaps due to a higher 
blood cell content matching that of serum. In most subjects a 
fall in Na , glucose and a previously unchanged Alk P indicated 
their dilution on haemolysis, and although this sometimes occurred 
with true CPK, several subjects showed virtually no change, whereas 
others (1, 9 and 12 especially), showed a clear increase in nett 
CPK-Bk as if blood cell often contained as much or even more CPK 
than serum.
In a second series of 9 known DMD carriers (Table XVI) nett 
CPK-Bk detected 8 decisively (almost 2 to 50 fold elevations) and
1 barely, but ALD only 3 clearly (3 to 13 fold elevations) and 2
marginally. AKI was slightly elevated in only 4 instances and 
therefore of little use in carrier detection, to be expected due 
to AMP suppression and its irregular release from platelets on 
clotting (Todd ^  , 1964), Further, although CPK and ALD
correlated very highly indeed, there was no correlation between 
either and AKI. A high AKI therefore^ could occur with a marginal 
CPK elevation to give a false carrier diagnosis unless first 
subtracted. True CPK and ALD were grossly elevated in all DMD
patients, but AKI rather less so; even in AK assay without AMP
inhibition the elevations are much less than those of CPK (Kleine 
and Chlond, 1966). CPK and ALD correlated highly, contrary to 
the report of Harano ^  (1973), and AKI only with CPK. Values
in the BMD patient 19 were similar, but even CPK failed to detect
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Table XVI opposite
Enzyme activities (in i.u./l at 25°G) in serum from 9 
(female) DMD carriers, 8 (male) DMD patients, 1 (female) 
BMD carrier, 1 (male) BMD patient, 7 patients with 
hepatitis-A and 2 patients after a myocardial infarction. 
In each case the blood was allowed to clot at room tem­
perature for 1 hour. It was then centrifuged and the 
serum was assayed immediately on separation.
TABLE XVI
CPK, AKI & ALD IN DMD 
MYOCARDIAL INFARCTION
& BMD CARRIERS AND PATIENTS, HEPATITIS-A AND
No. Age Affected CPK-Bk AKI Nett ALD
(yrs) Relatives CPK-Bk
DMD carrier females
1 8* 60 lb 2541 2 .4 7 2538 28.87
2 9 .9 2 2b 1256 1 .7 3 1254 1 4 .4 4
3 2 8 .1 2 lb; Is 1 1 8 .4 0 .7 4 1 1 7 .7 1 .4 8
4 2 9 .1 8 2s 4 1 3 .2 2 .4 7 4 1 0 .7 4 .0 4
5 3 4 .2 8 Is 263.8 2 .5 9 261.2 2.45
6 38.99 Is 53.77 1 .2 3 5 2 .5 4 1 .0 4
7 46.79 2b ; Is 88.06 1 .4 8 86.58 1.86
8 53.16 lb ; 2s 1 0 9 .0 0 .2 5 108.8 1.75
9 5 4 .8 4 Imss; 2mb; 2s 1 9 7 .3 0.74 1 9 6 .6 6 .61
Correlations (7 df): CPK/AKI = 0 .5122
CPK/ALD = 0 .9875 ***
ALD/AKI = 0 .4378
DMD male patients (A = ambulant; W = wheelchair)
10 3.12 lb (A) 1766 2 .7 1 ' 1764 3 2 .3 7
11 3 .2 4 Nil (A) 6882 2 4 .9 1 6857 5 8 .4 1
12 3 .8 2 Nil (A) 4925 4 .1 9 4921 66.74
13 6 .4 1 Imb (A) 4775 4 . 69 4771 6 8 .9 2
14 10.12 Nil (W) 2062 4 .1 9 2058 18.46
15 11.06 Nil (W) 2084 3.21 2081 1 4 .7 1
16 1 2 .3 8 Nil (W) 965.0 3 .9 5 961.0 7 .9 5
17 1 4 .0 3 Nil (W) 2163 1 .4 8 2162 1 4 .9 8
Correlations (6 df) CPK/AKI 
CPK/ALD 
ALD/AKI
= 0.7573 
= 0.8735
= 0.4197
BMD carrier female
18 3 3 .2 3 Is; f 
BMD male patient
3 5 .5 2 0.-74 34.78 2.11
19 10.65 mf 2131 2.22 2129 3 3 .4 1
Hepatitis-A patients GOT GPT
20 8 .4 4 5 .9 2 4 .1 9 1.73 28.28 1141 1553
21 1 1 .4 1 4.93 2 .7 1 2.22 2 .9 1 4 8 .6 0 1 7 9 .1
22 11.56 1 4 .0 6 O ..49 1 3 .5 7 2 .2 7 3 1 .7 3 200.3
23 12.85 16.28 0 .9 9 1 5 .2 9 6 .0 4 1 2 2 .9 6 2 8 .4
24 16.33 9 .6 2 1 .9 3 7.65 2 9 .7 4 6 4 4.6 1754
25 1 8 .0 1 10.61 3 .2 1 7 .4 0 1 9 .2 3 7 8 7 .7 1918
26 2 7 .3 9 7 .8 9 2 .9 6 4 .9 3 26.56 9 0 1 .8 1373
Myocardial infarction
27 4 6 .2 4 5 hours after 7 7 .7 0 0 .9 9 76.71 1.61 8.44 6.08
24 hours after 762.2 2 .9 6 7 5 9 .2 5 .7 4 70.76 16.99
28 5 1 .4 9 12 hours sfter 2 9 9 .5 2 .9 6 2 9 6 .5 1.66 26.44 6 .6 4
his carrier mother 18.
All hepatitis A patients (20-26, Table XVI) had elevated 
aminotransferases and ALD, but only slightly raised AKI. Nett 
CPK-Bk was extremely low, however, and, in all patients but one, 
even below the lowest limit of the normal range (Table IV). The 
presence of a dissociable inhibitor of CPK was therefore investi­
gated, Mixing sera from hepatitis A patients and normal individuals 
gave only the expected CPK activity. Nor was any difference found 
between sera dialysed overnight and control sera, and the dialysate 
had the same effect as saline when used to dilute normal serum.
Frozen hepatitis serum showed no increase in activity when stored 
for up to 4 weeks. Thus these very low CPK values, which seem 
typical of the condition (Thomson, 1971), and may indeed be assoc­
iated with the unusually marked physical weakness of the early 
stages of the disease, may be due to a cold-stable, firmly bound 
inhibitor. In myocardial infarction patients 27 and 28 AKI had 
begun to show only slight elevations 12 hours after the event, and 
other enzyme values were as expected.
Differential centrifugation of heparinised blood from 3 subjects
(Table XVII) enabled some formal assignation of enzyme changes to
+ +rbcs or wbcs. The relatively unchanged Na and K in the wbc 
suspension after chilling and vortex mixing indicates disruption 
of only a small volume of cells, but the large increases in PK 
(comparable to those arising from rbcs, and chiefly of type L 
(subject 2) raising % alanine inhibition and lowering M/LM ratio) 
suggest a very high PK content in the small number of wbcs present.
In contrast LDH increases from wbcs were much more modest compared 
with those from rbcs. There was a slight fall in true CPK (subject 3)
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Table XVII opposite
Enzyme activities (in i,u./l at 25°G), and concentrations 
of glucose (in rag/lOOml) and electrolytes (in mequiv/l), 
in plasma separated from erythrocyte and leucocyte 
suspensions prepared from the blood of 3 healthy subjects 
(1 female and 2 male) as described on P. 25. The plasma 
was separated
(a) immediately after the preparation of the suspensions
(b) after storage of the suspensions at 1.5^C for 24 hours
(c) after storage of the suspensions at 1.5°C for 24 hours 
and subjection to 1 minute of vortex mixing to disrupt 
the blood cells.
TABLE XVII
BLOOD CELL CONTENTS OF HEALTHY SUBJECTS
Procedures: (a). Plasma separated forthwith
(h) 24 hours at 1,5°0, plasma separated 
(c) 24 hours at 1.5^C, 1 min. in vortex mixer to 
disrupt cells, plasma separated
Assay BBC suspension 
(a) (b) (c)
WBC suspension
(a) (h)
No. 1 Female Aged 32.05 years 
PK
PK-LM
PK-Ala 
PK-M
% inhn 
Ratio
CPK-Bg 
CPK-Bk
LDH 
Alk P
Glucose 
Na+
K+
(c)
1 7 .4 5
21.01
18.60
21.84
4 0 .1 3
4 7 .0 3
1 5 .3 6
16.93
18.60 5 2 .1 0
9 .7 2
8.36
8 .2 6  
6 • 06
1 7 .2 4
1 3 .1 7
8 .4 7
8 .0 5
4 4 .3 1
0 ,4 0
55.62
0.28
5 7 .0 3
0.28
45.61
0 .4 8
1 9 .2 4
24.67
1 9 .8 2
2 4 .6 7
3 2 .9 4
4 4 .1 5
1 7 .4 9
2 4 .4 2
1 7 .9 3
2 4 .6 7
1 9 .1 4
2 5 .4 1
91 .15
76.89
1 3 9 .6
7 7 .8 8
3 4 7 .4  
6 4.68
85.08
77 .55
1 0 4 .6 1 7 7 .9
7 0 .9 9
140
4.3
63.66 
133  
1 0 .9
5 5 .8 8
126
1 6 .6
7 7 .4 0
140
4 .2
140
4 .5
140
4.8
No. 2 Male Aged 23.17 years
PK 12 *.44 3 8 .7 7 121.7 12.12 54.18
PK-LM 13.69 4 6 .5 0 1 4 4 .7 12.96 7 4 .0 4
PK-Ala 8 .5 7 1 2 .9 6 5 0 .6 8 8 .1 5 2 3 .2 5
PK-M 8 .1 5 1 2 .4 4 3 0 .3 1 8.26 1 9 .2 3
% inhn 3 1 .0 9 66 .58 5 8 .3 7 3 2 .7 5 5 7 .0 9
Ratio 0.60 0 .2 7 0.21 0 .64 0.26
CPK-Bg 2 2 .4 5 2 0 .4 1 1 0 5 .8 2 2 .4 5 2 1 .8 7
CPK-Bk 2 4 .1 7 27.87 1 2 6 .8 2 4 .6 7 2 7 .2 6
LDH 
Alk P
Glucose 
+Na
K+
1 7 9 .8 188.4 1117 1 4 8 .4 274.7
4 5 .2 1 46.53 3 7 .9 5 4 5 .5 4 4 4 .7 2
6 3 .2 0 5 5 .4 2 4 6 .2 6 65.95 62.06
140 137 124 139 139
4.0 7.2 1 5 .6 4 . 0 4.4
Continued
TABLE XVII (Continued) 
Assay BBC suspension 
(a) (b)
No. 3 Male Aged 23.27 years
(c)
WBC suspension
(a) (b) (c)
PK
PK-LM
1 4 .4 2
1 3 .7 9
2 5 .8 1
3 3 .0 2
9 3 .5 3
122.8
12,75
1 4 .7 4
12.12 6 9 .7 0
PK-Ala
PK-M
9 .9 3
8 .1 5
8.88
1 0 .0 3
1 8 .2 9
2 4 .0 4
9 .0 9
8.88
% inhn 
Ratio
31.16
0 .3 9
6 5 .5 9
0 .3 0
8 0 .4 5
0.20
28.69
0.60
CPK-Bg
CPK-Bk
18.08
28.86
1 5 .7 4
2 6 .1 5
1 4 5 .8
1 7 6 .8
1 8 .0 8
28.86
1 8 .0 8
2 6 .7 2
1 9 .6 8
26.89
AKI
Nett CPK-Bk
1 .7 3
2 7 .1 3
0 .9 9
2 5 .1 6
1 4 5 .5
30.83
0 .7 4
2 8 .1 2
0 .4 1
2 6 .3 1
1.11
2 5 .7 8
LDH 
Alk P
1 0 7 .4
56.76
2 5 2 .2
6 0 .7 2
1808
3 3 .6 6
1 0 9 .9
5 4 .4 5
122.0
5 5 .9 9
3 5 1 .9
58.41
Glucose
Na+
K+
7 0 .3 0
138
4 .3
6 7 .3 2
135
6 .3
67.37
125
1 7 .7
7 6 .7 2
140
4 .3
7 4 .8 8
140
4.6
74.08
142
4 . 9
on cell disruption as if absent from wbcs and the disparity between
CPK-Bg and CPK-Bk (without AKI subtraction) in 2 may again be due
to the action of glutathione reductase. After the same procedures
+ +with the rbc suspension large changes were noted in Na and K , 
greater than previously found where cells are protected by incorp­
oration in a clot, and indicating considerable cell disruption.
The very large increases of LDH and PK, chiefly the liver form 
as in wbcs, likewise found in males 2 and 3 were not so marked in 
female 1. Both CPK-Bg and CPK-Bk showed marked elevations, again 
in males, but most of this was caused by AKI (subject 3)» confirming 
the work of Todd ^  al. (19&4) who found that rbcs had 30 times 
more AK than leucocytes, even if the far less numerous platelets 
did contain moderate amounts. Nevertheless, although true CPK 
was expected to fall slightly by its absence from rbcs, as did 
Alk P, glucose and Na*, there was instead a 20% rise on haemolysis. 
In whole blood, therefore, changes in serum CPK (nett CPK-Bk), AKI, 
electrolytes and most of those in LDH are demonstrated to arise 
from rbcs, not wbcs, though both cell types can affect serum PK 
values.
This formal determination of the origins of these changes with 
subtraction of AKI to give true CPK, permitted vivo examination 
of enzyme behaviour in whole blood by increasing the serum content 
after severe exercise. Several reports that serum enzymes are not 
elevated after exercise seem to conflict with established evidence 
(Swaiman and Awad, 1964; Forssell et al,, 1973; Galteau ^  al., 
1976), but these workers probably allowed either too little time 
for efflux to occur or else exercised their subjects only submax- 
imally. More substantial studies, however, show that efflux does 
occur after prolonged exercise (Griffiths, 1966a; Shapiro et ,
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1 9 7 3), after a time-lapse from the end of a short period of exercise 
(Nuttall and Jones, 1968; King at al., 1976), and after indications 
of marked depletion of ATP (Thomson at , 1973&), Table XVIII 
shows that serum separated forthwith - procedure (a) - from blood 
taken on successive days after a severe evening training session 
showed little change in electrolytes, glucose or AKI. There was 
a small transient rise in LDH and a much larger prolonged elevation 
in true CPK, the enzyme most sensitive to the effects of exercise 
according to Sanders and Bloor (1975). These increases returned 
to pre-exercise values by day 4 or 5, a decline both Ahlborg and 
Brohult (196 6) and King _et al. (1976) confirmed and found exponential. 
Simultaneous chilling of clotted blood aliquots for 24 hours at 
1.5^G without - procedure (b) - or with - procedure (c) - mechan­
ical haemolysis disclosed the underlying enzyme movements. Both 
these procedures caused very similar changes in Na*, K* and glucose 
on successive days, indicating a similar degree of efflux and of 
cell disruption. Like changes in AKI occurred but far less prec­
isely. The sudden 2 fold increase of rbc LDH, shown by chilling 
and haemolysis on day 1, which returned to normal on day 2, suggests 
rapid incorporation, then release, of effluent muscle LDH. This 
LDH is then presumably cleared from serum by the tissues - Sweetin 
and Thomson (1973b) demonstrated that enzyme clearance may be a 
property of- the normal cell - with rbcs in effect acting to buffer 
the rise in serum LDH, therefore reducing the magnitude of these 
elevations.
After day 1 serum CPK showed small oscillatory changes of (c) 
compared with (b), as if there was continuous movement of CPK 
across the cell membrane in an attempt to attain an equilibrium 
between cells and serum. It seems unlikely that simple membrane
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Table XVIII opposite
Enzyme activities ( in i.u./l at 25^G), and concentration 
of glucose (in rag/100 ml) and electrolytes (in mequiv/l), 
in serum separated from the clotted blood of a healthy 
male before, and on the 5 consecutive days after, a 2 
hour period of severe exercise. Each specimen of whole 
blood was divided into 3 aliquots which were treated as 
follows
(a) allowed to clot at room temperature for 1 hour 
before the serum was separated and analysed
(b) stored at 1.3°C for 24 hours before the serum was 
separated and analysed
(a) stored at 1.3°G for 24 hours and subjected to 1 minute 
of vortex mixing to disrupt the blood cells before 
the serum was separated and analysed 
Each CPK or AKI activity given is the mean of two 
estimations.
TABLE XVIII
EFFECT OF EXERCISE ON SERUM AND BLOOD CELL ENZYMES IN A HEALTHY 
MALE (AGED 23.27 YEARS)
Procedures: (a) Serum separated forthwith
(h) Clotted blood incubated 24 hours 1.5°C, serum separated
(c) Clotted blood incubated 24 hours 1.3^C, 1 min. in 
vortex mixer to haemolyse, serum separated
Days after Procedure CPK-Bk AKI Nett LDH Glue. Na* K*
exercise CPK-Bk
0 (a) 28.63 0 .6 2 2 8 .0 0 1 1 1 .9 8 3 .1 3 145 4 .3
(■b) 30.34 1 .7 3 2 8 .6 1 2 2 1 .8 8 1 .0 7 137 8 .9
(c) 44.28 1 4 .8 0 2 9 .4 8 4 5 4 .7 7 0 .5 3 134 1 1 .7
1 (a) 80.29 0 8 0 .2 9 1 2 5 .1 _88.85 145 3 . 9
(b) 97.06 1 .6 0 95 .46 5 1 7 .0 80,15 138 8 .8
(c) 123.4 36.75 8 8 .6 8 8 8 6 .2 7 3 .9 7 133 1 2 .2
2 (a) 76.71 0 .3 7 76.34 1 3 0 .7 86.56 142 4 .8
(b) 73.51 2 ,5 9 7 0 .9 2 238.0 7 9 .6 9 139 8.6
(c) 8 4 .4 8 11.64 7 2 .6 4 4 5 1 .7 7 0 .0 7 135 1 1 ,4
3 (a) 4 0 .3 3 0 .2 5 4 0 .0 8 1 1 7 .0 8 9 .5 4 142 4 . 4
(b) 44-28 0 .7 4 4 3 .5 4 263.3 82.44 138 8.8
(c) 6 9 .3 1 2 8 .7 4 40.58 518.0 77.86 134 11.6
4- (a) 35.64 2.10 33.55 1 0 9 .4 93.66 141 4 .5
(b) 37.99 6 .0 4 3 1 .9 4 2 2 7 .4 86.10 137 8.5
(c) 5 4 .3 9 1 9 .7 3 3 4 .6 6 4 6 2.3 7 9 .0 0 134 11.6
3 (a) 2 9 .2 3 1.85 27.38 1 0 5 .8 9 0 .68 140 4 .4
(b) 3 0 .5 9 2 .7 1 2 7 .8 7 185.3 9 0 .0 0 136 8.0
(c) 4 2 .8 0 1 5 .9 1 2 6 .8 9 3 9 2 .5 7 3 .5 1 132 1 1 .4
Each CPK and AKI value given is the mean of two estimations.
attachment could explain these observations. On day 1, a marked 
CPK efflux occurred from erythrocytes to serum (b), and simultaneously,
(c) showed that these rbcs, now disrupted, contained less CPK than 
the (b) serum into which the CPK was being discharged, though still 
with a higher content than the (a) serum. This implies that during 
chilling CPK had been actively expelled from rbcs tolerant only of 
equilibrium, and also suggests that serum CPK values had been higher 
previously, a fact that accords well with reports that maximum 
values of CPK in serum are reached some 11 hours after physical 
exertion (Nuttall and Jones, 1968; King ^  al., 1976). Thus rbc 
CPK content responds as delayed but similar changes to those in 
serum; likewise an explanation is found for the prompt emphatic 
response of serum CPK compared with the smaller and slower changes 
of LDH in the same circumstances.
In carrier detection therefore,, if serum CPK is assayed in 
precisely defined conditions (Thomson, 1969b; 1971), with the 
further refinements proposed here, i.e. the use of dithiothreitol 
as CPK activator and the subtraction of AKI from true CPK, then 
the enzyme is undoubtedly far more sensitive and dependable than 
the less stable and more inconvenient PK. This superiority of 
CPK is further enhanced by its relative stability at room temper­
ature in serum and clotted blood allowing overnight posting, which 
is a considerable practical convenience in e.g. population studies.
The AKI deduction removes false elevations due to haemolysis, so 
irredeemable in PK, ALD and LDH. The apparent equivalence of CPK 
in serum and erythrocytes likewise discounts the effect of efflux 
even without visible haemolysis, an ever present but often unsus­
pected risk in these other enzymes present in blood cells in very 
large amounts.
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No doubt still further improvements might be made to the CPK 
assay, AMP, apart from its effect on AK, is said to exert some 
inhibition on CPK itself (Hess at , 1968), thereby reducing 
the assay sensitivity. Diadenosine pentaphosphate (Lienhard and 
Secemski, 1973; Feldhaus et al. , 1975) and fluoride (Rosano et , 
1976) have been suggested as alternative AK inhibitors but, although 
further work on the effect of diadenosine pentaphosphate on CPK 
appears necessary, fluoride inhibits CPK by some 6% (Szasz et , 
1976a). Szasz £t (1976b) report that a compromise between 
inhibition of CPK and AK by using 3 mM AMP seems superior, but use of 
this may be restricted after storage or haemolysis, or for research 
purposes. Rosano ^  al. (1976) state that CPK could be accurately 
measured by the use of a blank correction method, equivilant to 
AKI subtraction but with no AK inhibitor added, and this does, in 
fact, appear to be the only worthwhile suggestion so far.
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CHAPTER IV 
DMD AND PURINE mTABOLISH 
A double-blind trial ; Results
A 16-point scale of physical improvements (Table XIX) emerged
during the double-blind trials of allopurinol, PA3 and PA5* From 
Table XX changes in the clinical status over the three 6 week 
periods can be followed in each patient (the numbering used to 
identify each individual was allocated after the trials were 
completed). In period B restoration of departed functions was 
clearly noted; thus of 8 patients (1-8) taking allopurinol daily 
7 improved clinically and 1 did not, while in the placebo group 
(9-16) 2 improved and 6 did not. Using Fisher's Exact Probability 
Test this marked difference of effect was found to be significant* 
(P = 0 .0406). The mean values of enzymes (Table XXI) in the Z 
improved placebo patients, 9 and 11, were significantly increased 
by over 50% (Table XXIII, GOT* and CPK** respectively) and these, 
along with the small increase of GOT* in 16, were the only enzyme 
elevations increased in period B, CPK* and ALD** did, however, 
fall by about 20% in allopurinol patient 4< In patients 1-8 the 
values of 2(-GT, which occurs in liver but not in muscle (Orlowski 
and Szewczuk, i960) and is a sensitive monitor of liver health 
(Zein and Discombe, 1970), were quite normal indicating specificity 
of gene action and absence of liver damage by allopurinol.
Table XXII gives the mean values of other parameters tested.
Only patients receiving allopurinol showed decreased serum and
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Table XIX opposite
This table was used to determine the clinical status 
of the 16 DMD patients in the double-blind trials of 
allopurinol and procaine adenylates.
TABLE XIX
CLINICAL STATUS OF PATIENTS DURING TRIAL 
Wheelchair - (1) Slumps in wheelchair, unable to hold head up.
(2) Slumps in wheelchair, holds head up.
(3) Sits up unsteadily, kicks feebly with dependent 
leg.
(4) Sits upright confidently, lifts knee from chair 
but cannot raise arms.
(5) Raises both arms above head,
(6) Raises both feet up to seat level of wheelchair.
(7) Can climb up from floor to sit on kitchen chair.
(8) Can climb from kitchen chair to standing up 
unsteadily, both hands gripping nearby furniture.
Ambulant - (9) Frequent collapse due to knees giving way,
prefers being carried to walking,
(10) Walks slowly with rolling gait and very marked 
lordosis, unable to rise from chair unaided.
(11) Rises unaided from chair, but cannot attain 
standing from supine position without help.
(12) Walks less slowly, can stand up from supine 
position only by climbing up furniture.
(13) Stands up from supine position by climbing up 
own legs (Gowers' sign), still walks slowly 
with marked waddle and some lordosis, tires 
quickly and falls often, has sore legs and 
frequent muscle cramps after exertion.
(14) Gan keep up with others walking quickly, minimal 
roll and lordosis, fewer falls and muscle cramps 
after exertion.
(15) Shares prolonged vigorous adventures with friends 
without usual rapid fatigue and sore legs, no 
more falls, minimal Gowers' sign.
(16) Gowers' sign and waddle disappear, normal activity, 
no more muscle cramps after exertion.
Table XX opposite
Changes in clinical status of the 16 DMD patients described 
during the double-blind trials of allopurinol and procaine 
adenylates.
TABLE XX
EFFECTS OF ALLOPURINOL & ADENYLATE 
A = ambulant W = wheelchair
TABLET ALLOCATIONS CLINICAL STATUS CLINICAL
No. Age
(yrs)
Periods on 
allopurinol
Adenylate 
in Period. C
at end 
A
of
B
Period
C
IMPROVEMENT 
B V A C V B
1 (A) 5.06 BC Nil 13 15 16 +
2 (A) 6.67 EG Nil 13 14 15 + +
3 00 8.37 EG Nil 2 3 6 4" +
4 (W) 11.36 BC Nil 1 4 5 f 4-
3 (A) 5.28 BC PA5 12 12 12 0 0
6 (A) 7.74 BC PA5 13 15 16 +
7 (W) 8.31 BC PA5 2 5 5 + 0
8 (W) 13.39 BC PA5 5 7 8 •1*
9 (A) 3.39 C Nil 13 15 15 + 0
10 (A) 7.42 c Nil 11 11 12 0 +
11 (A) 8.38 c Nil 10 11 11 + 0
12 00 14.29 c Nil 5 5 6 0 +
13 (A) 8.31 G PA3 13 13 15 0 +
14 (A) 8.44 C PA3 10 9 12 0
15 ■0 0 10.36 G PA3 2 2 5 0 +
16 0 0 11.99 C PA3 3 3 5 0 +
Table XXI
,-0Serum enzyme activities (in i.u,/l at 25^0) for each of 
the DMD patients shown in Table XX, Each figure is the 
mean of 6 estimations made at weekly intervals throughout 
each period.
TABLE XXI
MEAN VALUES OF ENZYMES FOR EACH 6 WEEK PERIOD
Patient Period Nétt
CPK-Bk
ALD GOT X-GT
1 A 6933 83.39 164.1 3 .6 0
B 7491 97.01 210.1 3.67
G 6471 86.99 1 59 .8 4 .2 6
2 A 3609 49.28 118.8 2 .24
B 4082 54.04 1 4 3.4 2 .34
G 3422 52.64 149.8 2 . 91.
3 A 1677 14.57 27.13 2.77
B 1793 16.43 3 1 .9 1 2 .0 5
C 1660 17.33 36.79 2.34
4 A 1340 10.11 39 .01 5.33
B 1044 7.37 33 .32 4 .3 9
C 1173 7.71 3 9 .37 3 .9 9
5 A 4547 47.92 142 .0 1 .4 5
B 4398 51.82 1 5 7 .8 2.56
C 3670 39.37 132.7 3 .12
6 A 2864 33.42 77 .79 3 .1 5
B 3433 36.28 106.6 2 .7 2
C 2817 30.02 89.65 2 .7 2
7 A 1983 17.29 7 2 .1 9 1 0. 64
B 1734 17.68 7 3 .1 3 1 0 .7 7
C 1440 14.59 70.05 9 .1 8
8 A 1348 14.92 45 .93 3 .4 5
B 1322 13 .96 49.25 3 .13
C 1228 14.63 44 .33 3 .0 9
9 A 2279 4 7 .9 1 92.38 3 .7 7
B 2873 60.25 1 4 6.8 2 .3 2
C 2837 6 4. 83 1 4 2 .1 2 .0 7
10 A 1783 14.98 52.76 2 .7 2
B 2153 18.95 63.92 2.86
C 1966 17.01 52.56 3 .6 6
11 A 1805 1 8 .9 0 4 4 .7 8 3 .4 9
B 2713 24.87 58.29 2 .6 4
G 2369 2 9 .7 6 74.71 2 .80
12 A 1647 1 5 .0 3 4 9 .7 6 2.96
B 1400 1 5 .75 46.37 3 .2 9
C 1689 17.03
Qc
54.78 3.18
Continued .. .
Table XXII opposite
Mean values of serum urate concentration (in rag/lOOml), 
urinary urate and creatinine outputs (in mg/ 2 4  hours), 
manometric performance (height in cm of mercury, see 
P. 33) and time taken to climb the same flight of 10 
stairs (in seconds) for each DMD patient shown in 
Table XX, Each figure is the mean of 6 estimations 
made at weekly intervals throughout each period.
TABLE XXI (Continued)
Patient Period Nett
CPK-Bk
ALD GOT y -GT
15 A 1907 2 4 .9 0 5 3 .4 7 1 .46
B 2096 24.63 60.08 2.56
C 1934 22.66 5 9 .3 0 3 .0 7
14 A 2065 1 7 .8 0 6 6 .8 7 2 .5 6
B 1827 1 7 .0 0 61.94 2.67
C 2073 2 0 .0 5 8 2 .0 9 2 .4 8
15 A 1604 1 5 .7 2 5 2 .8 6 3 .7 7
B 1357 1 4 .0 5 4 5 .5 6 4 .0 7
C 1323 1 4 .7 1 4 6 .8 3 4 .1 5
16 A 1008 9 .1 4 4 2 .0 5 9 .0 5
B 1201 9.62 5 1 .8 4 1 1 .3 1
C 1076 8 .5 1 46.97 7 .3 5
TABLE XXII
MEAN VALUES OF OTHER PARAMETERS FOR EACH 6 WEEK PERIOD
Patient Period Serum 24 hr output Manometry Stai]
urate Urate Creat­ 1 hand Both
inine hands
1 A 3.83 180.7 2 2 1 .7 16.7 9 .8
B 2 .5 8 1 3 5 .7 2 3 4 .1 1 9 .9 8.8
C 2.79 112.3 200..2 2 3 .0 8 .3
2 A 3.88 1 1 9 .8 1 3 5 .7 1 2 .3 1 4 .8
B 2 .9 0 63.97 118.8 16.2 11.8
G 2 .9 2 77.85 126.7 1 9 .7 9 .8
3 A 3 .2 9 236.5 1 9 6 .8 9 .0 18.8
B 2 .4 6 1 9 2 .2 234 .-1 12.3 2 4 .2
C 2.33 162.1 218.3 1 4 .6 2 4.4
4 A 2 .8 9 261.1 1 5 7 .2 11 ..4 2 0 .9
B 2 .0 3 1 9 4 .2 1 7 7 .6 11.3 22,8
C 2.21 2 5 0 .2 2 1 9 .4 1 3 .3 2 2 .5
Continued ,..
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TABLE XXII (Continued)
Patient Period
A
B
G
A
B
C
A
B
C
A
B
C
7
10
11
12
13
14
13
16
A
B
G
A
B
C
A
B
G
A
B
C
A
B
C
A
B
C
A
B
G
A
B
G
Serum
urate
3.03
2.83
3.33
3.21
2.74
3.11
24 hr output 
Urate Creat­
inine
293.1 261.3
243.8 270.3
2 9 6 .6 2 8 7 .5
Manometry 
1 hand Both 
hands
9»7
1 1 .7
1 3 . 4
388.9
310.1
433.6
371.0
436.6
437.7
18.6
22.1
2 9 .4
3 1 .2
33.0
3 7 .1
Stairs
37.8
34.3
36.7
8.3
9 .2
8.8
3.57
2 .9 2
3 .2 3
386.9
263.3
2 7 7 .6
2 1 2.6 
2 2 7 .3  
2 5 0 .0
4.3
6 .1
1 4 .2
1 2 .9
1 3 .9
20.3
3.62
2 .5 7
3 .4 6
3 1 9 .5
2 0 5 .6
2 7 5 .7
3 0 7 .6
3 5 9 .7
338.2
1 4 .3
1 9 .0
2 7 .6
2 5 .0
2 7 .9
34.3
3 .3 6
3.69
2.34
2 0 0 .9
1 3 9 .5
1 2 8 .5
2 2 1 .7
1 7 4 .2
188.9
7.8
1 5 .1
1 9 .1
16.0
1 2 .7
9.1
3.76
3 .4 0
3.20
262.7
2 5 6 .2
2 3 0 .0
2 0 2 .4
1 9 2 .3
2 3 1 .9
1 1 .7
1 3 .5
16.6
7 1 .2
1 0 1 .5
1 0 4 .8
3 .7 0
3 .1 5
2.22
3 1 9 .6
2 5 8 .0
185.9
260.1
2 1 4 .9
2 5 6 .7
1 5 .1
18.3
21.4
53.6
4 2 .5
36.8
4 .0 5
4 .6 0
3 .7 0
3 0 9 .7
369.3
287.4
2 9 5 .2
365.3 
376.6
1 8 .4
2 4 .3
26.7
26.2
2 7 .7
33.4
3 .3 1
3.28
2.81
2 7 7 .6
3 2 7 .5
2 3 6 .3
3 2 2 .4
381.-1
365.3
21.6
2 3 .8
26.8
1 1 .5
10.3
9.2
3.67
3 .8 8
4 .0 9
2 9 3 .6
280.4
2 9 2 .4
2 5 2 .2
2 8 5 .0
2 6 9 .4
1 5 .1
18.7
20.3
28.8
2 9 .9
3 0 .6
3 .0 1
3,43
3.34
3 7 8 .8
3 0 6 .9  
3 3 0 .2
3 1 3 .3  
2 2 4 .9
2 5 3 .3
11.2
12.7
1 3 .7
2 2 .9
2 5 .8
2 4 .7
3.58
3 .1 5
3.33
166.1
189.8
1 5 3 .2
1 0 9 .7
118.8 
112.0
8.3
9 .9
10.2
20.1 
21.3 
2 4.6
U e
urinary output of urate, significant only in some (Table XXIII). 
Interestingly, patient 5, who alone showed no clinical improvement 
on allopurinol, had the smallest drop both in 24 hour urinary and 
in serum, urate. As nearly all patients in period B improved their 
performance on manometry, using 1 and both hands, with most of the 
ambulant boys ascending the stairs more quickly, little information 
was given by these measurements on an individual basis. However, 
although no significant differences were found between the group 
means of enzyme values from period A to B, this comparison proved 
useful when applied elsewhere (Table XXIV). Thus the fall of 
serum*** and urinary*** urate, and the rise of creatinine output*, 
became significant in 1-8 after allopurinol (1-8A v 1-8B), whereas 
no significant changes in these values occurred in the placebo 
group (9-16). Manometry using both hands revealed significant 
mean increases of physical performance in period B, in both allo­
purinol (18.43 up to 21.19***) and placebo (19.27 up to 2 1 .92***) 
groups, with the improvement of the treated group marginally higher. 
Using 1 hand however, the increase did become significant only 
with allopurinol*. As expected, there were no differences between 
the 2 groups in period A (1-8A v 9-16A), while in period B only 
the serum urate*** was significantly different.
In Table XXV the mean percentage differences between periods 
are listed, in order to illustrate better the changes in means. 
These differences are compared to zero (no change occurring) and 
to the mean percentage difference of the other group (1-8 v 9-16). 
In the allopurinol group, serum and 24 hour urinary urate fell** by 
2 6.58% and 2 7.49% respectively, while creatinine output rose by 
8 .73%*, moreover the percentage manual improvement (both hands, 
1 6.75%) was likewise significantly greater** than zero. Manometry
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Table XXIII opposite
Percentage differences, and their significance, between 
the means in periods A and B of each parameter measured 
in the DMD patients shown in Tables XX, XXI and XXII.
TABLE XXIII
SIGNIFICANCE AND PERCENTAGE DIFFERENCE 
OF PERIODS A & B - ENZYMES
BETWEEN INDIVIDUAL MEANS
Patient Nett CPK-Bk ALD GOT ^-GT
1 + 7.70 +1 3 .6 0 +2 8 .0 5 + 1 .6 9
2 +13.11 + 9 .6 7 +2 0 .7 3 + 4.83
3 + 7.00 +1 2 .7 4 +1 7 .6 2 -26.21
4 -22.05 * -2 7 .1 2 ** - 8 .9 5 -1 7 .5 7
5 + 1.12 + 8 .2 8 +11.11 +76.00
6 +20.58 + 8 .5 6 +3 7 .0 1 -1 3 .6 8
7 -11.65 + 2 .2 8 + 1 .2 9 + 1 .26
8 - 1.92 — 6 .4 2 + 7 .2 1 - 8 .61
9 +2 6 .2 0 +2 5 ,7 6 +5 8 .9 1 * -38.58
10 +2 0 .7 4 +2 6 .5 0 +2 1 .1 7 + 4 .96
11 +5 0 .2 9 ** +31.60 +30.16 -2 4 .3 0 **
12 —1 4.99 + 4 .8 1 — 6 .8 2 +1 0 .9 0
13 + 9 .94 - 1 .0 8 +12.35 +7 5 .7 6
14 -1 1 .5 3 - 4 .4 9 - 7 .3 7 + 4 .2 2
15 -1 5 .4 3 -10.64 -13.81 + 7 .8 5
16 +1 9 .1 4 + 5 .3 0 +2 3 .2 9 * +2 4 .9 9 *
- OTHER 
Patient
PARAMETERS 
Serum 24 hr 
Urate Urate
Output
Cr/nine
Manometry 
1 Hand Both Stairs
1 -32.63* -2 4 .9 1 + 5 .6 1 +1 9 .2 6 -1 0.1 7*
2 -55.86** -46.62* -1 2 .5 0 +3 1 .09** -2 0.2 3**
3 -2 5.1 4*** -1 8 .7 4 +18.79 +3 7 .03* +2 8.89**
4 -2 9 .8 8 -2 5 .6 1 +12.95 - 0.74 + 8 .76*
5 - 7 .2 8 -1 6 .1 7 + 3 .4 6 +20.69* - 1.32
6 -1 4 .6 1 -2 0 .2 8 +1 7 .6 8 +1 8 .8 3* + 5 .8 8 +1 0 .01*
7 -18.28* -3 1 .9 4 + 6 .9 1 +4 3 .1 3* + 7 .7 4
8 -2 8 .92*** -3 5 .6 5** +1 6 .9 1 +3 3 .3 3*** +11.67
9 + 3 .5 0 -3 0 .5 7 -2 1 .4 3 +9 2.56** -20.83**
10 - 9 .7 8 - 2 .4 8 - 5 .0 3 +1 5 .3 8 +42.56**
11 -1 4 .8 5 -1 9 .2 9 -1 7 ,3 9 +7 4.67*** +2 1 .00** -2 0.71**
13 - 0.76 +1 7 .9 9 +18.25 +5 1.01* +1 0 .0 4 -1 0.1 5*
14 + 5 .6 9 - 4 .5 1 +1 3 .0 0 +22.68** + 3 .9 1
15 +1 4 .1 6 -1 8.98* -2 8.5 2** +1 3 .0 2 +12.81*
16 -1 2 .1 5 +1 4 .2 5 + 8 .2 5 +1 9 .0 1 + 6.22
12 +1 4 .1 4 +1 9 .2 6 +2 3 .7 5
6 3 Q_
+3 1 .6 7** + 5.60
Table XXIV opposite
Mean values, calculated from Tables XXI and XXII, of 
serum enzyme activities (in i.u./l at 25^0) 
serum urate concentration (in mg/lOOml) _ 
urinary urate and creatinine outputs (in mg/24 hours) 
manometric performance (height in cm of mercury) 
time taken to climb the same 10 stairs (in seconds) 
for the group of DMD patients who received allopurinol 
in period B (nos. 1-8) and for the group who received a 
placebo in period B (nos. 9-16) and the significance of 
the differences between them.
TABLE XXIV
GROUP MEANS FOR PERIODS A & B WITH SIGNIFICANCE OF DIFFERENCES
MEANS Nos. 1-8 Period A
Nos. 9-16 
Period A
Nos. 1-8 
Period B
Nos. 9-K 
Period B
Nett CPK-Bk
ALD
GOT
3042
3 4 .1 1
85.87
1764
2 0 .5 5
56.87
3194
36.82
101.0
1955
2 3 .1 4
66.85
Serum urate 3 .4 2 3 .5 8 2.63 3 .5 7
24 hr output 
Urate
Creatinine
273.3
2 3 2 .0
2 7 6 .1
2 4 7 .1
2 0 1 .3
2 5 7 .3
265 .9
2 4 4.4
Manometry 
1 hand 
Both hands
1 1 .5 0
1 8 .4 3
1 3 .2 6
1 9 .2 7
1 4 .1 7
2 1 .1 9
16.38
21 .92
Stairs 1 7 .1 2 38.08 15.61 41.75
SIGNIFICANCES 1“8(A) V 1-8 (B)
9“16(A) V 
9-16(3)
1-8(A) V 
9“16(a )
1“8(B) V 
9-16(B)
Nett CPK-Bk
ALD
GOT
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Serum urate P<0.001 NS NS PO.OOl
24 hr output 
Urate
Creatinine
P<0.001
PcO.05
NS
NS
NS
NS
NS
NS
Manometry 
1 hand 
Both hands
P<0.05 
P<0. 001
NS
P<0.01
NS
NS
NS
NS
Stairs NS NS NS NS
UT>
Table XXV opposite
Mean changes, calculated from Tables XXIII and XXVI, in 
serum enzyme activities (in i.u,/l at 25^0 ) 
serum urate concentration (in mg/lOOral) 
urinary urate and creatinine outputs (in mg/24 hours) 
manometric performance (height in cm of mercury) 
time taken to climb the same 10 stairs (in seconds) 
in the successive periods of the experiment for each 
group of the DMD patients shown in Table XX. The change 
between periods is expressed in percentage terms for 
each parameter measured. The extreme right hand column
(b) indicates whether the change is significantly 
different between groups, column (a) indicates whether 
the percentage change shown is significantly different 
from zero.
TABLE XXV
MEAN PERCENTAGE DIFFERENCE BETWEEN PERIODS A&B AND B&C
(a) - Significance of difference from 0
(b) » Significance of difference between ...
BETWEEN A&B Nos.
1-8 (a)
Nos,
9"16 (a)
(b)...
(l-8)&(9-l6)
Nett CPK-Bk
ALD
GOT
+ 1.74 
+ 2.97 
+14.26
NS
NS
P<0.05
+1 0 .5 5  
+ 9 .7 2  
+1 4 .74
NS
NS
NS
NS
NS
NS
Serum urate -26.58 P<D.01 - 0.01 NS PCO.OI
24 hr output 
Urate 
Creatinine
“27.49 
+ 8.75
P<0.001
P<0.05
- 3 .0 4
— 1.14
NS
NS
P<0.01
NS
Manometry 
1 hand 
Both hands
+2 6 .3 2
+16.75
P<0.01 
KO. 01
+2 7 .4 8
+2 0 .9 4
P<0.01
NS
NS
NS
Stairs - 5 .4 3 NS — 2 .28 NS NS
BETWEEN B&C Nos.5-8 (a)
Nos.
1—4 (a)
(b)...
(1—4)&(5"8)
Nett CPK-Bk
ALD
GOT
- 1 5 .90 
-1 3 .5 0  
-1 1 .5 0
PcO.0 5
NS
KO. 05
- 6 .2 5
- 0.68 
+ 1.66
NS
NS
NS
NS
NS
NS
Serum urate +1 9 .2 0 PcO.05 + 3 .0 7 NS KO. 05
24 hr output 
Urate 
Creatinine
+ 2 6.63
+ 2.63
NS
NS
+ 4 .40  
+ 2 .2 5
NS
NS
NS
NS
Manometry 
1 hand 
Both hands
+7 0 .4 3
+2 4 .1 1
NS
NS
+1 7 .5 8  
+ 9 .2 7 NS NS
Stairs + 1 .1 3 - -1 1 ,7 5 *“ —
BETWEEN B&C Nos.13-16 (a)
Nos.
9-12 (a)
(b).,.
(9-12)&(13-16)
Nett CPK-Bk
ALD
GOT
- 1 .7 9
+ 0.77 
+ 6 .1 6
NS
NS
NS
- 0.36
+ 6 .2 9
+ 6.34
NS
NS
NS
NS
NS
NS
Serum urate - 1 .5 1 NS -1 9 .4 5 NS NS
24 hr output 
Urate 
Creatinine
- 8.82 
- 0 .5 4
NS
NS
-1 7 .0 6
+1 2 .9 0
P<0.05
NS
NS
NS
Manometry 
1 hand 
Both hands
+1 9 .7 3  
+ 6.40
NS
NS
+10.01
+21.87 P<0.01 PCO, 05
Stairs -11.28 — -12.79 NS
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performance with 1 hand was increased to the same extent in both 
groups, this being the only placebo parameter differing signifi­
cantly from zero. A 14.26%* rise of GOT in the allopurinol group 
was the sole significant enzyme change.
It is difficult to determine if PA3 or PA5 had any perceptible 
clinical effect (Table XX), especially since improvement on allo­
purinol alone continued in period C (1-4). Only 5 showed no 
clinical improvement at all, whereas the rest maintained and even 
improved their progress of period B. The mean values of parameters 
tested in period C are given in Tables XXI and XXII. There was 
no significant percentage difference of individual enzyme means 
between periods B and C in any patient receiving either a PA5 or a 
PA3 placebo (Table XXVI, 1-4 and 9-12), however in those receiving 
PA5 (5-8), CPK* and ALD* in 5, and ALD* alone in 7, decreased by 
about 20%; while PA3 (13-16), GOT* rose in 14. Those on PA5 had 
also increased urate values, whereas PA3 patients showed little 
change, the effects of allopurinol and PA3 presumably being equiv­
alent but opposite. All patients taking PA3, but only 2 placebo 
patients bettered their manometry performance, however.
Comparisons of the PA3 group means (Table XXVII) showed few 
significant changes; with the urate values of 5-8 in period C 
increasing* (B v c) and the creatinine excretion of those receiving 
PA5 being significantly greater* than the placebo group in period 
C, but not in B. The PA5, but not the placebo group, improved 
their performance on manometry using 1** and both* hands. Of the 
PA3 group means (Table XXVIII), in patients receiving allopurinol 
for the first time, only those taking placebo PA3 tablets as well 
showed a fall in serum urate*, with a rise in creatinine output*
64
Table XXVI opposite
Percentage differences, and their significance, between 
the means in periods B and C of each parameter measured 
in the DMD patients shown in Tables XX, XXI and XXII.
TABLE XXVI
SIGNIFICANCE AND PERCENTAGE DIFFERENCE BETWEEN INDIVIDUAL MEANS 
OF PERIODS B & C -  ENZYMES
Patient Nett CPK-Bk ALD GOT %-GT
1 -1 3 .6 2 -10.33 -2 3 .9 2 +29.52
2 -16.17 - 2.60 + 4* 44 +24.16
5 - 7.52 + 5 • 64 +15.29 +14.46
4 +12.32 + 4.57 +10.83 - 9.20
5 -20.18 * -2 4 .0 3 * -1 5 .9 0 +22.08
6 -18.41 -17.25 -1 5 .8 9 0
7 -1 7 .8 5 "17.48 * - 4.21 -14.75
8 - 7.11 + 4.77 - 9.99 - 1.97
9 — 0 • 64 + 7.60 - 3.18 -10.45
10 - 8.74 -10.20 -1 7 .7 8 +28.30
11 -12.66 +1 9 .6 5 +28.17 + 6.14
12 +20.61 + 8.11 +18.14 - 3 .2 9
13 - 7.75 - 8.00 - 1.29 +1 9 .9 7
14 +1 3 .4 8 +17.92 +3 2 .5 3 * - 7.09
15 - 2.46 + 4.71 + 2 .7 9 + 1.99
16 -10.43 -11.56 - 9.41 -35.00
- OTHER PARAMETERS
Patient
Serum
Urate
24 hr
Urate
Output
Cr/nine
1 + 8.01 -1 7 .2 6 -I4 .4 9
2 + 0.62 +2 1 .6 9 + 6.67
3 - 5 .4 9 -1 5 .6 8 - 6 .7 6
4 + 9 .1 4 +28.86 +2 3 .5 7
5 +1 7 .6 9** +2 0 .6 9 + 6 .2 8
6 +1 3 .4 6 +46.30** + 0.26
7 +1 1 .3 2 + 5 .4 2 + 9 .9 5
8 +3 4.3 2*** +3 4 .0 9 - 5.97
Manometry
1 Hand
+18.24
+16.92
Both Stairs
+15.48** - 6.60
+21.65*** -16.90* 
+ 1.03 
-  1.10
+15.00** + 6.80 
+33.21*** +12.37** - 4.55
+1 3 2.9*** +46.10***
+4 5 .17*** +2 2 .98**
9 -36.54* - 7 .8 6 + 8.44 +2 6.52*
10 - 5.77 -1 0 .2 4 +20.59 +22.84*
11 -1 5.95*** -2 7 .9 3 +1 9 .4 7 +10.05 +1 7.3 5***
12 -1 9.54*** -2 2 .1 9 + 3 .1 0 + 9 .9 7 +2 0.78**
13 -1 4.4 7* -2 7 .86** - 4 .1 5 +6 2.1 7*** +12.63***
14 + 5 .4 9 + 4 .2 8 - 5.56 + 8 .92** + 2 .2 3
15 - 2.80 + 7 .5 9 +1 3 .1 3 + 5 .2 9 - 4 .5 1
16 + 5 .7 2 -1 9 .2 9 - 5 .7 1 + 2 .5 2 +1 5 .2 3*
-2 8 .2 9*** 
+ 3 .2 5  
-13.33**
•11.28**
ékd
Table XXVII opposite
Mean values, calculated from Tables XXI and XXII, of 
serum enzyme activities (in i.u./l at 25°G) 
serum urate concentration (in mg/100 ml) 
urinary urate and creatinine outputs (in mg/ 2 4  hours) 
manometric performance (height in cm of mercury) 
time taken to climb the same 10 stairs (in seconds) 
for the group of DMD patients who received allopurinol 
and PA5 in period C (nos. 5-8) and for the group who 
received allopurinol and a placebo in period G (nos, 1-4) 
and the significance of the differences between them.
TABLE XXVII
PA5 GROUP mANS FOR PERIODS B & C  WITH SIGNIFICANCE OF DIFFEI
I'-!EANS Nos. 1-4 Period B
Nos, 3-8 
Period B
Nos. 1-4 
Period C
Nos. 5-8 
Period C
Nett CPK-Bk
ALD
GOT
3603
4 5 .7 1
1 0 3 .2
2782
2 9 .9 4
9 6 .7 0
3182
4 1 .1 7
96.44
2289
2 4 .0 6
84.18
Serum urate 2 .4 9 2,77 2 .5 6 3 .2 9
24 hr output 
Urate
Creatinine
1 4 6 .3
1 9 1 .2
2 5 6 .2
3 2 3 .5
1 5 0 .6
1 9 1 .2
3 2 5 .9
3 2 8 .3
Manometry 
1 hand 
Both hands 1 9 .9 8
1 5 .7 3
21.63 2 2 .4
2 3 .7 3
26.28
Stairs
SIGNIFICANCES 1-4(B) V 1-4(0)
5-8(B) V 
5-8(0)
1-4(B) V 
5-8(5)
1-4(0) V 
5-8(0
Nett CPK-Bk
ALD
GOT
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Serum urate NS P<0.05 NS P<0.05
24 hr output 
Urate
Creatinihe
NS
NS
NS
NS
P<0.05
NS
P<0.05
P<0.05
Manometry 
1 hand 
Both hands NS
P<0. 01 
p<0.05 NS NS
Stairs
Table XXVIII opposite
Mean values, calculated from Tables XXI and XXII, of 
serum enzyme activities (in i.u./l at 25°C) 
serum urate concentration (in mg/100 ml) 
urinary urate and creatinine outputs (in mg/ 2 4  hours) 
manometric performance (height in cm of mercury) 
time taken to climb the same 10 stairs (in seconds) 
for the group of DMD patients v/ho received allopurinol 
and PA5 in period G (nos. 13-16) and for the group who 
received allopurinol and a placebo in period C (nos. 9-12) 
and the significance of the differences between them.
TABLE XXVIII
PA3 GROUP Î4EANS FOR PERIODS B & C WITH SIGNIFICANCE OF DIFFERENCES
MEANS Nos. 9-12 Period B
Nos. 13-16 
Period B
Nos. 9-12 
Period C
Nos. 13-16 
Period C
Nett CPK-Bk
ALD
GOT
2286
2 9 .9 6
78.60
1620
16.33
5 4 .8 6
2220
32.16
8 1 .0 4
1602 
16 .48  
58.80
Serum urate 3 .7 1 3 .4 4 2.87 3 .3 9
24 hr output 
Urate
Creatinine
2 5 5 .8
2 3 6 .7
2 3 9 .1
2 5 2 .5
2 0 8 .0
263.5
2 5 3 .0
2 5 0 .0
Manometry 
1 hand 
Both hands 18.7
1 3 .8
2 5 .2 22.6
1 4 .7
26.7
Stairs 5 2 .2 5 0 .2
SIGNIFICANCES 9-12 (B)v 9-12(0
13-16(B)v 
13-16(0)
9-12 (B)v
13-16(B)
9-12(C)v 
13-16(0)
Nett CPK-Bk
ALD
GOT
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Serum urate p<0.05 NS NS NS
24 hr output 
Urate
Creatinine
NS
P<0.05
NS
NS
NS
NS
NS
NS
Manometry 
1 hand 
Both hands P<0,05
NS
NS NS NS
Stairs NS
Lkc
and manometry performance* (both hands). The percentage differences 
between periods B and C (Table XXV), of CPK* and GOT* in patients 
taking PA5 (5-8) were lower than zero, with the increase in serum 
urate* greater than in the placebos (1-4). With the PA5 groups 
those receiving the placebo performed better with both hands* 
than did those on PA3*
A final comparison of period A with C can give little specific 
information on allopurinol, PA3 or PA5, but it does indicate, 
clinically and biochemically, a general effect of intervention 
in purine metabolism. Thus, in 9 and 11 (Table XXIX), the 2 
patients receiving the placebo in period B who improved clinically, 
but did have increased enzyme elevations, maintained these new 
values, whereas 4 and 7 had decreases of ALD** and CPK* respectively 
2 other patients more than doubled their original 2C-GT values, but 
these elevations were still below the adult normal range (Table 
III), Of the other parameters, many patients showed reduced urate 
values and 4 had a 40% increase*in creatinine output. All patients 
improved their manometry performance, in many instances markedly, 
though in period B several taking only placebo tablets did like­
wise.
The standard deviations and coefficients of variation, calcu­
lated for all parameters in every patient at the end of each 
period, showed completely random non-signifieant changes. Likewise 
the correlation coefficients of CPK/GOT and ALD, and GOT/ALD were 
not si gni fic ant.
12 of the 16 patients, compared with a reported 80% (Emery, 
1972), had values higher than expected by age for the algebraic
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Table XXIX opposite
Percentage differences, and their significance, between 
the means in periods A and C of each parameter measured 
in the DkTD patients shown in Tables XX, XXI and XXII.
TABLE XXIX
SIGNIFICANCE AND PERCENTAGE DIFFERENCE BETWEEN INDIVIDUAL MEANS 
OF PERIODS A & C - ENZYMES
Patient
3
4
3
7
Nett CPK-Bk ALD
-23.79**
-27.45**
GOT %-GT
+35.60***
+114.9*'
9
11
13
+25.39' +35.31* +53.85*
+66.83*
+110.9*
- OTHER PARAMETERS
Serum 
Patient Urate
24 hr Output 
Urate Cr/nine
-37.87*
-2 4.7 7**
-2 9.2 5*** -3 1 .4 8**
+39.57*
Manometry 
1 Hand Both Stairs
+3 7 .72** -16.10**
+59.47*** -33.71***
+6 2.0 3*** +30.22***
+1 6.06* + 7 .5 7*
+3 8 .7 9***
+5 8.3 0*** +1 8 .98***
+2 2 3.3 *** +5 7 .4 1***
+93.56*** +37.33***
9
10
11
12
13
14
15
16
■1 4.98* 
.4 0,02***
.1 5.1 2* -1 4.8 8*
+1 4 3.6*** -4 3.2 3*** 
+4 1.75*** +4 5 .3 5** 
+92.2 3** +4 1 .99*** -3 1 .2 8 * * * 
+4 4.8 0*** +2 7.5 5**
+144.9*** +2 3 .94*** -2 0.2 9*** 
+34.81*** + 6.22*
+2 1.94*
+2 2 .4 1***
sum of the R and S waves in lead VI of the EGG. During periods 
B and C, however, these changed only slightly and at random to 
give no information, in accord with an origin anatomic rather than 
metabolic (Perloff et , 1966).
Discussion
In DMD muscle the full effects of the dystrophic X-chromosome 
performing alone appear as the classically rapid progressive 
wasting towards a fatal issue. Serum CPK elevations in DMD spec­
ifically measure active dystrophic muscle mass and decline expon­
entially at the same rate in both ambulant and wheelchair cases 
with a half-life, estimated by Thomson et (1974)» of 6.63 
years. This value was originally obtained using GPK-Bg but, as 
has already been shown, nett CPK-Bk is much more accurate and when 
assayed in 22 ambulant patients of different ages gave a revised 
linear regression of log (CPK) on age (y = 3-9436 - 5*2529x10””^ .x; 
P<0.01, 20 degrees of freedom) with a half-life of 4.7731 years. 
From serum ALD, likewise elevated in DMD due to muscle efflux 
(Schmidt and Schmidt, 1967), log (ALD) on age (y = 1.9940 - 
5.2516x10"^.x; P<0.001, 38 degrees of freedom) gave a similar 
slope and half-life (t-g- = 4-7763 years). In contrast, log (GOT) 
on age (y = 2.3446 - 4*6742x10 ^.x; P<0.001, 24 degrees of freedom) 
gave a larger half-life of 5*3663 years probably due to the smaller 
contribution of muscle GOT compared to that of liver and heart.
The close identity of the true CPK and ALD half-life indicates 
they may in fact measure the half-life of the decaying muscle mass 
whence these enzyme elevations arise, so that although a DMD 
patient ambulant at 4.8 years has lost 50% of his muscle, he 
reaches the wheelchair at 9-^  years with some 25% still left.
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That functioning muscle survives as long sug^sts that modest 
metabolic support in the appropriate area could enable indefinite 
survival.
In female DMD carriers, however, random fusion of myoblasts 
from clones with one or other X-chromosome already randomly inac­
tivated (Lyon, 1962), gives a mature multinucleated muscle cell 
with a dual population of nuclei regulated by either a normal or 
dystrophic X-chromosome. Different proportions in different 
individuals gives a uniform X-chromosomal mosaic (Emery, 1965) 
with a range of carrier manifestation from the undetectable to 
grossly elevated serum enzymes and minor symptoms, but non-progr­
essive and with normal life expectancy in all but rare instances 
(Thomson at ad., 1975h). The carrier state therefore resembles a 
supported DMD, protected from progression by even a small propor­
tion of normal muscle nuclei.
Thus in the affected muscle cell some limit is implied, beyond 
which, as in DMD, lack of normal nuclei causes eventual cell death 
with clinical progression, and within which, as in the carrier, 
their presence ensures survival by providing essential support 
the DMD nuclei cannot. In DMD patients such provision by other 
means would bring them within this limit to resemble carriers, 
still with marked serum enzyme elevations, but no longer clinically 
progressive.
The serious depletion of total muscle adenine nucleotides 
(Stengel-Rutkowski and Barthelmai, 1973), which may in fact wholly 
explain very many other features of DMD (Thomson ^  a2., 1975b), 
suggests some defect in muscle purine metabolism, either by
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insufficient synthesis or excessive irreversible catabolism to 
urate. In a comparison of 16 DMD patients (period A, mean age 
8 .6 7 years) and 20 normal boys (mean age 9 -32 years), without 
significant difference in age (t = 1.0268; NS, 34 degrees of 
freedom), the urinary urate excretion (2 7 4 -7 and 366.4 mg/24 hours 
respectively) was significantly** lower in DMD. Although no 
similar comparison is possible with serum urate, the same 16 DMD 
patients had a range of 2,6 - 4-7 (mean 3-6) mg/100 ml, whereas 
Harkness and Nicol (1969) found, using plasma from 113 normal 
boys, a range of 1.2 - 6.8 (mean 4 .O) mg/lOO ml. Further, since 
DMD muscle disapears rapidly with increasing age, the lack of 
significance in linear regressions of 24 hour urate excretion on 
age both in 20 normal boys (y = 339-73 + 0.1049.x; NS, 18 degrees of 
freedom) and 16 DMD patients (y = 208.63 + 7*6178.x; NS, I4 degrees 
of freedom), suggests that urinary urate output is independent of 
body muscle mass. Thus, these subnormal urate values suggest 
that the DMD gene may exert its effect by insufficient provision 
of essential muscle purines; and this study tests this hypothesis 
by using allopurinol to promote salvage and recycling of what 
purines may be available. Stevens £t (1973) found an optimal 
concentration of serum urate for human learning and the abnormally 
low values in DMD may partly explain the mental retardation 
sometimes associated with this disease (Dubowita, I9 65). This 
symptom is invariably present in the L^ch-Nyhan syndrome (Le^h 
and Nyhan, I9 6 4) characterised by gross overproduction of urate.
Allopurinol markedly increases salvage of hypoxanthine and 
there are many reports of its administration causing a substantial 
rise of intracellular ATP (Cunningham ^  , 1974; Hopkins _et al. ,
1973; Keaveny et , 1973; Lindsay et , 1973; Manze and
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Dc5rner, 1973)- In. DMD muscle any increase of adenine nucleotide 
content after allopurinol should be accompanied by better function 
of the remaining muscle with appropriate clinical improvement, 
which if maintained must then resemble the non-progressive mani­
festing carrier state. Further clinical progress can only be 
expected if there is regeneration of muscle to replace that 
previously lost, or if the progressive restrictions of shrinking 
fibrous tissue replacement can be dealt with. In health, marked 
serum elevations of muscle enzymes during prolonged severe exertion 
(Griffiths, 1966a) suggest that muscle function, not enzyme 
retention (Thomson _et , 1973a) has prior claims on ATP,
Evidence of increased muscle purine content in DMD, independently 
verifiable at biopsy, should therefore appear primarily as improved 
function with any diminution of enzyme elevations quite secondary 
to this; conversely, over-exertion without increased ATP will 
result in even higher elevations.
This study thus comprises 2 independent parts : periods A and 
B testing allopurinol alone using double-blind techniques, then 
period G likewise testing sublingual PA3 and PA3 superimposed on 
allopurinol. The duration of the study was deliberately brief to 
exclude any effect of increased growth or fibrous contraction with 
age, and because effective metabolic intervention should give 
measurable results within 6 weeks.
A small daily dose of allopurinol did produce a clear and 
significant clinical improvement in DMD patients, further enhanced 
by increased enzyme elevations implying over-exertion in the 2 
placebo patients showing false clinical progress. Though most
other individual serum enzyme elevations changed little, improvement
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in 4 was confirmed by a decline in enzyme values after allopurinol. 
The expected fall of urate occurred as a direct effect of 
allopurinol, and a concomitant rise in hypoxanthine, xanthine and 
probably in muscle ATP, is thereby implied. The increased creat­
inine output, from typically low values, is important as it implies
mass
increased activity in a rauscl^likely to have changed little over 
such a short period. Diet seems to have little effect on urinary 
creatinine output (Van Pilsum and Seljeskog, 1958) which normally 
correlates closely with muscle mass (Ryan ejt al., 1957). Although 
virtually all patients did improve their performance on hand-bulb 
manometry, as if by practice, the allopurinol patients as a group 
improved most.
PA3 superimposed on allopurinol did not offer any obvious 
additional benefit, though the administration of allopurinol for 
the first time to this group, and the small number of patients 
tested makes assessment difficult. However, even though improvement 
on allopurinol continued in period G, PA5 did show an added effect, 
biochemically and physically. Its clinical effect could not, 
however, be measured with refinement using the comparatively large 
steps of Table XIX.
During the final 12 weeks of the trial, 15 of the 16 patients 
showed definite clinical improvement. This assumes particular 
interest since, in a condition characterised by rapidly progressive 
muscular weakness, all improvements attained by period C, which 
occurred in patients at every stage of the disease, have been 
maintained for well over 6 months on the same daily dose of 
allopurinol. In gout, where overproduction of urate occurs, 
allopurinol often, but not invariably (Kelley ejb , 1968), reduces
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the total amount of hypoxanthine, xanthine and urate excreted 
(Wyngaarden et al., 1965; Bundles £t a2., I966). This is presumably 
due to hypoxanthine-guanine phosphoribosyl transferase (inosine 
monophosphate (IMP) : pyrophosphate phosphoribosyltransferase,
E.G. 2.4^2.8.; HGPRT) salvaging the elevated hypoxanthine (Krenitsky 
et al., 1 9 6 9) by its reaction with PRPP to form IMP. Thus, the 
concentration of PRPP, a substrate for glutamine phosphoribosyl- 
pyrophosphate amidotransferase in the initial rate limiting step 
of ^  novo synthesis (Caskey ^  al., 1964), is lowered (Kelley 
and Wyngaarden, 1970) thereby reducing ^  novo purine production. 
This feedback inhibition is most noticable in patients with 
excessive urate excretion who received very high doses of allopu­
rinol (Bundles _et a2., I9 66). However, there is no evidence that 
allopurinol has this effect in DMD, since its results are constant 
and persistent, thus raising the question of how much, if any, 
de novo synthesis does in fact occur in this disease.
These findings support the view that DMD may have some basis 
in defective purine metabolism, perhaps by failure of synthetic 
pathways. Further, if the abnormally low adenine nucleotides 
found in DMD muscle (Stengel-Rutkowski and Barthelmai, 1973) were 
shown to increase after allopurinol then this view would be greatly 
substantiated. In addition, a simple and clinically effective 
circumvention of the prospective defect seems possible using 
allopurinol, though only further experience, with more exact 
studies of allopurinol dosage and even of additional preformed 
purines, can determine its value.
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Effect of allopurinol in DMD muscle ; Results and discussion
Muscle biopsy specimens were assayed, for ATP, ADP, AMP, CP 
and G-6-P, in healthy male controls undergoing surgical repair 
and in ambulant DMD patients before and after 6 months and 1 year 
on allopurinol. Their clinical status had been initially, with 
differences in degree, that of 13 in Table XIX; after 4 to 8 weeks 
on allopurinol this improved in all but one to 15 and even 16, 
where it remained (Table XXX). Thus allopurinol appeared to 
prevent the steady progression characteristic of DMD,
For assay of normal muscle constituents, wet weight is the 
simplest and easiest reference available, though not for abnormal 
muscle, as DMD specimens may contain only a small amount of actual 
muscle with a very large amount of fat and fibrous tissue of quite 
different composition (Lilienthal et , 1 9 5 0 ) ,  The use of NON 
as a reference therefore eliminates errors arising from such 
abnormal composition.
Muscle content is reported here using both wet weight (Tables 
XXXI and XXXII) and NCE (Tables XXXIII and XXXIV) for reference.
Wet weight as a standard was rejected as it leads to erroneous 
results due to the admixture of dystrophic muscle with fat and 
fibrous tissue. This gives a false apparent decrease in muscle 
content; for example, against wet weight group B has 27% of normal 
muscle ATP, and not 40% as with NCN. The NGN content of DMD muscle 
before allopurinol, expressed as wet weight (Table XXXI), was not 
found significantly different from that of normal muscle (Table 
XXXII, B/A), but NGN content in patients after allopurinol (E), 
although higher than in patients before allopurinol (B), was
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Table XXX opposite
Details of all subjects who underwent a muscle biopsy.
All biopsies on DMD patients were performed on the vastus 
lateralis.
TABLE XXX 
BIOPSY SUBJECTS
Subjects No. Age Clinical status Dai]
(yrs) Before After allc
5 healthy males (A) 1 12.51
2 20.80
3 58.91
4- 4 8 .6 5
3 5 6 .3 2
5 ambulant untreated 6 3.67
DMD patients (B) 7 4 .3 2
8 4 .7 7
9 9 .0 2
10 1 0 .1 4
4 ambulant DMD 11 4 .1 1 13 15 100
patients after 6 12 4.81 13 15 100
months allopurinol (C) 13 5 .3 1 13 15 100
14 9 .5 2 13 13 150
3 ambulant DMD 15 4 .5 7 13 15 100
patients after 1 year 16 6.23 13 16 100
allopurinol (D) 17 7 .7 9 13 16 100
18 8.83 13 15 150
19 9 .4 6 13 15 100
All 9 treated DMD 
patients (E)
1/ Type of operation and muscle blopsied In normal males:-
1 Bilateral vesico-ureteric reflex (congenital) - pyramidalis
2 Remedial treatment for persistant shoulder dislocation - 
pactoralis major
3 Laparotomy for lumbar sympathectomy - internal abdominal oblique
4 Fractured femur repair - vastus lateralis 
3 Artho plasty (Howe) - gluteus medius
12a.
Table XXXI opposite
Muscle content (in moles x 10”^/g wet weight) of ATP, 
ADP, AMP, total adenine nucleotides, CP and G-6-P, with 
the amount of non-collagen nitrogen (in mg/g wet weight) 
in
(A) 5 healthy males
(B) 5 (male) DMD patients before treatment
(C) 4 (male) DMD patients after 6 months on allopurinol 
daily
(D) 5 (male) DMD patients after 1 year of allopurinol 
daily
(E) the 9 treated patients of (C) and (D) combined.
TABLE XXXI
MUSCLE CONTENT AS MOLES X 10"^/g WET WEIGHT
Total NCN-mg/g
No. ATP ADP AMP Aden. CP G—6™P Wet Wt.
A 1 4.73 0.73 0.10 5.59 17.46 0.73 25.99
2 3.39 0.84 0.11 6.34 1 9 .0 0 0.43 28.14
3 4.16 0.69 0.03 4.88 13-59 0.36 23.68
4 3.77 0 .5 2 0.09 4.38 11.60 0.18 19.72
5 3.84 0.59 0.24 4.67 11.67 0.81 22.26
Mean 4.38 0.67 0.11 5.17 14.67 0.50 23.96
SD 0,68 0.13 0.08 0.79 3.40 0.26 3.26
B 6 1.38 0.75 0.05 2.18 3.49 0.56 18.74
7 1.46 0.54 0.09 2.09 2.02 0,49 15.66
8 0.89 0.67 0.11 1.67 2.11 0.21 27.19
9 0 .7 1 0 .3 0 0.13 1.13 1.68 0.20 1 4 .9 1
10 1.38 0.55 0.12 2.05 2.64 0.23 1 1 .8 9
Mean 1.16 0.56 0.10 1 .8 2 2.39 0.34 1 7 .6 8
SD 0.34 0.17 0.03 0.43 0.71 0.17 5.85
C 11 . 2.38 1.05 0.06 3.49 6.88 0.11 2 0 ,7 9
12 2.10 0.75 0 .24 3.09 5.89 0.76 21.36
13 2 .8 2 0.94 0.35 4.11 6.46 0.64 2 2 .5 1
14 1.87 1.05 0.19 3.10 6.90 0.18 1 5 .4 9
Mean 2 .2 9 0.-95 0.21 3.45 6.53 0 .4 2 2 0 .0 4
SD 0.41 0.14 0.12 0.48 0.47 0.33 3 .1 2
D 13 3.32 0.66 0.15 4,32 8.55 0.33 2 3 .8 2
16 3.24 0.43 0.05 3.72 8.2 0.15 21.82
17 2.21 0.32 0.22 2.75 5.11 0.19 18.79
18 3.26 0.63 0,18 4.08 9.27 0.23 2 0 .2 7
19 2.29 0.18 0.22 2.68 6.73 0.08 1 3 .5 5
Mean 2 .9 0 0.44 0.16 3.51 7.57 0.20 1 9 .6 5
SD 0.61 0.20 0.07 0.76 1.66 0.09 3 .8 9
E
Mean 2.-63 0.67 0.19 3.48 7.11 0 .3 0 1 9 .8 2
SD 0.39 0.31 0.09 0.61 1.33 0.24 3.35
Table XXXII opposite
Ratios and significance of differences between the means 
of the muscle metabolite content, measured against wet 
weight and given in Table XXXI in
(A) 5 healthy males
(B) 5 (male) DMD patients before treatment
(G) 4 (male) DMD patients after 6 months on allopurinol 
daily
(D) 5 (male) DMD patients after 1 year on allopurinol 
daily
(E) the 9 treated patients of (C) and (D) combined.
TABLE XXXII
RATIOS AND SIGNIFICANCE OF DIFFERENCE BETWEEN MEANS (WET WT.)
Comparisons 
of means ATP ADP AMP
Total
Aden. CP G—6—P NON
Ratio B/A 0.27 0.85 0.89 0.35 0.16 0.67 0.74
Difference PO.OOl NS NS P^O.OOl P<0.001 NS NS
Ratio C/A 0 .5 2 1.40 1.87 0,67 0.45 0.84 0.84
Difference PO.OOl P<0.05 NS PCO.Ol P<0.01 NS NS
Ratio D/A 0,66 0.66 1.44 0.68 0 .5 2 0 .3 9 0 .8 2
Difference P<0.01 NS NS PCO.Ol P<0.01 P<0.05 NS
Ratio E/A 0,60 0.99 1.63 0.-67 0.48 0.59 0.83
Difference P<0.001 NS NS P</0.001 P<0.001 NS P<0.05
Ratio C/B 1.97 1.69 2 .1 1 1.89 2.74 1 .2 5 1 .1 3
Difference PCO.Ol P<0.01 NS P<0.001 P<0.001 NS NS
Ratio D/B 2.50 0.79 1*63 1.93 3.17 0.58 1 .1 1
Difference P20.001 NS NS P<0.001 P<0.001 NS NS
Ratio E/B 2 .2 6 1.19 1.84 1.91 2 .9 8 0 .8 8 1 .1 2
Difference P20.001 NS NS P<0.001 P<0.001 NS NS
Ratio D/C 1.27 0.47 0.77 1 .0 2 1 .1 6 0 .4 6 0 .9 8
Difference NS P<0.01 NS NS NS NS NS
12c
significantly lower* than normal.
In health, muscle adenylate content, against NGN, was 
remarkably constant, as shown by the small standard deviation of 
A in Table XXXIII, and quite unrelated to age; but CP showed a 
high negative correlation with age (r = “*0,9466; t = 5.0847,
P<0.05, 3 degrees of freedom) indicating some decline in energy 
reserves. In untreated DMD, ADP and AMP values were the same as 
normal, conflicting with the findings of Stengel-Rutkowski and 
Barthelmai (1973), v/ho reported reductions of over 70% in DMD, 
but supporting the observations of Vignos and Warner (1963).
Total adenylate was only 52%, ATP 40% and CP a mere 24% of normal 
(Table XXXIV). These gross reductions were all highly significant 
even in these small numbers.
6 months of allopurinol (group G) then more than doubled CP** 
and increased total adenylate by half**, with a similar but not 
significant rise in ATP (Table XXXIV, C/B). After 1 year on 
allopurinol, however, though CP and total adenylate increased only 
slightly, ATP had risen to 81% of normal (D/A), mainly at the 
expense of ADP, which was reduced by half** from values signifi­
cantly* higher than normal reached after 6 months treatment. The 
main improvements in DMD after allopurinol thus clearly occur in 
ATP and CP with increases of 205 and 270% respectively, compared 
with untreated patients (D/B). A basic adequacy of both oxidative 
phosphorylation and GPK activity in DMD muscle is therefore implied, 
and the indifference throughout of G-6-P suggests a sufficient 
glycolysis.
These results indicate that the increased adenylate content
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Table XXXIII opposite
Muscle content (in moles x 10” /g non-collagen nitrogen) 
of ATP, ADP, AMP, total adenine nucleotides, CP and 
G-6-P in
(A) 5 healthy males
(B) 5 (male) DMD patients before treatment
(C) 4 (male) DMD patients after 6 months on allopurinol 
daily
(D) 5 (male) DMD patients after 1 year on allopurinol 
daily
(E) the 9 patients of (C) and (D) combined.
TABLE XXXIII
MUSCLE CONTENT AS MOLES X 10"^/g NON
Total
No. ATP ADP AMP Aden. GP G—6—P
A 1 18.29 2.82 0.38 2 1 .5 0 6 7 .1 9 2 .7 9
2 19.15 2 .9 8 0 .4 0 2 2 .5 3 6 7 .5 2 1.5
3 17.55 2.93 0.12 20.60 5 7 .4 0 1.53
4 19.14 2.62 0 .4 4 22.20 58.81 0 .9 1
5 17.25 2.65 1 .0 9 20.99 54.44 3 .6 4
Mean 18.28 2.80 0.49 21.56 61.07 2.08
SD 0.88 0.16 0.36 0 .8 1 5 .9 5 1.11
B 6 7.38 3 .9 8 0.26 11.62 1 8 .6 2 3 .0 1
7 9.32 3 .4 4 0.58 1 3 .3 4 1 2 .9 1 3 .1 2
8 3.28 2. Zj-6 0 .4 1 6.16 7 .7 5 0.77
9 4.73 1 .9 8 0.85 7 .5 7 1 1 .2 4 1 .3 2
10 11.57 4 .6 0 1 .0 4 1 7 .2 2 2 2 .2 3 1 .9 2
Mean 7.26 3 .2 9 0.63 11.18 1 4 .5 5 2 .0 3
SD 3.36 1.07 0.32 4 .4 6 5 .8 2 1 .0 3
G 11 11. ii-4 5.06 0 .3 0 1 6 .8 0 33.08 0.54
12 9.81 3 .5 1 1 .1 4 1 4 .4 7 2 7 .5 7 3 .5 5
13 1 2 .5 2 4 .16 1.58 18.26 2 8 .7 1 2.86
14 12.06 6 .76 1.22 2 0 .0 4 44 .5 4 1 .1 4
Mean 11.46 4 .8 7 1.06 1 7 .3 9 3 3 .4 7 2.02
SD 1.18 1 .4 1 0.54 2.36 7 .7 5 1 .4 2
D 15 14.76 2 .7 6 0.63 1 8 .1 5 3 5 .8 8 1 .4 0
16 1 4 .8 7 1 .9 6 0 .2 4 1 7 .0 7 37.61 0 .6 9
17 1 1 .7 4 1 .7 1 1.16 1 4 .6 2 2 7 .1 9 1.01
18 1 6 .0 9 3.13 0 .9 1 20.12 4 5 .7 2 1.12
19 16.86 1 .3 2 1.62 1 9 .8 0 4 9 .6 9 0.60
Mean 1 4 .8 7 2 .1 8 0 .9 1 1 7 .95 3 9 .2 2 0 .9 6
SD 1 .9 5 0 .7 5 0 .5 2 2 .2 4 8.81 0.33
E
Mean 1 3 .3 5 3.37 0 .9 8 1 7 .7 0 36.59 1 .4 3
SD 2.38 1.74 0 .5 0 2.16 8 .4 0 1.06
1-3 CL
Table XXXIV opposite
Ratios and significance of differences between the means 
of the muscle metabolite content, measured against non­
collagen nitrogen and given in Table XXXIII in
(A) 5 healthy males
(B) 5 (male) DMD patients before treatment
(C) 4 (male) DMD patients after 6 months on allopurinol 
daily
(D) 5 (male) DMD patients after 1 year on allopurinol 
daily
(E) the 9 treated patients of (C) and (D) combined.
TABLE XXXIV
RATIOS AND SIGNIFICANCE OF DIFFERENCE BETWEEN MEANS (NON) 
Comparisons Total
of means ATP ADP AMP Aden. CP G-6-P
Ratio B/A 0.40 1*18 1.50 0.52 0.24 0,97
Difference P<0.001 NS NS P<0.001 PcO.OOl NS
Ratio C/A 0.65 1.74 2.18 0.81 0.55 0.97
Difference P<0.001 P<0.05 NS P<0.01 PO.OOl NS
Ratio D/A 0.8l 0.78 0.49 0,83 0,64 O .4 6
Difference P<0.001 NS NS PO.OOl PO.OOl. NS
Ratio E/A 0.73 1.21 2.01 0.82 0.60 0.69
Difference P<0.001 NS NS P<0.01, PO.OOl NS
Ratio C/B 1.58 1 .4 8 1.68 1.56 2.30 1.00
Difference NS NS NS P<0.0 5 PO.Ol NS
Ratio D/B 2.05 0,66 1.44 1.61 2.70 O .4 8
Difference PO.Ol NS NS P<0.05 PO.OOl NS
Ratio E/B I .8 4 1.02 1,55 1.58 2.52 0.71
Difference PO.Ol NS NS PO.Ol PO.OOl NS
Ratio D/C 1 .3 0  0,45 0.86 1,05 1.17 O .4 8
Difference P<0.05 PO.Ol NS NS NS NS
after allopurinol may offer a similar support to that from normal 
nuclei in muscle of manifesting carriers, thus ensuring preserv­
ation of the DMD muscle fibre population. If some prospect of 
sustained clinical arrest may now seem possible, studies of purine 
synthesis in DMD should prove rewarding. Moreover, neonatal 
diagnosis (Zellweger and Antonik, 1975; Beckmann, 1977), with 
early intervention, become important and in older children some 
means, whether biochemically or by advanced orthopaedic procedures, 
to prevent the shrinking fibrous tissue progressively impeding 
residual muscle action.
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